WO2016207226A1

WO2016207226A1 - New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them

Info

Publication number: WO2016207226A1
Application number: PCT/EP2016/064436
Authority: WO
Inventors: Zoltán SZLÁVIK; Zoltán SZABÓ; Márton Csékei; Attila Paczal; András Kotschy; Alain Bruno; Olivier Geneste; I-Jen Chen; James Edward Paul Davidson; James Brooke MURRAY; Levente Ondi; Gábor Radics; Szabolcs SIPOS; Ágnes Proszenyák; Françoise PERRON-SIERRA; Balázs Bálint
Original assignee: Les Laboratoires Servier; Vernalis (R&D) Limited
Priority date: 2015-06-23
Filing date: 2016-06-22
Publication date: 2016-12-29
Also published as: MA42232B1; UY36733A; UA123267C2; PL3313850T3; HK1252113B; SV2017005588A; TWI631124B; MX368845B; AR105101A1; MA42232A; EA201890123A1; RS57961B1; US10457687B2; IL256191A; KR20180015261A; HK1250234A1; JO3430B1; DK3313850T3; TN2017000521A1; AU2016282837A1

Abstract

Compounds of formula (I): wherein R₁, R₂, R₅, R₆, R₇, R₁₂, X, Y, A, E and n are as defined in the description. Medicaments.

Description

NEW AMINOACID DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The present invention relates to new amino acid derivatives, to a process for their preparation and to pharmaceutical compositions containing them.

The compounds of the present invention are new and have very valuable pharmacological characteristics in the field of apoptosis and cancerology. Apoptosis, or programmed cell death, is a physiological process that is crucial for embryonic development and maintenance of tissue homeostasis.

Apoptotic-type cell death involves morphological changes such as condensation of the nucleus, DNA fragmentation and also biochemical phenomena such as the activation of caspases which cause damage to key structural components of the cell, so inducing its disassembly and death. Regulation of the process of apoptosis is complex and involves the activation or repression of several intracellular signalling pathways (Cory S. et al., Nature Review Cancer 2002, 2, 647-656).

Deregulation of apoptosis is involved in certain pathologies. Increased apoptosis is associated with neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease and ischaemia. Conversely, deficits in the implementation of apoptosis play a significant role in the development of cancers and their chemoresistance, in auto-immune diseases, inflammatory diseases and viral infections. Accordingly, absence of apoptosis is one of the phenotypic signatures of cancer (Hanahan D. et al., Cell 2000, 100, 57-70).

The anti-apoptotic proteins of the Bcl-2 family are associated with numerous pathologies. The involvement of proteins of the Bcl-2 family is described in numerous types of cancer, such as colon cancer, breast cancer, small-cell lung cancer, non-small-cell lung cancer, bladder cancer, ovarian cancer, prostate cancer, chronic lymphoid leukaemia, lymphoma, myeloma, acute myeloid leukemia, pancreatic cancer, etc. Overexpression of the anti- apoptotic proteins of the Bcl-2 family is involved in tumorigenesis, in resistance to chemotherapy and in the clinical prognosis of patients affected by cancer. Notably, Mcl-1 , an anti-apoptotic Bcl-2 family member, is overexpressed in various types of cancer (Beroukhim R. et al., Nature 2010, 899-905). There is, therefore, a therapeutic need for compounds that inhibit the anti-apoptotic activity of the proteins of the Bcl-2 family.

In addition to being new, the compounds of the present invention have pro-apoptotic properties making it possible to use them in pathologies involving a defect in apoptosis, such as, for example, in the treatment of cancer and of immune and auto-immune diseases.

The present invention relates more especially to compounds of formula (I):

in which 1 is linked to the -NH- group and 2 is linked to the aromatic ring,

♦ E represents a cycloalkyl group, a heterocycloalkyl group, an aryl group or a heteroaryl group,

♦ X represents a nitrogen atom or a C-R4 group,

♦ Y represents a nitrogen atom or a C-R3 group,

♦ Ri represents a halogen atom, a linear or branched (Ci-Ce)alkyl group, a linear or branched (C₂-Ce)alkenyl group, a linear or branched (C₂-Ce)alkynyl group, a linear or branched (Ci-Ce)polyhaloalkyl group, a hydroxy group, a hydroxy(Ci-C6)alkyl group, a linear or branched (Ci-Ce)alkoxy group, -S-(Ci-Ce)alkyl, a cyano group, a nitro group, -alkyl(Co-C₆)-NR₉R9', -0-alkyl(Ci-C₆)-NR₉R9', -0-alkyl(Ci-C₆)-Rio, -C(0)-OR₉, -0-C(0)-R₉, -C(0)-NR₉R₉', -NR₉-C(0)-R₉', -NR₉-C(0)-OR₉', -alkyl(Ci-C₆)-NR₉-C(0)-R₉', -S0₂-NR₉R₉', -S0₂-alkyl(Ci-C₆),

♦ R₂, R3, R4 and R₅ independently of one another represent a hydrogen atom, a halogen atom, a linear or branched (Ci-Ce)alkyl group, a linear or branched (C₂-C6)alkenyl group, a linear or branched (C₂-C₆)alkynyl group, a linear or branched (Ci-C6)polyhaloalkyl group, a hydroxy group, a hydroxy(Ci-Ce)alkyl group, a linear or branched (Ci-Ce)alkoxy group, -S-(Ci-Ce)alkyl, a cyano group, a nitro group, -alkyl(C₀-C₆)-NR₉R₉', -0-alkyl(Ci-C₆)-NR₉R₉', -0-alkyl(Ci-C₆)-Rio, -C(0)-OR₉, -0-C(0)-R₉, -C(0)-NR₉R₉', -NR₉-C(0)-R₉', -NR₉-C(0)-OR₉', -alkyl(Ci-C₆)-NR₉-C(0)-R₉', -S0₂-NR₉R₉', or -S0₂-alkyl(Ci-C₆),

or the substituents of the pair (R_{l s} R₂) form together with the carbon atoms carrying them an aromatic or non-aromatic ring composed of from 5 to 7 ring members, which may contain from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, it being understood that resulting ring may be substituted by from 1 to 2 groups selected from halogen, linear or branched (Ci-Ce)alkyl, -alkyl(C₀-C₆)-NR₉R₉', -NRnRn ', -alkyl(C₀-C₆)-Cyi, or oxo,

♦ R6 represents a hydrogen atom, a halogen atom, a linear or branched (Ci-Ce)alkyl group, a linear or branched (C₂-Ce)alkenyl group, a linear or branched (C₂-C₆)alkynyl group, a linear or branched (Ci-Ce)polyhaloalkyl group, a hydroxy group, a linear or branched (Ci-Ce)alkoxy group, -S-(Ci-Ce)alkyl, a cyano group, a nitro group, -alkyl(C₀-C₆)-NR₉R₉', -O-Cyi, -alkyl(C₀-C₆)-Cyi, -alkenyl(C₂-C₆)-Cyi, -alkynyl(C₂-C₆)-Cyi, -0-alkyl(Ci-C₆)-Rio, -C(0)-OR₉, -0-C(0)-R₉, -C(0)-NR₉R₉', -NR₉-C(0)-R₉', -NR₉-C(0)-OR₉', -alkyl(Ci-C₆)-NR₉-C(0)-R₉', -S0₂-NR₉R₉', or -S0₂-alkyl(Ci-C₆),

♦ R₇ represents a hydrogen atom, a linear or branched (Ci-Cs)alkyl group, a -CHRaRb group, an aryl group, a heteroaryl group, an arylalkyl(Ci-C₆) group, or a heteroarylalkyl(Ci-Ce) group,

♦ R8 represents a linear or branched (Ci-Ce)alkyl group, a linear or branched (C₂-C₆)alkenyl group, a linear or branched (C₂-C₆)alkynyl group, -Cy₂, a halogen atom, a cyano group, -C(0)-Rn, or -C(0)-NRnRn',

♦ R₉ and R₉' independently of one another represent a hydrogen atom, a linear or branched (Ci-Ce)alkyl group,

or the substituents of the pair (R₉, R₉') form together with the nitrogen atom carrying them an aromatic or non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen atom from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, it being understood that the nitrogen in question may be substituted by a group representing a hydrogen atom, or a linear or branched (Ci-Ce)alkyl group,

♦ Rio represents -Cy₃, -Cy₃-alkyl(C₀-C₆)-Cy₄, -C(0)-NR₉R₉', -NR9R9', -OR9, -NR₉-C(0)-R₉', -0-alkyl(Ci-C₆)-OR₉, -SO2-R9, -C(0)-OR₉,or -NH-C(0)-NH-R₉,

♦ R_{1 1} and Rn ' independently of one another represent a hydrogen atom or an optionally substituted linear or branched (Ci-C₆)alkyl group,

♦ R₁₂ represents a hydrogen atom, a hydroxy group, or a hydroxy(Ci-C₆)alkyl group,

♦ R_a represents a hydrogen atom or a linear or branched (Ci-Ce)alkyl group,

♦ R_b represents a -0-C(0)-0-R_c group, a -0-C(0)-NR_cR_c' group, or a -0-P(0)(OR_c)₂ group,

♦ R_c and R_c' independently of one another represent a hydrogen atom, a linear or branched (Ci-Cs)alkyl group, a cycloalkyl group, a (Ci-C₆)alkoxy(Ci-C₆)alkyl group, a (Ci-C₆)alkoxycarbonyl(Ci-C₆)alkyl group,

or the substituents of the pair (R_c, R_c') form together with the nitrogen atom carrying them a non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen atom from 1 to 3 heteroatoms selected from oxygen and nitrogen, it being understood that the nitrogen in question may be substituted by a group representing a linear or branched (Ci-Ce)alkyl group,

♦ Cyi, Cy₂, Cy₃ and Cy₄ independently of one another, represent a cycloalkyl group, a heterocycloalkyl group, an aryl group or a heteroaryl group,

♦ n is an integer equal to 0, 1 or 2, ing understood that:

- "aryl" means a phenyl, naphthyl, biphenyl group,

"heteroaryl" means any mono- or bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, "cycloalkyl" means any mono- or bi-cyclic non-aromatic carbocyclic group containing from 3 to 10 ring members,

"heterocycloalkyl" means any mono- or bi-cyclic non-aromatic carbocyclic group containing from 3 to 10 ring members, and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, which may include fused, bridged or spiro ring systems, it being possible for the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups so defined and the alkyl, alkenyl, alkynyl, alkoxy groups, to be substituted by from 1 to 4 groups selected from optionally substituted linear or branched (Ci-Ce)alkyl, optionally substituted linear or branched (C₂-C₆)alkenyl, optionally substituted linear or branched (C₂-C₆)alkynyl, optionally substituted linear or branched (Ci-Ce)alkoxy, optionally substituted (Ci-C₆)alkyl-S-, hydroxy, hydroxy(Ci-C₆)alkyl, oxo (or N-oxide where appropriate), nitro, cyano, -C(0)-OR', -0-C(0)-R', -C(0)-NR'R", -0-C(0)-NR'R", -NR'R", -(C=NR')-OR", -0-P(0)(OR')₂, -0-P(0)(0^~M⁺)₂, linear or branched (Ci-Ce)polyhaloalkyl, trifluoromethoxy, halogen, or an aldohexose of formula:

in which each R' is independent; it being understood that R' and R" independently of one another represent a hydrogen atom or an optionally substituted linear or branched (Ci-C₆)alkyl group and M⁺ represents a pharmaceutically acceptable monovalent cation, their enantiomers, diastereoisomers and atropisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.

Advantageously, the present invention relates to compounds of formula (I) wherein:

♦ Ri and R₂ independently of one another represent a halogen atom, a linear or branched (Ci-Ce)alkyl group, a hydroxy group, a hydroxy(Ci-C₆)alkyl group, a linear or branched (Ci-C₆)alkoxy group,

or the substituents of the pair (R_{l s} R₂) form together with the carbon atoms carrying them an aromatic ring composed of from 5 to 7 ring members, which may contain from 1 to 3 nitrogen atoms, it being understood that resulting ring may be substituted by from 1 to 2 groups selected from halogen, linear or branched (Ci-C₆)alkyl, or -alkyl(Co-C₆)-NR₉R9',

♦ R₃ represents a hydrogen atom, a halogen atom, a linear or branched (Ci-Ce)alkyl group, a hydroxy group, a linear or branched (Ci-Ce)alkoxy group, or -0-alkyl(Ci-C₆)-NR₉R9',

♦ R4 and R₅ independently of one another represent a hydrogen atom, a halogen atom, a linear or branched (Ci-Ce)alkyl group, a hydroxy group, a linear or branched (Ci-Ce)alkoxy group,

♦ R6 represents a hydrogen atom, a halogen atom, a linear or branched (Ci-Ce)alkyl group, a linear or branched (Ci-Ce)polyhaloalkyl group, a hydroxy group, a linear or branched (Ci-Ce)alkoxy group, a cyano group, a nitro group, -alkyl(Co-C₆)-NR₉R9' , -alkyl(C₀-C₆)-Cyi, -0-alkyl(Ci-C₆)-Rio or -C(0)-NR₉R₉',

♦ R₇ represents a hydrogen atom, a linear or branched (Ci-Cs)alkyl group, a -CHR_aR_b group, or a heteroarylalkyl(Ci-Ce) group,

♦ R8 represents a linear or branched (Ci-Ce)alkyl group, a linear or branched (C₂-C₆)alkenyl group, a linear or branched (C₂-C₆)alkynyl group, -Cy₂, a halogen atom, or -C(0)-Rn,

or the substituents of the pair (R₉, R₉') form together with the nitrogen atom carrying them a non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen atom from 1 to 3 heteroatoms selected from oxygen and nitrogen, it being understood that the nitrogen in question may be substituted by a group representing a linear or branched (Ci-Ce)alkyl group,

♦ Rio represents -Cy₃ or -Cy₃-alkyl(Co-Ce)-Cy4,

♦ R_{1 1} represents a linear or branched (Ci-C₆)alkyl group, it being possible for the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups so defined and the alkyl, alkenyl, alkynyl, alkoxy groups, to be substituted by from 1 to 4 groups selected from optionally substituted linear or branched (Ci-Ce)alkyl, optionally substituted linear or branched (Ci-Ce)alkoxy, hydroxy, hydroxy(Ci-C6)alkyl, oxo (or N-oxide where appropriate), -C(0)-OR', -C(0)-NR'R", -0-C(0)-NR'R", -NR'R", -0-P(0)(OR')₂, -0-P(0)(0^~M⁺)₂, linear or branched (Ci-Ce)polyhaloalkyl, halogen, or an aldohexose of formula:

in which each R' is independent; it being understood that R' and R" independently of one another represent a hydrogen atom or an optionally substituted linear or branched (Ci-C₆)alkyl group and M⁺ represents a pharmaceutically acceptable monovalent cation.

Among the pharmaceutically acceptable acids there may be mentioned, without implying any limitation, hydrochloric acid, hydrobromic acid, sulphuric acid, phosphonic acid, acetic acid, trifluoroacetic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, tartaric acid, maleic acid, citric acid, ascorbic acid, oxalic acid, methanesulphonic acid, camphoric acid etc.

Among the pharmaceutically acceptable bases there may be mentioned, without implying any limitation, sodium hydroxide, potassium hydroxide, triethylamine, tert-butylamine etc. More especially, compounds of formula (I) to which preference is given are compounds wherein n is an integer equal to 1.

In another embodiment of the invention, an advantageous possibility consists of compounds of formula (I-a):

wherein A, E, R_{l s} R₂, R₅, 5, R7, R12, X, Y and n are as defined for formula (I).

Atropisomers are stereoisomers arising because of hindered rotation about a single bond, where energy differences due to steric strain or other contributors create a barrier to rotation that is high enough to allow for isolation of individual conformers. For compounds according to the invention, atropisomers are as follows:

Preferred atropisomer is (5S_a) when X represents a C-R4 group and Y represents a C-R3 group. Advantageously, at least one of the groups selected from R₂, R3, R4 and R₅ does not represent a hydrogen atom.

Preferably, R₁₂ represents a hydrogen atom, a hydroxymethyl group or a hydroxy ethyl group. More preferably, R₁₂ represents a hydrogen atom.

In the preferred compounds of the invention, Ri represents a linear or branched (Ci-C₆)alkyl group or a halogen atom. More preferably, Ri represents a methyl group, an ethyl group, a bromine atom or a chlorine atom. Even more preferably, Ri represents a methyl group.

Advantageously, R₂ represents a halogen atom, a hydroxy group, a linear or branched (Ci-C₆)alkoxy group. More preferably, R₂ represents a methoxy group, a hydroxy group, a fluorine atom, a bromine atom or a chlorine atom. Even more preferably, R₂ represents a chlorine atom.

In some preferred embodiment of the invention, when the substituents of the pair (R_{l s} R₂) form together with the carbon atoms carrying them an aromatic ring,

wherein Ri₃ represents a hydrogen atom, a linear or branched (Ci-C₆)alkyl group or -alkyl(Co-C₆)-NR9Rc)' in which R9 and R9 ' are as defined for formula (I), and R14 represents a hydrogen atom, a halogen atom or a linear or branched (Ci-C₆)alkyl group. Ri₃ represents preferably a hydrogen atom, a methyl group or -(CH₂)_m-NR9R ' in which m is an integer equal to 2 or 3 and, R9 and R9' represent a methyl group or the substituents of the pair (R9, R9') form together with the nitrogen atom carrying them a pyrrolidinyl, a piperidinyl, a morpholinyl or a 4-methyl-piperazin-l-yl group. Ri4 represents advantageously a hydrogen atom, a bromine atom, an iodine atom, a chlorine atom or a methyl group. R14 is preferably substituted at β position from the nitrogen atom.

Preferably, X represents a C-R₄ group. In a preferred embodiment of the invention, Y represents a C-R₃ group. R₃ advantageously represents a hydrogen atom, a linear or branched (Ci-Ce)alkoxy group or -0-alkyl(Ci-C6)-NR9R )'. R4 preferably represents a hydrogen atom.

In some preferred embodiment of the invention,

wherein Ri, R₂, R₉ and R₉' are as defined for formula

In the preferred compounds of the invention,

wherein R₉ and R₉' are as defined for formula (I).

R₅ preferably represents a hydrogen atom. In an advantageous embodiment, the substituents of the pair (R_{l s} R5) are identical and the substituents of the pair (R₂, R4) are identical. In the preferred compounds of the invention, the substituents of the pair (R_{l s} R₅) are identical and represent a (Ci-C6)alkyl group, preferably a methyl group, whereas the substituents of the pair (R₂, R4) are identical and represent a halogen atom, preferably a chlorine atom, or a hydrogen atom.

In another embodiment of the invention, E represents a phenyl group, a pyridin-2-yl, a cyclohexyl group, a pyrazol-l-yl group, a cyclopentyl group, an indol-4-yl group, a cyclopropyl group, a pyridin-3-yl group, an indol-3-yl group, a naphth-l-yl group, an imidazol-4-yl group or a pyridin-4-yl group. Advantageously, E represents a phenyl group.

In the preferred compounds of the invention, R^ represents a hydrogen atom; a fluorine atom; a chlorine atom; a bromine atom; a methyl group; a trifluoromethyl group; a hydroxy group; a methoxy group; a linear (Ci-C6)alkoxy group substituted by halogen atoms, a -C(0)-NR'R" group or a -NR'R" group; a cyano; a nitro group; an aminomethyl group; a benzyl group; -0-alkyl(Ci-C6)-Rio; -C(0)-NR9Rc>'. Preferably, Re represents a methoxy group, a 2,2,2-trifluoroethoxy group or -0-alkyl(Ci-C6)-Rio-

In another embodiment of the invention, an advantageous possibility consists of compounds of formula (I-b):

wherein R_{l s} R₂, R5, R5, R7, R12, X, Y, A and n are as defined for formula (I).

In another embodiment of the invention, an advantageous possibility consists of compounds of formula (I-c):

wherein R^, R₇, R₉, R₉', Ri₂ and A are as defined for formula (I).

Preferably, R₇ represents a hydrogen atom, a -CHRaRb group, an optionally substituted linear or branched (Ci-Cs)alkyl group, or a heteroarylalkyl(Ci-Ce) group. Preferably, R₇ represents a -CHRaRb group in which Ra represents a hydrogen atom or a methyl group and R_b represents a -0-C(0)-0-(Ci-Cs)alkyl group; a -0-C(0)-0-cycloalkyl group; a -0-C(0)-NR_cR_c' group, in which R_c and R_c' independently of one another represent a hydrogen atom, a linear or branched (Ci-Cs)alkyl group, a (Ci-C₆)alkoxy(Ci-C₆)alkyl group, a (Ci-C₆)alkoxycarbonyl(Ci-C₆)alkyl group, or the substituents of the pair (R_c, R_c') form together with the nitrogen atom carrying them a non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen atom from 1 to 3 heteroatoms selected from oxygen and nitrogen; or a -0-P(0)(OH)₂ group. Preferred R₇ groups are as follows: hydrogen; methyl; ethyl; (5-methyl-2-oxo-l ,3-dioxol-4-yl)methyl; a -CHRaRb group in which Ra represents a methyl group and Rb represents a -0-C(0)-0-CH₂CH₃ group or a -0-C(0)-N(CH₃)₂ group. Even more preferably, R₇ represents hydrogen.

In the preferred compounds of the invention, Rs represents a linear or branched (C₂-C₆)alkynyl group, an aryl group or a heteroaryl group. More preferably, Rs represents a prop-l-yn-l-yl group, a phenyl group or a furan-2-yl group. In a more preferred embodiment, R₈ represents a prop-l-yn-l-yl group, a 4-fluorophenyl group or a 5-fluorofuran-2-yl group. Even more preferentially, Rs represents a 4-fluorophenyl group. In the preferred compounds of the invention, R₉ and R9' independently of one another represent a linear or branched (Ci-Ce)alkyl group, or the substituents of the pair (R₉, R₉') form together with the nitrogen atom carrying them a non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen atom from 1 to 3 heteroatoms selected from oxygen and nitrogen, it being understood that the nitrogen in question may be substituted by a linear or branched (Ci-C₆)alkyl group. More preferably, R₉ and R₉' represent a methyl group, or the substituents of the pair (R₉, R₉') form together a 4-methyl-piperazinyl group.

Advantageously, Rio represents -Cy₃ or -Cy₃-alkyl(Co-C6)-Cy₄. Preferably, Rio represents -Cy₃ or -Cy₃-Cy₄.

Cy₃ preferably represents a cycloalkyl group, particularly, a cyclopentyl group. In a preferred embodiment, Cy₃ represents an aryl group, particularly, a phenyl group. Advantageously, Cy₃ represents a heteroaryl group, particularly, a pyrimidinyl group, a pyrazolyl group or a pyridinyl group. More preferably, Cy₃ represents a pyrimidin-4-yl group, a pyrazol-5-yl group or a pyridin-2-yl group. In the preferred compounds of the invention, Cy₃ represents a pyrimidin-4-yl group. In another embodiment of the invention, Cy₃ represents a heteroaryl group which is substituted by an optionally substituted linear or branched (Ci-Ce)alkyl group, an optionally substituted linear or branched (Ci-Ce)alkoxy group or a linear or branched (Ci-Ce)polyhaloalkyl group. Preferably, Cy₃ represents a heteroaryl group which is substituted by a 2,2,2-trifluoroethoxy group, a 2-methoxyethyl group, an ethoxy group; a tert-butyl group, an ethyl group, a n-butyl group, a 2,2,2-trifluoroethyl group or a methyl group.

Cy₄ preferably represents a phenyl group, a pyridinyl group, a pyridazinyl group, a pyrazinyl group, a pyrimidinyl group or a morpholinyl group. More preferably, Cy₄ represents a phenyl group.

Other compounds of the invention to which preference is given are those wherein, Rio represents

in which p is an integer equal to 0 or 1 and R15 represents a hydrogen atom, a hydroxy group, an optionally substituted linear or branched (Ci-C₆)alkyl group, a linear or branched (Ci-C₆)alkoxy group, a -0-(CHRi₆-CHRi₇-0)_q-R' group, a -0-P(0)(OR')₂ group, a -0-P(0)(0^~M⁺)₂ group, a -0-C(0)-NRi₈Ri9 group, a di(Ci-C₆)alkylamino(Ci-C₆)alkoxy group, a halogen atom, or an aldohexose of formula:

in which each R' is independent; it being understood that:

♦ R' represents a hydrogen atom or a linear or branched (Ci-Ce)alkyl group,

♦ Ri6 represents a hydrogen atom or a (Ci-C₆)alkoxy(Ci-Ce)alkyl group,

♦ Ri₇ represents a hydrogen atom or a hydroxy(Ci-Ce)alkyl group,

♦ Ri8 represents a hydrogen atom or a (Ci-C₆)alkoxy(Ci-Ce)alkyl group,

♦ Rig represents a (Ci-C6)alkoxy(Ci-C6)alkyl group, a -(CH₂)_r-NR9R )' group or a -(CH₂)_r-0-(CHR₁₆-CHR₁₇-0)_q-R' group,

♦ q is an integer equal to 1 , 2 or 3 and r is an integer equal to 0 or 1 ,

♦ M⁺ represents a pharmaceutically acceptable monovalent cation.

The aldohexose according to the invention is preferably D-mannose. Advantageously, R15 represents a methoxy group, a 2-methoxyethoxy group or fluorine. Preferably, the group -(CH₂)_P-Ri5 is located at ortho position of the phenyl group. Among the preferred compounds of the invention there may be mentioned:

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(4-fluoro pheny l)thieno [2,3- ]pyrimidin-4-yl] -2- [( 1 -methyl- IH-pyrazo 1-5 -yl)methoxy] -D- phenylalanine

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(4-fluoro pheny l)thieno [2,3- ]pyrimidin-4-yl] -2- [(2-ethoxypyrimidin-4-yl)methoxy] -D- phenylalanine

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(4-fluoro phenyl)thieno[2,3-(i]pyrimidin-4-yl]-2-{[2-(2-methoxyphenyl)pyrimidin-4-yl] methoxy } -D-phenylalanine

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(furan-2- yl)thieno[2,3-(i]pyrimidin-4-yl]-2-methoxy-Z⁾-phenylalanine

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(5- fluorofuran-2-yl)thieno[2,3-(i]pyrimidin-4-yl]-2-methoxy-Z⁾-phenylalanine

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(5-fluoro furan-2-yl)thieno[2,3- ]pyrimidin-4-yl]-2-(2,2,2-trifluoroethoxy)-Z⁾-phenylalanine

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(5-fluoro furan-2-yl)thieno[2,3- ]pyrimidin-4-yl]-2-(pyridin-2-ylmethoxy)-Z⁾-phenylalanine

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(5-fluoro furan-2-yl)thieno [2,3- ]pyrimidin-4-yl] -2- [( 1 -methyl- IH-pyrazo 1-5 -yl)methoxy] - D-phenylalanine

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(5-fluoro furan-2-yl)thieno [2,3- ]pyrimidin-4-yl] -2- [( 1 -ethyl- IH-pyrazo 1-5 -yl)methoxy] -D- phenylalanine

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(5-fluoro furan-2-yl)thieno[2,3- ]pyrimidin-4-yl]-2-[(2-ethoxypyrimidin-4-yl)methoxy]-Z⁾- phenylalanine

2- [( 1 -butyl- lH-pyrazol-5 -yl)methoxy] -N- [5 - {3 -chloro-2-methyl-4- [2-(4-methyl piperazin- 1 -yl)ethoxy]phenyl} -6-(5-fluorofuran-2-yl)thieno[2,3-<i]pyrimidin-4-yl]- D-phenylalanine - N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(5-fiuoro furan-2-yl)thieno[2,3-d]pyrimidin^

yljmethoxy} -D-phenylalanine

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(5-fiuoro furan-2-yl)thieno[2,3- ]pyrimidin-4-yl]-2-{[2-(2-methoxyphenyl)pyrimidin-4-yl] methoxy } -D-phenylalanine

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(prop- 1 - yn- 1 -yl)thieno[2,3-(i]pyrimidin-4-yl]-2-methoxy-Z⁾-phenylalanine

2- [( 1 -tert-butyl- IH-pyrazo 1-5 -yl)methoxy] -N- [5 - {3 -chloro-2-methyl-4- [2-(4-methyl piperazin- 1 -yl)ethoxy]phenyl} -6-(prop- 1-yn- 1 -yl)thieno[2,3-<i]pyrimidin-4-yl]-Z)- phenylalanine

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(prop- 1 - yn-l-yl)thieno[2,3- ]pyrimidin-4-yl]-2-{[2-(2-methoxyethyl)pyrimidin-4-yl] methoxy} -D-phenylalanine

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(prop- 1 - yn- 1 -yl)thieno[2,3-(i]pyrimidin-4-yl]-2- {[ 1 -(2,2,2-trifiuoroethyl)- lH-pyrazol-5-yl] methoxy} -D-phenylalanine

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(prop- 1 - yn-l-yl)thieno[2,3- ]pyrimidin-4-yl]-2-{[2-(morpholin-4-yl)pyrimidin-4-yl] methoxy} -D-phenylalanine

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(prop- 1 - yn-l-yl)thieno[2,3- ]pyrimidin-4-yl]-2-{[2-(2,2,2-trifluoroethoxy)pyrimidin-4-yl] methoxy} -D-phenylalanine

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(prop- 1 - yn-l-yl)thieno[2,3- ]pyrimidin-4-yl]-2-{[2-(2-methoxyphenyl)pyrimidin-4-yl] methoxy} -D-phenylalanine

- N-[5- {3-chloro-4-[2-(dimethylamino)ethoxy]-2-methylphenyl} -6-(prop- 1 -yn- 1 -yl) thieno[2,3-(i]pyrimidin-4-yl]-2- {[ 1 -(2,2,2-trifiuoroethyl)- lH-pyrazol-5-yl] methoxy} -D-phenylalanine

- N-[5- {3-chloro-4-[2-(dimethylamino)ethoxy]-2-methylphenyl} -6-(prop- 1 -yn- 1 -yl) thieno[2,3- ]pyrimidin-4-yl]-2-{[2-(morpholin-4-yl)pyrimidin-4-yl]methoxy}-D- phenylalanine - N-[5- {3-chloro-4-[2-(dimethylamino)ethoxy]-2-methylphenyl} -6-(prop- 1 -yn- 1 -yl) thieno[2,3- ]pyrimidin-4-yl]-2-{[2-(2,2,2-trinuoroethoxy)pyrimidin-4-yl] methoxy } -D-phenylalanine

- N-[5- {3-chloro-4-[2-(dimethylamino)ethoxy]-2-methylphenyl} -6-(prop- 1 -yn- 1 -yl) thieno[2,3-d]pyrimidin-4-yl]-2-{[2-(2-metho

phenylalanine

N-[5- {3-chloro-4-[2-(dimethylamino)ethoxy]-2-methylphenyl} -6-(4-fluorophenyl) thieno[2,3- ]pyrimidin-4-yl]-2-({2-[2-(2-methoxyethoxy)phenyl]pyrimidin-4-yl} methoxy)-D-phenylalanine

ethyl N-[(5Sa)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -

6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]-2- {[2-(2-methoxyphenyl) pyrimidin-4-yl]methoxy}-Z⁾-phenylalaninate

ethyl N-[(5Sa)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} - 6-(prop- 1 -yn- 1 -yl)thieno [2,3 - ]pyrimidin-4-yl] -2- { [2-(2-methoxyphenyl) pyrimidin-4-yl]methoxy}-Z⁾-phenylalaninate

ethyl N-[(5Sa)-5- {3-chloro-4-[2-(dimethylamino)ethoxy]-2-methylphenyl} -6-(prop- 1 -yn- 1 -yl)thieno [2,3 - ]pyrimidin-4-yl] -2- { [2-(2-methoxyphenyl)pyrimidin-4-yl] methoxy} -D-phenylalaninate

N-[5-{3,5-dichloro-2,6-dimethyl-4-[2-(4-methylpiperazin-l-yl)

ethoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]-2-{[2-(2- methoxyphenyl)pyrimidin-4-yl]methoxy} -D-phenylalanine

The invention relates also to a process for the preparation of compounds of formula (I), which process is characterised in that there is used as starting material the compound of formula (Il-a):

wherein Z represents bromine or iodine and A is as defined for formula (I) in which 1 is linked to the chlorine atom and 2 is linked to the Z group, which compound of formula (Il-a) is subjected to coupling with a compound of formula (III):

wherein R^, R₁₂, E and n are as defined for formula (I), and Alk represents a linear or branched (Ci-C₆)alkyl group, to yield the compound of formula (IV):

wherein R^, R₁₂, A, E and n are as defined for formula (I) and, Z and Alk is as defined before, compound of formula (IV) which is further subjected to coupling with compound of formula (V):

wherein R_{L S} R₂, R5, X and Y are as defined for formula (I), and RBI and RB₂ represent a hydrogen atom, a linear or branched (Ci-C₆) alkyl group, or R_Bi and RB₂ form with the oxygen carrying them an optionally methylated ring, to yield the compound of formula (VI):

wherein R_{l s} R₂, R₅, 5, R₁₂, X, Y, A, E and n are as defined for formula (I) and Alk is as defined before, the Alk-O-C(O)- ester function of which compound of formula (VI) is hydro lysed to yield the carboxylic acid, which may optionally be reacted with an alcohol of formula R₇'-OH or a chlorinated compound of formula R₇'-C1 wherein R₇' represents a linear or branched (Ci-Cs)alkyl group, a -CHR_aR_b group, an aryl group, a heteroaryl group, an arylalkyl(Ci-C₆) group, or a heteroarylalkyl(Ci-Ce) group, Ra and Rb are as defined for formula (I), to yield the compound of formula (I), which may be purified according to a conventional separation technique, which is converted, if desired, into its addition salts with a pharmaceutically acceptable acid or base and which is optionally separated into its isomers according to a conventional separation technique,

it being understood that at any moment considered appropriate during the course of the process described above, some groups (hydroxy, amino...) of the starting reagents or of the synthesis intermediates can be protected, subsequently deprotected and functionalized, as required by the synthesis.

In an other embodiment of the invention, compounds of formula (I) may be obtained using an alternative process, which process is characterised in that there is used as starting material the compound of formula (Il-b):

wherein A is as defined in formula (I) in which 1 is linked to the chlorine atom and 2 is linked to the iodine atom, which compound of formula (Il-b) is subjected to coupling with a compound of formula (V):

wherein R_{L S} R₂, R₅, X and Y are as defined for formula (I), and RBI and RB₂ represent a hydrogen atom, a linear or branched (Ci-C₆) alkyl group, or R_Bi and RB₂ form with the oxygen carrying them an optionally methylated ring, to yield the compound of formula (VII):

wherein R_{l s} R₂, R5, A, X and Y are as defined in formula (I), which compound of formula (VII) is further subjected to coupling with a compound of formula (III):

wherein R^, R12, E and n are as defined for formula (I), and Alk represents a linear or branched (Ci-Ce)alkyl group, to yield the compound of formula (VI) :

wherein R_{l s} R₂, R5, R5, R12, X, Y, A, E and n are as defined for formula (I) and Alk is as defined before, the Alk-O-C(O)- ester function of which compound of formula (VI) is hydro lysed to yield the carboxylic acid, which may optionally be reacted with an alcohol of formula Ry '-OH or a chlorinated compound of formula Ry'-Cl wherein R₇ ' represents a linear or branched (Ci-Cs)alkyl group, a -CHRaRb group, an aryl group, a heteroaryl group, an arylalkyl(Ci-C₆) group, or a heteroarylalkyl(Ci-Ce) group, Ra and Rb are as defined for formula (I), to yield the compound of formula (I), which may be purified according to a conventional separation technique, which is converted, if desired, into its addition salts with a pharmaceutically acceptable acid or base and which is optionally separated into its isomers according to a conventional separation technique, it being understood that at any moment considered appropriate during the course of the process described above, some groups (hydroxy, amino...) of the starting reagents or of the synthesis intermediates can be protected, subsequently deprotected and functionalized, as required by the synthesis. The compounds of formulae (Il-a), (Il-b), (III), (V), R₇'-OH and R₇'-C1 are either commercially available or can be obtained by the person skilled in the art using conventional chemical reactions described in the literature.

Pharmacological study of the compounds of the invention has shown that they have pro- apoptotic properties. The ability to reactivate the apoptotic process in cancerous cells is of major therapeutic interest in the treatment of cancers and of immune and auto-immune diseases.

More especially, the compounds according to the invention will be useful in the treatment of chemo- or radio -resistant cancers.

Among the cancer treatments envisaged there may be mentioned, without implying any limitation, treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemias, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer. The present invention relates also to pharmaceutical compositions comprising at least one compound of formula (I) in combination with one or more pharmaceutically acceptable excipients.

Among the pharmaceutical compositions according to the invention there may be mentioned more especially those that are suitable for oral, parenteral, nasal, per- or trans-cutaneous, rectal, perlingual, ocular or respiratory administration, especially tablets or dragees, sublingual tablets, sachets, paquets, capsules, glossettes, lozenges, suppositories, creams, ointments, dermal gels, and drinkable or injectable ampoules.

The dosage varies according to the sex, age and weight of the patient, the administration route, the nature of the therapeutic indication, or of any associated treatments, and ranges from 0.01 mg to 1 g per 24 hours in one or more administrations.

Furthermore, the present invention relates also to the combination of a compound of formula (I) with an anticancer agent selected from genotoxic agents, mitotic poisons, antimetabolites, proteasome inhibitors, kinase inhibitors and antibodies, and also to pharmaceutical compositions comprising that type of combination and their use in the manufacture of medicaments for use in the treatment of cancer.

Advantageously, the present invention relates to the combination of a compound of formula (I) with an EGFR inhibitor, and also to pharmaceutical compositions comprising that type of combination.

In another embodiment, the present invention relates to the combination of a compound of formula (I) with a mTOR/PBK inhibitor, and also to pharmaceutical compositions comprising that type of combination.

In a preferred embodiment, the present invention relates to the combination of a compound of formula (I) with a MEK inhibitor, and also to pharmaceutical compositions comprising that type of combination.

Preferably, the present invention relates to the combination of a compound of formula (I) with a HER2 inhibitor, and also to pharmaceutical compositions comprising that type of combination.

Advantageously, the present invention relates to the combination of a compound of formula (I) with a RAF inhibitor, and also to pharmaceutical compositions comprising that type of combination.

In another embodiment, the present invention relates to the combination of a compound of formula (I) with a EGFR/HER2 inhibitor, and also to pharmaceutical compositions comprising that type of combination. In a preferred embodiment, the present invention relates to the combination of a compound of formula (I) with a taxane, and also to pharmaceutical compositions comprising that type of combination.

In another embodiment, the present invention relates to the combination of a compound of formula (I) with a proteasome inhibitor, an immunomodulator or an alkylating agent, and also to pharmaceutical compositions comprising that type of combination.

The combination of a compound of formula (I) with an anticancer agent may be administered simultaneously or sequentially. The administration route is preferably the oral route, and the corresponding pharmaceutical compositions may allow the instantaneous or delayed release of the active ingredients. The compounds of the combination may moreover be administered in the form of two separate pharmaceutical compositions, each containing one of the active ingredients, or in the form of a single pharmaceutical composition, in which the active ingredients are in admixture.

The compounds of the invention may also be used in combination with radiotherapy in the treatment of cancer.

Finally, the compounds of the invention may be linked to monoclonal antibodies or fragments thereof or linked to scaffold proteins that can be related or not to monoclonal antibodies.

Antibody fragments must be understood as fragments of Fv, scFv, Fab, F(ab')2, F(ab'), scFv-Fc type or diabodies, which generally have the same specificity of binding as the antibody from which they are descended. According to the present invention, antibody fragments of the invention can be obtained starting from antibodies by methods such as digestion by enzymes, such as pepsin or papain, and/or by cleavage of the disulfide bridges by chemical reduction. In another manner, the antibody fragments comprised in the present invention can be obtained by techniques of genetic recombination likewise well known to the person skilled in the art or else by peptide synthesis by means of, for example, automatic peptide synthesizers such as those supplied by the company Applied Biosystems, etc. Scaffold proteins that can be related or not to monoclonal antibodies are understood to mean a protein that contains or not an immunoglobulin fold and that yields a binding capacity similar to a monoclonal antibody. The man skilled in the art knows how to select the protein scaffold. More particularly, it is known that, to be selected, such a scaffold should display several features as follow (Skerra A., J. Mol. Recogn. 2000, 13, 167-187): phylogenetically good conservation, robust architecture with a well-known three- dimensional molecular organization (such as, for example, crystallography or NMR), small size, no or only a low degree of post-translational modifications, easy to produce, express and purify. Such a protein scaffold can be, but without limitation, a structure selected from the group consisting in fibronectin and preferentially the tenth fibronectin type III domain (FNfnlO), lipocalin, anticalin (Skerra A., J. Biotechnol. 2001, 74(4):257-75), the protein Z derivative from the domain B of staphylococcal protein A, thioredoxin A or any protein with a repeated domain such as an "ankyrin repeat" (Kohl et al., PNAS 2003, 100(4), 1700-1705), "armadillo repeat", "leucine-rich repeat" or "tetratricopeptide repeat". There could also be mentioned a scaffold derivative from toxins (such as, for example, scorpion, insect, plant or mollusc toxins) or protein inhibitors of neuronal nitric oxide synthase (PIN).

The following Preparations and Examples illustrate the invention but do not limit it in any way. General Procedures

All reagents obtained from commercial sources were used without further purification. Anhydrous solvents were obtained from commercial sources and used without further drying.

Flash chromatography was performed on ISCO CombiFlash Rf 200i with pre-packed silica-gel cartridges (RediSe/?^®i?_f Gold High Performance).

Thin layer chromatography was conducted with 5 x 10 cm plates coated with Merck Type 60 F254 silica-gel. Microwave heating was performed in an Anton Parr MonoWave or CEM Discover® instrument.

Preparative HPLC purifications were performed on an Armen Spot Liquid Chromatography system with a Gemini-NX^® 10 μΜ CI 8, 250 mm x 50 mm i.d. column running at a flow rate of 118 mL min^"1 with UV diode array detection (210 - 400 nm) using 25 mM aqueous NH₄HCO₃ solution and MeCN as eluents unless specified otherwise.

Analytical LC-MS: The compounds of the present invention were characterized by high performance liquid chromatography-mass spectroscopy (HPLC-MS) on Agilent HP 1200 with Agilent 6140 quadrupole LC/MS, operating in positive or negative ion electrospray ionisation mode. Molecular weight scan range is 100 to 1350. Parallel UV detection was done at 210 nm and 254 nm. Samples were supplied as a 1 mM solution in ACN, or in THF/H₂0 (1 : 1) with 5 loop injection. LCMS analyses were performed on two instruments, one of which was operated with basic, and the other with acidic eluents.

Basic LCMS: Gemini-NX, 3 μιη, C18, 50 mm x 3.00 mm i.d. column at 23 °C, at a flow rate of 1 mL min^"1 using 5 mM ammonium bicarbonate (Solvent A) and acetonitrile (Solvent B) with a gradient starting from 100% Solvent A and finishing at 100% Solvent B over various/certain duration of time.

Acidic LCMS: ZORBAX Eclipse XDB-C18, 1.8 μιη, 50 mm x 4.6 mm i.d. column at 40 °C, at a flow rate of 1 mL min^"1 using 0.02% v/v aqueous formic acid (Solvent A) and 0.02% v/v formic acid in acetonitrile (Solvent B) with a gradient starting from 100% Solvent A and finishing at 100% Solvent B over various/certain duration of time.

¹H-NMPv measurements were performed on Bruker Avance III 500 MHz spectrometer and Bruker Avance III 400 MHz spectrometer, using DMSO-d₆ or CDCI₃ as solvent. 1H NMR data is in the form of delta values, given in part per million (ppm), using the residual peak of the solvent (2.50 ppm for DMSO-d₆ and 7.26 ppm for CDCI₃) as internal standard. Splitting patterns are designated as: s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), m (multiplet), br s (broad singlet), dd (doublet of doublets), td (triplet of doublets), dt (doublet of triplets), ddd (doublet of doublet of doublets).

Combination gas chromatography and low resolution mass spectrometry were performed on Agilent 6850 gas chromatograph and Agilent 5975C mass spectrometer using 15 m x 0.25 mm column with 0.25 μιη HP-5MS coating and helium as carrier gas. Ion source: EI⁺, 70 eV, 230°C, quadrupole: 150°C, interface: 300°C.

HRMS were determined on a Shimadzu IT-TOF, ion source temperature 200°C, ESI +/-, ionization voltage: (+-)4.5 kV. Mass resolution min. 10000.

Elementary analyses were performed on a Thermo Flash EA 1112 Elemental Analyzer.

List of abbreviations

Abbreviation Name

2-Me-THF 2-methyl-tetrahydrofurane

Ac acetyl

Ad adamantyl

aq. aqueous

AtaPhos bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)

dichloropalladium(II)

BuPAd2 butyl-di(adamant- 1 -yl)phosphane

cc. concentrated

DAST diethylaminosulfur trifluoride

dba dibenzylideneacetone

DCM methylene chloride

DIPA diisopropylamine

DMA dimethylacetamide

DME 1,2-dimethoxyethane

DMF dimethylformamide DMSO dimethyl sulfoxide

dppf 1 , 1 '-bis(diphenylphosphino)ferrocene

eq. equivalent

Et ethyl

HILIC hydrophilic interaction liquid chromatography

HMDS hexamethyldisilazane

'Pr isopropyl

LDA lithium diisopropylamide

Me methyl

MeCN acetonitrile

MTBE methyl tert-butyl ether

MW microwave

NBS N-bromosuccinimide

nBu n-butyl

NCS N-chlorosuccinimide

Ph phenyl

P¾u₃ x HBF₄ tri-tert-butylphosphonium tetrafluoroborate

PCy₃ x HBF₄ tricyclohexylphosphonium tetrafluoroborate

Q-Phos 1 ,2,3 ,4,5-pentaphenyl- 1 '-(di-tert-butylphosphino)ferrocene r.t. room temperature

TBAF tetrabutyl ammonium fluoride

'Bu tert-butyl

TEA triethylamine

TFA trifluoroacetic acid

THF tetrahydrofurane

TIPSC1 triisopropylsilyl chloride

XantPhos 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene

General Procedure la:

1 eq. of the appropriate 4-chloro-thieno[2,3-d]pyrimidine derivative, 2 eq. of the appropriate amino acid derivative and 2 eq. K₂C0₃ were mixed in feuOH: water 4: 1 (4 mL/mmol) and stirred at reflux temperature (or in MW reactor at 100 °C if it is needed) until no further conversion was observed. The mixture was then diluted with water, acidified with 1M HC1 solution (to pH = 1, or to pH = 6 in the presence of a basic amino group) and extracted with EtOAc, or the precipitate formed after acidification was isolated by filtration. In the case of extractive purification the combined organic phases were washed with brine, dried over MgS0₄, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via preparative reversed phase chromatography using 25 mM aqueous NH₄HCO₃ and acetonitrile as eluents unless otherwise stated. General Procedure lb:

1 eq. of the appropriate 4-chloro-thieno[2,3-d]pyrimidine derivative, 2 eq. of the appropriate amino acid derivative and 3 eq. K₂CO₃ were mixed in DMSO (10 mL/mmol) and stirred at 50 °C until no further conversion was observed. The mixture was then diluted with water, acidified with 1M HC1 solution (to pH = 1, or to pH = 6 in the presence of a basic amino group) and extracted with EtOAc, or the precipitate formed after acidification was isolated by filtration. In the case of extractive purification the combined organic phases were washed with brine, dried over MgS0₄, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via preparative reversed phase chromatography using 25 mM aqueous NH₄HCO₃ and acetonitrile as eluents unless otherwise stated.

General Procedure Ic:

1 eq. of the appropriate 4-chloro-thieno[2,3-d]pyrimidine derivative, 1.5 eq. of the appropriate amino acid derivative and 1.5 eq. CS₂CO₃ were mixed in DMSO (6 mL/mmol) and stirred at 70 °C until no further conversion was observed. The mixture was then diluted with water, acidified with 1M HC1 solution (to pH = 1, or to pH = 6 in the presence of a basic amino group) and extracted with EtOAc, or the precipitate formed after acidification was isolated by filtration. In the case of extractive purification the combined organic phases were washed with brine, dried over MgS0₄, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via preparative reversed phase chromatography using 25 mM aqueous NH₄HCO₃ solution and acetonitrile as eluents unless otherwise stated.

General Procedure Ila:

1 eq. of the appropriate 5- (or 6)-iodo-thieno[2,3-d]pyrimidine derivative and 3 eq. of the appropriate boronic acid derivative were dissolved in DME (15 mL/mmol), then 5 eq. K₂CO₃, 0.2 eq. Pd₂dba₃, 0.4 eq. "BuPAd₂ and water (5 mL/mmol) were added and the mixture was stirred at 60 °C in MW reactor until no further conversion was observed. The volatiles were then removed in vacuo and the residue was purified via preparative reversed phase chromatography, using 25 mM aqueous NH₄HCO₃ solution and acetonitrile as eluents unless otherwise stated.

General Procedure lib:

1 eq. of the appropriate 5-iodo-thieno[2,3-d]pyrimidine derivative and 5 eq. of the appropriate boronic acid derivative were dissolved in 2-Me-THF (8 mL/mmol), then 5 eq. K₂C0₃, 0.1 eq. Q-Phos and 0.05 eq. Pd₂dba₃ were added and the mixture was stirred at 80 °C until no further conversion was observed. The mixture was filtered through a pad of Celite, the filtrate was concentrated under reduced pressure. The crude product was purified via flash chromatography using heptane and EtOAc as eluents unless otherwise stated.

General Procedure lie:

1 eq. of the appropriate 5-(or 6)-iodo-thieno[2,3-d]pyrimidine derivative and 1.1 eq. of the appropriate boronic acid derivative were dissolved in 2-Me-THF (8 mL/mmol), then 1.1 eq. Ag₂C0₃ and 0.1 eq. Pd(PPh₃)₄ were added and the mixture was stirred at 100 °C until no further conversion was observed. The mixture was filtered through a pad of Celite, the filtrate was concentrated under reduced pressure. The crude product was purified via flash chromatography using heptane and EtOAc as eluents unless otherwise stated.

General Procedure lid:

1 eq. of the appropriate 5-iodo-thieno[2,3-d]pyrimidine derivative and 3 eq. of the appropriate boronic acid derivative were dissolved in dioxane: water 2: 1 mixture (10 mL/mmol), then 2 eq. Cs₂C0₃, 5 mol% Pd(OAc)₂ and 0.2 eq. PⁱBu₃xHBF₄ were added and the mixture was stirred at 120 °C in MW reactor until no further conversion was observed. The mixture was neutralized with 1M HC1 solution and extracted with DCM. The combined organic phases were dried over Na₂S0₄, filtered and the filtrate was concentrated in vacuo. The crude product was purified via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents unless otherwise stated.

General Procedure Ilia:

1 eq. of the appropriate 6-iodo-thieno[2,3-d]pyrimidine derivative and 4 eq. of the appropriate boronic acid derivative were dissolved in dioxane: water 4: 1 mixture (10 mL/mmol), then 2.2 eq. Cs₂C0₃ and 0.1 eq. Pd(dppf)Cl₂ were added and the mixture was stirred at 40°C until no further conversion was observed. The mixture was then diluted with water and extracted with DCM. The combined organic phases were washed with water, dried over MgS0₄, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified using preparative reversed phase chromatography using 25 mM aqueous NH₄HC0₃ solution and acetonitrile as eluents unless otherwise stated.

General Procedure Mb:

1 eq. of the appropriate 6-iodo-thieno[2,3-d]pyrimidine derivative and 3 eq. of the appropriate boronic acid derivative were dissolved in THF: water 1 : 1 mixture (10 mL/mmol), then 3 eq. Cs₂C0₃ and 0.1 eq. AtaPhos were added and the mixture was stirred at 100 °C in MW reactor until no further conversion was observed. The volatiles were evaporated under reduced pressure, and the residue was purified via preparative reversed phase chromatography using 25 mM aqueous NH₄HC0₃ solution and acetonitrile as eluents unless otherwise stated. General Procedure IVa:

1 eq. Preparation 4i was dissolved in dry THF (5 mL/mmol) and cooled to -78 °C. LDA solution (1.2 eq. 2M in THF, heptane, EtPh) was added dropwise under Argon and the mixture was stirred for 1.5 hours. Then 1.2 eq. of the appropriate electrophilic-reagent either in solution (dissolved in 3mL/mmol dry THF), or neat was added at -78 °C and the mixture was allowed to warm up to r.t. It was stirred until no further conversion was observed. The reaction mixture was quenched by the careful addition of cc. NH₄C1 solution. The mixture was extracted with MTBE, the organic layer was washed with brine, dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via flash chromatography using heptane and EtOAc as eluents unless otherwise stated.

General procedure Va:

1 eq. of the appropriate acetal was stirred in 2M HC1 solution (3 mL/mmol) at 60 °C until no further conversion was observed. The reaction mixture was cooled to 0 °C, then 5.7 eq. NaOH was added portionwise. The pH was adjusted to 8 using 10% K₂CO₃ solution, then

2 eq. sodium borohydride was added portionwise keeping the temperature below 5 °C. After the addition the mixture was stirred at 0 °C until no further conversion was observed. The mixture was extracted with EtOAc, the combined organic phases were dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via flash chromatography using heptane and EtOAc as eluents unless otherwise stated.

General Procedure Vb:

Step A

To a solution of 1 eq. of the appropriate N-alkyl pyrazole in dry THF (1.5 mL/mmol), 1.1 eq. "BuLi was added dropwise at -78 °C. The mixture was stirred for 30 minutes and then allowed to warm up to 0 °C where it was stirred for 30 minutes, then cooled back to -78 °C again. 1.1 eq. DMF was added dropwise, then the reaction mixture was allowed to reach r.t. and it was stirred overnight. The mixture was quenched with cc. NH₄C1 solution. The phases were separated and the aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. The residue was used in the next step without further purification.

Step B To a solution of 1 eq. of the appropriate crude aldehyde in EtOH (0.5 mL/mmol), 1.3 eq. sodium boro hydride was added portionwise at -15 °C and the reaction mixture was stirred at r.t. until no further conversion was observed. The mixture was poured onto crushed ice and stirred for 16 hours. The precipitate was filtered off, and the filtrate was concentrated under reduced pressure. The oily phase was separated, and the aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. The product was further purified by flash chromatography if necessary.

General procedure Vc:

To the mixture of 1.2 eq. of the appropriate amidine salt and 1 eq. Preparation 8a in dry methanol (0.5 mL/mmol) 1.2 eq. sodium methoxide was added portionwise and the mixture was stirred at 75 °C until no further conversion was observed. The reaction mixture was cooled and concentrated under reduced pressure. Water was added to the residue, and it was extracted with DCM. The combined organic layers were dried over MgS0₄, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via flash chromatography using heptane and EtOAc as eluents unless otherwise stated.

General Procedure Vd:

To the mixture of 1.2 eq. of the appropriate hydrazine or hydrazine hydrochloride and 1 eq. Preparation 8a in dry methanol (0.5 mL/mmol) 1.2 eq. sodium methoxide was added portionwise and the mixture was stirred at 75 °C until no further conversion was observed. The reaction mixture was cooled and concentrated under reduced pressure. Water was added to the residue, and it was extracted with DCM. The combined organic phases were dried over MgS0₄, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via flash chromatography using heptane and EtOAc as eluents unless otherwise stated.

General procedure Ve:

1 eq. of the appropriate acetal was stirred with 1M HC1 solution (3 mL/mmol) at 50 °C until no further conversion was observed. The reaction mixture was cooled to 0 °C, then 2.85 eq. solid NaOH was added portionwise. The pH was adjusted to 8 using 10 % K₂CO₃ solution, then 2 eq. sodium borohydride was added portionwise keeping the temperature below 5 °C and stirred at 0 °C until no further conversion was observed. The mixture was extracted with EtOAc, the combined organic phases were dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via flash chromatography using heptane and EtOAc as eluents unless otherwise stated.

General Procedure VI:

1 eq. of the appropriate phenol derivative, 2 eq. of the appropriate alcohol derivative, and 3 eq. PPh₃ were dissolved in dry toluene (7 mL/mmol) under N₂ atmosphere, then 3 eq. di-tert-butyl azodicarboxylate was added at r.t. Then the mixture was stirred at 50 °C until no further conversion was observed. The volatiles were removed in vacuo and the residue was purified via flash chromatography using heptane and EtOAc (and MeOH if needed) as eluents. If necessary, the product was further purified via preparative reversed phase chromatography using 25 mM aqueous NH₄HC0₃ solution and acetonitrile as eluents unless otherwise stated.

General Procedure VII:

1 eq. of the appropriate ester derivative was dissolved in THF (15 mL/mmol) then 10 eq. LiOHxH₂0 and water (15 mL/mmol) were added. The mixture was stirred at r.t. (or at 60 °C if needed) until no further conversion was observed. The pH was adjusted to 6 with 1M HC1 solution, then the mixture was diluted with brine, extracted with DCM or EtOAc. The organic layer was dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via preparative reversed phase chromatography using 25 mM aqueous NH₄HC0₃ solution and acetonitrile as eluents unless otherwise stated. General Procedure VIII:

1 eq. of the appropriate indole derivative and 2 eq. of the appropriate alcohol derivative were dissolved in dry toluene (8 mL/mmol) under N₂ atmosphere, and the mixture was cooled to 0 °C, then 2 eq. 2-(tributyl-phosphanylidene)acetonitrile was added. Then the mixture was heated to 100 °C and stirred until no further conversion was observed. The volatiles were removed in vacuo, then water (4 mL/mmol) 2M NaOH solution (1 mL/mmol) were added and the mixture was stirred until no further conversion was observed. The mixture was then acidified with 1M HC1 solution to pH = 6 and extracted with DCM. The combined organic phases were dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via preparative reversed phase chromatography using aqueous 40 mM NH₄OAc (pH = 4, adjusted with AcOH) solution and acetonitrile as eluents unless otherwise stated.

General procedure IXa:

Step A

1 eq. Preparation 9b was dissolved in dry toluene (8 mL/mmol), then 1.18 eq. PPh₃, 1.1 eq. of the appropriate alcohol derivative and 1.18 eq. diethylazodicarboxylate (40 % solution in toluene) were added at r.t. The mixture was stirred at r.t. until no further conversion was observed. The resulting precipitate was filtered off and the filtrate was washed sequentially with 10 % KHS0₄ solution, water, sat. NaHC0₃ solution and water again. The organic phase was dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. The residue was agitated with diethyl-ether (5 mL/mmol), the insoluble material was filtered off and the filtrate was concentrated under reduced pressure to obtain the crude product.

Step B

The product of Step A was treated with 10 eq. HC1 solution (4.9M in MeOH) and it was stirred at r.t. until no further conversion was observed. Then the mixture was concentrated under reduced pressure. The residue was partitioned between cold EtOAc and ice-cold water, the phases were separated and the organic phase was extracted with ice-cold 5 % KHS0₄ solution. The combined aqueous phase was basified with solid Na₂C0₃, and the product was extracted with EtOAc. The organic phase was dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure to obtain the methyl ester of the title product.

Step C 1 eq. of the methyl ester obtained in Step B was dissolved in MeOH (9 mL/mmol), then 1.05 eq. NaOH and water (1 mL/mmol) were added and the mixture was stirred at r.t. until no further conversion was observed. Methanol was removed under reduced pressure and the mixture was neutralized using 1M HC1 solution, then it was extracted with DCM. The organic phase was dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure to obtain the O-alkylated amino acid derivative which was used without further purification.

General procedure IXb:

Step A

1 eq. Preparation 9b was dissolved in dry DMF (10 mL/mmol) and 4 eq. K₂C0₃ and 2 eq. of the appropriate alkylating agent was added at r.t. The mixture was stirred at 50 °C until no further conversion was observed. The mixture was diluted with water, then extracted with DCM. The organic phase was dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. The crude material was purified via flash chromatography using DCM and methanol as eluents unless otherwise stated.

Step B and Step C are the same as described in General procedure IXa.

Preparation la: 5-Bromo-4-chloro-6-iodo-thieno [2,3-i j yrimidine

Step A: 6-Iodo-3H-thienof2, 3-dJpyrimidin-4-one

A 2 L round bottomed flask equipped with mechanical stirrer, thermometer and reflux condenser was charged with the solution of 433 mL acetic acid, 13 mL sulfuric acid and 87 mL water. 69.3 g 3H-thieno[2,3-d]pyrimidin-4-one (0.46 mol), 51.9 g periodic acid (0.23 mol) and 104 g iodine (0.41 mol) were added to the stirred solution, which was heated to 60 °C for 1 hour. The resulting suspension was cooled to r.t., filtered off, washed with a mixture of acetic acid and water (5: 1) and then with diethyl ether. The resulting beige crystalline solid was air dried. 1H NMR (500 MHz, DMSO-d₆) δ: 12.57 (br s, 1H), 8.09 (s, 1H), 7.65 (s, 1H) Step B: 4-Chloro-6-iodo-thieno[2, 3-dJpyrimidine

A I L round bottomed flask equipped with mechanical stirrer, thermometer, reflux condenser and a CaCl₂-tube was charged with 113 mL phosphorous oxychloride and 35 mL N,N-dimethylaniline (0.29 mol). 75.54 g 6-iodo-3H-thieno[2,3-d]pyrimidin-4-one (0.27 mol) was added to the mixture in portions during 5 minutes. The reaction mixture was stirred at 105 °C for 1 hour. The resulting suspension was cooled to 10 °C, filtered and washed with hexane. The crude product was added to ice water and stirred for 10 minutes, filtered off, washed with cold water, diethyl ether and air dried. Beige crystalline solid was obtained. 1H NMR (400 MHz, DMSO-de) δ: 8.89 (s, 1H), 7.98 (s, 1H) Step C: Preparation la

A 2 L round bottomed flask equipped with mechanical stirrer, thermometer and a bubbler was charged with 600 mL acetonitrile. 84.9 g 4-chloro-6-iodo-thieno[2,3-<i]pyrimidine (0.29 mol), 50.9 g NBS (0.29 mol) and 8.5 mL tetrafluoroboric acid diethyl ether complex were added. The reaction mixture was stirred at r.t. for 16 hours. Further 22.9 g (0.12 mol) NBS was added to the mixture in three portions. After cooling the suspension to 0 °C and stirring for further 1 hour the precipitate was filtered off, washed with acetonitrile and air dried. The product was obtained as beige crystalline solid. 1H NMR (500 MHz, DMSO-d₆) δ: 8.88 (s, 1H)

Preparation lb: 4-Chloro-5,6-diiodo-thieno[2,3-d]pyrimidine Step A: 5, 6-Diiodo-3H-thienof 2, 3-dJpyrimidin-4-one

To a well stirred slurry of 61.3 g 3H-thieno[2,3-d]pyrimidin-4-one (396 mmol), 92.4 g periodic acid (405 mmol), 1 L acetic acid, 200 mL water, 6 mL cc. sulfuric acid, and 203 g iodine (799 mmol) were added. The reaction mixture was heated to 110 °C and stirred for 3 hours. The suspension was cooled to r.t. then 940 mL diethyl ether was added and the mixture was stirred further at 10 °C for 30 minutes. The precipitate was filtered off, washed with a 2: 1 mixture of diethyl ether and ethanol (100 mL), finally with diethyl ether (3 x 250 mL), then it was air dried to give the product as a tan powder. 1H NMR (500 MHz, DMSO-dg) δ: 12.60 (br s, 1H), 8.13 (s, 1H) Step B: Preparation lb

To a well stirred slurry of 180 g 5,6-diiodo-3H-thieno[2,3-<i]pyrimidin-4-one (445 mmol) in 2.5 L phosphorous oxychloride 64 mL N,N-dimethylaniline was added. The reaction mixture was heated to 105 °C and stirred for 1.5 hours. The resulting suspension was cooled to r.t. and 1.5 L hexane was added and it was stirred for an additional 20 minutes. The precipitate was filtered off, washed with hexane (3 x 500 mL) and water (3 x 100 mL) then air dried to give the product as a grey crystalline solid. 1H NMR (400 MHz, DMSO- d₆) δ: 8.88 (s, 1H)

Preparation lc: 4-Chloro-5-iodo-thieno [2,3-i/] yrimidine

52.8 g Preparation lb (125 mmol) was dissolved in 400 mL dry THF and cooled to 0 °C. 100 mL feuMgCl (200 mmol, 2M in diethyl ether) was added over 15 minutes. Then 50 mL water was added and the solution was decanted and concentrated under reduced pressure. The crude product was sonicated in a mixture of acetonitrile and water (3: 1) and then collected by filtration. 1H NMR (400 MHz, DMSO-d₆) δ: 8.95 (s, 1H), 8.45 (s, 1H) Preparation 2a: 4-Chloro-6-ethyl-5-iodo-thieno [2,3-i ] pyrimidine

Step A: 6-Ethyl-3H-thienof2, 3-dJpyrimidin-4-one

The mixture of 701 g 2-amino-5-ethyl-thiophene-3-carboxylic acid ethyl ester (3.52 mol) and 2200 mL formamide was heated to 200 °C and the lower boiling point solvents were distilled off. After 2 hours further 250 mL formamide was added and the mixture was stirred at the same temperature for another hour then at r.t. for 16 hours. The resulting mixture was poured into 7.5 L water and the precipitate was filtered off, washed with 1.5 L toluene and 3 L water then air dried to give the product as a brown crystalline solid. 1H NMR (500 MHz, DMSO-d₆) δ: 12.40 (br s, 1H), 8.05 (s, 1H), 7.11 (t, 1H), 2.85 (qd, 2H), 1.27 (t, 3H) Step B: 6-Ethyl-5-iodo-3H-thienof2,3-dJpyrimidin-4-one

The mixture of 301 g 6-ethyl-3H-thieno[2,3-d]pyrimidin-4-one (1.67 mol), 847 g iodine (3.34 mol), 1040 g silver sulfate (3.34 mol) and 1.7 L ethanol was stirred at r.t. for 3 days. The resulting precipitate was filtered off and washed with ethanol (3 x 400 mL). The product was eluted from the filter cake with the following procedure: the filter cake was stirred with 800 mL DMF at 50 °C for 1 hour then the suspension was filtered. This sequence was repeated 6 times. The combined organic layer was evaporated to dryness to give the product as a tan crystalline solid.

Step C: Preparation 2a

The mixture of stirred 880 mL phosphorous oxychloride and 102 mL N,N-dimethylaniline was heated to 95 °C and 220 g 6-ethyl-5-iodo-3H-thieno[2,3-<i]pyrimidin-4-one (0.719 mol) was added quickly at the same temperature and then stirred for 15 minutes. The reaction mixture was cooled to 80 °C and poured on a stirred mixture of water (1 L), crushed ice (2 kg) and DCM (700 mL). The resulting mixture was stirred for further 30 minutes while the temperature was kept below 20 °C. The phases were separated, the inorganic layer was extracted with DCM (100 mL) and the organic layer was washed with water (100 mL). The combined organic layer was dried over MgS0₄, filtered and the filtrate was concentrated under reduced pressure to give the product as a tan crystalline solid. 1H NMR (400 MHz, DMSO-d₆) δ: 8.79 (s, 1H), 3.02 (q, 2H), 1.39 (t, 3H)

Preparation 2b: 5-Bromo-4-chloro-6-(4-fluor ophenyl)thieno [2,3-i ] pyrimidine

75.08 g Preparation la (200 mmol), 53.63 g 2-(4-fhiorophenyl)-4,4,5,5-tetramethyl- 1,3,2- dioxaborolane (240 mmol), 130 g cesium carbonate (400 mmol), 2.245 g Pd(OAc)₂ (10 mmol) and 8.50 g 'BuX-Phos (20 mmol) were placed in a 2 L flask. 600 mL THF and 200 mL water were added, and then stirred overnight at 70 °C under argon atmosphere. THF was evaporated, and then the product was collected by filtration. The crude product was sonicated in 250 mL acetonitrile and filtered again. Then Preparation 2b was crystalized from EtOH / THF (2: 1). 1H NMR (400 MHz, DMSO-d₆) δ: 9.02 (s, 1H), 7.80- 7.77 (m, 2H), 7.47-7.43 (m, 2H)

Preparation 2c: 4-Chloro-5-iodo-6-(prop-l-ynyl)-thieno[2,3-i ]pyrimidine

42.24 g Preparation lb (100 mmol), 3.509 g Pd(PPh₃)₂Cl (5 mmol) and 1.904 g Cul (10 mmol) were dissolved in 400 mL DIPA, then propyne was bubbled through the reaction mixture, which was stirred at r.t. until no further conversion was observed. The volatiles were evaporated under reduced pressure and the crude product was purified via flash chromatography using heptane / EtOAc as eluents. 1H NMR (400 MHz, DMSO-d₆) δ: 8.92 (s, 1H), 2.25 (s, 3H)

Preparation 2d: 4-Chloro-5-iodo-6-isopropyl-thieno [2,3-d\ yrimidine Step A: 6-Isopropyl-5-iodo-3H-thienof2,3-dJpyrimidin-4-one

The mixture of 2.858 g (14.7 mmol) 6-isopropyl-3H-thieno[2,3-<i]pyrimidin-4-one, 7.468 g (29.4 mmol) iodine, 9.175 g (29.4 mmol) silver sulfate, and 55 mL ethanol was stirred at r.t. for 3 days. The mixture was diluted with Et₂0, the resulting precipitate was filtered off and used without further purification.

1H NMR (400 MHz, DMSO-d₆) δ: 12.49 (br s, 1H), 8.1 1 (s, 1H), 3.35 (m, 1H, overlapped by H₂0 signal), 1.28 (d, 6H)

MS (M-H): 319.0

Step B: Preparation 2d

The mixture of 15 mL (161 mmol) phosphorous oxychloride and 1.9 mL (14.7 mmol) N,N-dimethylaniline was heated to 95°C and 25.9 g (14.7 mmol) 6-isopropyl-5-iodo-3H- thieno[2,3-d]pyrimidin-4-one (0.719 mol) was added quickly and then stirred for further 15 minutes at this temperature. The reaction mixture was cooled to 80 °C and poured into a stirred mixture of icy water (300 g) and EtOAc (200 mL). The resulting mixture was stirred for further 30 minutes while the temperature was kept below 20 °C. The phases were separated, the inorganic layer was extracted with EtOAc (100 mL) and the organic layer was washed with water and NaHC0₃ solution. The combined organic layer was dried over MgSC"4, filtered and the filtrate was concentrated under reduced pressure and purified via flash chromatography using heptane and EtOAC as eluents to give the title product. 1H NMR (400 MHz, CDC1₃) δ: 8.78 (s, 1H), 3.63 (septet, 1H), 1.41 (d, 6H)

MS (M+H): 339.0

Preparation 3a: (2R)-2- [(6-ethyl-5-iodo-thieno [2,3-i ] pyrimidin-4-yl)amino] -3-phenyl- propanoic acid Using General Procedure la and Preparation 2a as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and D-phenylalanine as the appropriate amino acid derivative, Preparation 3a was obtained.

1H NMR (500 MHz, DMSO-d₆) δ: 8.44 (s, 1H), 7.45 (d, 1H), 7.30-7.20 (m, 5H), 5.07 (m, 1H), 3.35 (dd, 1H), 3.16 (dd, 1H), 2.82 (q, 2H), 1.22 (t, 3H)

HPvMS calculated for Ci₇Hi₆IN₃0₂S: 453.0008; found: 454.0064 (M+H)

Preparation 4a: 4-chloro-5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl] -6-iodo-thieno [2,3- \ pyrimidine

Step A: 4-chloro-5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy]pheny

[2, 3 '-dj ¹ pyrimidine

Using General Procedure Ila and Preparation lc as the appropriate 5-iodo-thieno[2,3-<i] pyrimidine derivative and Preparation B4 as the appropriate boronic acid derivative, and purifying the product via flash chromatography using DCM and MeOH as eluents gave 4-chloro-5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy]phenyl]thieno[2,3-(i] pyrimidine. 1H NMR (400 MHz, DMSO-d₆) δ: 8.98 (s, 1H), 7.97 (s, 1H), 7.22 (d, 1H), 7.09 (s, 1H), 4.25-4.16 (m, 2H), 2.76 (t, 2H), 2.54 (br s, 4H), 2.32 (br s, 4H), 2.14 (s, 3H), 2.06 (s, 3H)

Step B: Preparation 4a

10.935 g 4-chloro-5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl] thieno[2,3-d]pyrimidine (25 mmol) was dissolved in 250 mL dry THF and cooled to -78 °C. 25 mL LDA solution (50 mmol, 2M in THF, heptane, ethyl benzene) was added drop wise under Argon atmosphere and the mixture was stirred for 15 minutes. Then 12.69 g (50 mmol) iodine was added at -78°C and the mixture was allowed to warm up to r.t. Then the mixture was diluted with EtOAc and was washed with NH₄C1 solution then with Na₂S₂0₃ solution, dried over Na₂S0₄, filtered and concentrated under reduced pressure. The crude product was purified via flash chromatography using DCM and MeOH as eluents to obtain Preparation 4a. 1H NMR (500 MHz, DMSO-d₆) δ: 8.93 (s, 1H), 7.15 (d, 1H), 7.13 (d, 1H), 4.22 (t, 2H), 2.77 (t, 2H), 2.56 (br s, 4H), 2.34 (br s, 4H), 2.16 (s, 3H), 2.00 (s, 3H) Preparation 4b: 4-chloro-5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl] -6-(2-furyl)thieno [2,3-i/] pyrimidine

Using General Procedure Ila and Preparation 4a as the appropriate 6-iodo-thieno[2,3-<i] pyrimidine derivative and 2-(2-furyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane as the appropriate boronic acid derivative, Preparation 4b was obtained. MS: (M+H) = 503.0

Preparation 4c: 4-chloro-5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl] -6-(5-fluoro-2-furyl)thieno [2,3-i/] pyrimidine

Using General Procedure Ilia and Preparation 4a as the appropriate 6-iodo-thieno[2,3-<i] pyrimidine derivative and 2-(5-fluoro-2-furyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane as the appropriate boronic acid derivative, Preparation 4c was obtained.

1H NMR (500 MHz, DMSO-d₆) δ: 8.93 (s, 1H), 7.24 (d, 1H), 7.18 (d, 1H), 5.92 (dd, 1H), 5.68 (t, 1H), 4.23 (t, 2H), 2.79 (t, 2H), 2.58 (br s, 4H), 2.38 (br s, 4H), 2.19 (s, 3H), 2.05 (s, 3H)

HRMS calculated for C24H23N4O2FSCI2: 520.0903; found: 521.0972 (M+H) Preparation 4d: 2-chloro-4-(4-chloro-6-iodo-thieno [2,3-i ] pyrimidin-5-yl)-3-methyl- phenol

Step A : [2-chloro-4-(4-chlorothieno[2,3-d]pyrimidin-5-yl)-3-methyl-phenoxy]- triisopropyl- silane

Using General Procedure Ila and Preparation lc as the appropriate 5-iodo-thieno[2,3-<i] pyrimidine derivative and Preparation B3 as the appropriate boronic acid derivative, [2-chloro-4-(4-chlorothieno [2,3 - ]pyrimidin-5 -yl)-3 -methyl-phenoxy] -triisopropyl- silane was obtained. 1H NMR (400 MHz, DMSO-d₆) δ: 8.95 (s, 1H), 7.98 (s, 1H), 7.13 (d, 1H), 6.91 (d, 1H), 2.05 (s, 3H), 1.40-1.29 (m, 3H), 1.10 (dd, 18H)

Step B: [2-chloro-4-(4-chloro-6-iodothienof2,3-dJpyrimidin-5-yl)-3-methyl-phenoxyJ- triisopropyl- silane

33.7 g [2-chloro-4-(4-chlorothieno[2,3-(i]pyrimidin-5-yl)-3-methyl-phenoxy]-triisopropyl- silane (72 mmol) was dissolved in 300 mL dry THF and cooled to -78 °C. 43.2 mL LDA solution (86.4 mmol, 2M in THF, heptane, ethyl benzene) was added dropwise under Argon and the mixture was stirred for 15 minutes. Then 23.8 g iodine (93.7 mmol) was added at -78 °C and the mixture was allowed to warm up to r.t. Then the mixture was diluted with EtOAc and was washed with NH₄C1 solution then with Na₂S₂0₃ solution. The organic layer was dried over Na₂S0₄, filtered and concentrated under reduced pressure. 1H NMR (400 MHz, DMSO-d₆) δ: 8.91 (s, 1H), 7.05 (d, 1H), 6.97 (d, 1H), 1.99 (s, 3H), 1.39-1.30 (m, 3H), 1.10 (dd, 18H)

Step C: Preparation 4d

10.0 g [2-chloro-4-(4-chloro-6-iodothieno[2,3-(i]pyrimidin-5-yl)-3-methyl-phenoxy]- triisopropyl-silane (16.85 mmol) was dissolved in 100 mL dry THF and 18.5 mL TBAF solution (18.5 mmol, 1M in THF) was added and the mixture was stirred at r.t. for 10 minutes. Then the mixture was diluted with EtOAc and washed with 1M HC1 solution and brine. The organic layer was dried over Na₂S0₄, filtered and concentrated under reduced pressure. The crude product was purified via flash chromatography using heptane and EtOAc as eluents to obtain Preparation 4d. HRMS calculated for Ci₃H₇Cl₂IN₂OS: 435.8701, found: 436.8780 (M+H)

Preparation 4e: 2- [2-chloro-4-(4-chloro-6-iodo-thieno [2,3-i/] pyrimidin-5-yl)-3-methyl- phenoxy] -TV^V-dimethyl-ethanamine

Using General Procedure VI and Preparation 4d as the appropriate phenol derivative and N,N-dimethylethanolamine as the appropriate alcohol, Preparation 4e was obtained. MS (M+H): 508.0

Preparation 4f: 2-chloro-4- [4-chloro-6-(3-thienyl)thieno [2,3-i/] pyrimidin-5-yl] -3- methyl-phenol

Using General Procedure Ilia and Preparation 4d as the appropriate 6-iodo-thieno[2,3-<i] pyrimidine derivative and thiophene-3-boronic acid pinacol ester as the appropriate boronic acid derivative, Preparation 4f was obtained. MS (M+H): 393.0

Preparation 4g: 4-chloro-5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl] -6-(3-thienyl)thieno [2,3-i ] pyrimidine Using General Procedure VI and Preparation 4f as the the appropriate 6-iodo-thieno [2,3-d]pyrimidine derivative and 2-(4-methylpiperazin-l-yl)ethanol as the appropriate alcohol, Preparation 4g was obtained.

1H NMR (500 MHz, DMSO-d₆) δ: 8.94 (s, 1H), 7.60 (dd, 1H), 7.56 (dd, 1H), 7.19 (d, 1H), 7.12 (d, 1H), 6.79 (dd, 1H), 4.21 (t, 1H), 2.77 (t, 1H), 2.56 (br, 4H), 2.33 (br, 4H), 2.15 (s, 3H), 2.04 (s, 3H)

HRMS calculated for C24H24CI2N4OS2: 518.0769; found: 519.0852 (M+H)

Preparation 4h: 4- [2- [2-chloro-4- [4-chloro-6-(3-thienyl)thieno [2,3-i j pyrimidin-5-yl] - 3-methyl-phenoxy] ethyl] morpholine

Using General Procedure VI and Preparation 4f as the appropriate phenol derivative and 2-morpholinoethanol as the appropriate alcohol, Preparation 4h was obtained.

Preparation 4i: 4-chloro-5-(l-naphthyl)thieno [2,3-i ] pyrimidine

Step A: ethyl 2-amino-4-(l-naphthyl)thiophene-3-carboxylate

50.00 g l-(l-naphthyl)ethanone (293.8 mmol), 43.66 g ethyl cyanoacetate (386.0 mmol), 18.84 g sulfur (587.5 mmol), 8.4 mL AcOH and 38.39 g morpholine were dissolved in 300 mL EtOH and stirred at 60 °C until no further conversion was observed. The volatiles were removed in vacuo, and the residue was purified via flash cromatorgaphy using heptane and EtOAc as eluents to obtain ethyl 2-amino-4-(l-naphthyl)thiophene-3- carboxylate. HRMS calculated for Ci₇Hi₅N0₂S: 297.0823; found: 298.0891 (M+H) Step B: 5-(l-naphthyl)-3H-thienof2,3-dJpyrimidin-4-one

9.40 g ethyl 2-amino-4-(l-naphthyl)thiophene-3-carboxylate (31.6 mmol) was dissolved in 45 mL formamide and stirred at 200 °C until no further conversion was observed. The mixture was cooled to r.t. and poured into water. The precipitated solid was filtered, washed with water, then dried to obtain 5-(l-naphthyl)-3H-thieno[2,3-<i] pyrimidin-4-one. HRMS calculated for Ci₆Hi₀N₂OS: 278.0514; found: 279.0582 (M+H)

Step C: Preparation 4i 8.50 g 5-(l-naphthyl)-3H-thieno[2,3-i/]pyri^midm-4-one (30.5 mmol), 4.07 g N,N-dimethylaniline (33.6 mmol) and 22.8 mL phosphorus oxychloride (244 mmol) were stirred at 100 °C for 1 hour. The mixture was cooled to r.t. and poured into stirred icy water. The precipitated solid was filtered and recrystallized from acetonitrile to obtain Preparation 4i. HRMS calculated for Ci₆H₉N₂SCl: 296.0175; found: 297.0255 (M+H)

Preparation 4j: 4-chloro-5-(3-chloro-2-methyl-phenyl)-6-ethyl-thieno [2,3-i/] pyrimidine

Using General Procedure lib and Preparation 2a as the appropriate 5-iodo-thieno[2,3-<i] pyrimidine derivative and (3-chloro-2-methyl-phenyl)boronic acid as the appropriate boronic acid derivative, Preparation 4j was obtained.

1H NMR (400 MHz, DMSO-d₆) δ: 8.89 (s, 1H), 7.55 (dd, 1H), 7.33 (t, 1H), 7.23 (dd, 1H), 2.65 (m, 2H), 2.03 (s, 3H), 1.17 (t, 3H)

HRMS calculated for C15H12CI2N2S : 322.0098; found: 323.0164 (M+H)

Preparation 4k: 4-chloro-6-ethyl-5-(l-naphthyl)thieno [2,3-i ] pyrimidine

Using General Procedure lib and Preparation 2a as the appropriate 5-iodo-thieno[2,3-<i] pyrimidine derivative and 1-naphthaleneboronic acid neopentyl glycol ester as the appropriate boronic acid derivative, Preparation 4k was obtained.

1H NMR (400 MHz, DMSO-d₆) δ: 8.91 (s, 1H), 8.07 (dd, 1H), 8.03 (dm, 1H), 7.63 (dd, 1H), 7.55 (tm, 1H), 7.51 (dd, 1H), 7.44 (tm, 1H), 7.33 (dm, 1H), 2.61 (q, 2H), 1.13 (t, 3H) HRMS calculated for Ci₈Hi₃ClN₂S: 324.0488; found: 325.0562 (M+H)

Preparation 41: 4-chloro-6-methyl-5-(l-naphthyl)thieno[2,3-</] pyrimidine

Using General Procedure IVa and methyl- iodide as the appropriate electrophile, Preparation 41 was obtained.

1H NMR (400 MHz, DMSO-d₆) δ: 8.90 (s, 1H), 8.04 (dd, 2H), 7.63 (dd, 1H), 7.54 (td, 1H), 7.49 (dd, 1H), 7.43 (td, 1H), 7.32 (d, 1H), 2.28 (s, 3H)

MS (M+H): 311.0

Preparation 4m: [4-chloro-5-(l-naphthyl)thieno [2,3-i ] pyrimidin-6-yl] methanol Step A: 4-chloro-5-(l-naphthyl)thieno[ 2, 3-d]pyrimidine-6-carbaldehyde Using General Procedure IVa and DMF as the appropriate electrophile, 4-chloro-5-(l- naphthyl)thieno[2,3-d]pyrimidine-6-carbaldehyde was obtained. 1H NMR (400 MHz, CDCI3) δ: 9.65 (s, 1H), 9.00 (s, 1H), 8.07 (d, 1H), 7.99 (d, 1H), 7.68-7.52 (m, 3H), 7.47 (t, 1H), 7.33 (d, 1H)

Step B: Preparation 4m

4-chloro-5-(l-naphthyl)thieno[2,3-(i]pyrimidine-6-carbaldehyde was dissolved in THF:MeOH 1 : 1 (4 mL/mmol) and 3 eq. NaBFL, was added at 0 °C. The mixture was stirred for 10 minutes, then quenched with 1M citric acid. The mixture was extracted with DCM, washed with NaHCC"3 solution and brine, dried over Na₂S0₄, filtered and the filtrate was concentrated in vacuo. The crude product was purified via flash chromatography using heptane and EtOAc as eluents to obtain Preparation 4m.

1H NMR (400 MHz, DMSO-de) δ: 8.92 (s, 1H), 8.06 (d, 1H), 8.03 (d, 1H), 7.62 (m, 1H), 7.58-7.49 (m, 2H), 7.44 (m, 1H), 7.35 (d, 1H), 5.99 (t, 1H), 4.54 (dd, 1H), 4.33 (dd, 1H) MS (M+H): 327.0

Preparation 4nl and Preparation 4n2: 1- [4-chloro-5-(l-naphthyl)thieno [2,3-i ] pyrimidin-6-yl] ethanol

Using General Procedure IVa and acetaldehyde as the appropriate electrophilic reagent the crude product was obtained as a mixture of diastereoisomers that were separated by sequential flash chromatography using DCM-acetone and heptane-MTBE as eluents. The order of elution of the diastereomeric-pairs was the same in both eluent systems.

Preparation 4nl was obtained as the earlier eluting diastereoisomer (racemate).

1H NMR (400 MHz, CDC1₃) δ: 8.85 (s, 1H), 7.99 (d, 1H), 7.95 (d, 1H), 7.60-7.49 (m, 2H),

7.46-7.34 (m, 3H), 4.84 (m, 1H), 2.06 (d, 1H) 1.53 (d, 3H)

MS (M+H): 341.0

Preparation 4n2 was obtained as the later eluting diastereoisomer (racemate).

1H NMR (400 MHz, CDC1₃) δ: 8.85 (s, 1H), 7.99 (d, 1H), 7.94 (d, 1H), 7.60-7.49 (m, 2H),

7.46 (dd, 1H) 7.43-7.37 (m, 1H), 7.27 (overlap, 1H), 4.98 (m, 1H), 2.14 (d, 1H) 1.35 (d,

3H)

MS (M+H): 341.0 Preparation 4o: l-[4-chloro-5-(l-naphthyl)thieno[2,3-^pyrimidin-6-yl]ethanone

157 mg Dess-Martin reagent (0.37 mmol) was dissolved in 2 mL DCM, then a mixture of Preparation 4nl and Preparation 4n2 (120 mg, 0.35 mmol dissolved in 10 mL DCM) was added and the mixture was stirred until no further conversion was observed. Then the mixture was diluted with DCM, washed with NaOH and NaHC0₃ solutions and brine, dried over Na₂S0₄, filtered and concentrated under reduced pressure. The crude product was purified via flash chromatography using heptane and EtOAc as eluents to obtain Preparation 4o.

1H NMR (500 MHz, DMSO-d₆) δ: 9.09 (s, 1H), 8.16 (dd, 1H), 8.08 (d, 1H), 7.72-7.65 (m, 2H), 7.62-7.57 (m, 1H), 7.52-7.43 (m, 2H), 1.71 (s, 3H)

MS (M+H): 339.0

Preparation 4p: 2- [4-chloro-5-(l-naphthyl)thieno [2,3-i j pyrimidin-6-yl]propan-2-ol

Using General Procedure IVa and acetone as the appropriate electrophile, Preparation 4p was obtained.

1H NMR (400 MHz, CDC1₃) δ: 8.80 (s, 1H), 7.98 (d, 1H), 7.92 (d, 1H), 7.59-7.46 (m, 2H), 7.46-7.34 (m, 2H), 7.30 (d, 1H), 2.53 (br s, 1H), 1.54 (s, 3H), 1.21 (s, 3H)

MS (M+H): 355.0

Preparation 4q: 4-chloro-6-isopropyl-5-(l-naphthyl)thieno [2,3-i ] pyrimidine

Step A: 6-isopropyl-5-(l-naphthyl)-3H-thienof2,3-dJpyrimidin-4-one

250 mg Preparation 4p (0.705 mmol) and 1.75 mL Et₃SiH (10.9 mmol) were placed in a flask and treated with 10 mL TFA at -10 °C. The mixture was then stirred at 50 °C until no further conversion was observed. The mixture was then diluted with DCM, neutralized with solid K₂C0₃ and NaHC0₃ solution. After separation of the phases the organic phase was washed with brine, dried over Na₂S0₄, filtered and concentrated in vacuo to obtain 6-isopropyl-5-(l-naphthyl)-3H-thieno[2,3-(i]pyrimidin-4-one as a crude intermediate. MS (Μ+Η): 321.0

Step B: Preparation 4q 2 mL phosphorous oxychloride and 0.161 mL N,N-dimethylaniline (1.27 mmol) were placed in a flask under Argon and 1.22 g 6-isopropyl-5-(l-naphthyl)-3H-thieno[2,3-<i] pyrimidin-4-one was added to the mixture in portions during 5 minutes. The reaction mixture was stirred at 100 °C until no further conversion was observed. The mixture was cooled to r.t. and poured into stirred icy water. The obtained aqueous media was neutralized by the careful addition of solid NaHC0₃. After the evolution of gas have ceased, the product was extracted three times with DCM. The combined organic layer was dried over Na₂S0₄, filtered and concentrated under reduced pressure. The crude product was purified via flash chromatography using heptane and EtOAc as eluents to obtain Preparation 4q.

1H NMR (500 MHz, CDC1₃) δ: 8.80 (s, 1H), 7.97 (d, 1H), 7.94 (d, 1H), 7.57 (dd, 1H), 7.54-7.49 (m, 1H), 7.42-7.37 (m, 2H), 7.34 (d, 1H), 3.02 (septet, 1H), 1.31 (d, 3H), 1.20 (d, 3H)

MS (M+H): 339.0 Preparation 4r: 4-chloro-6-(difluoromethyl)-5-(l-naphthyl)thieno [2,3-i/] yrimidine

0.250 g 4-chloro-5-(l-naphthyl)thieno[2,3-(i]pyrimidine-6-carbaldehyde (Step A intermediate in the synthesis of Preparation 4m, 0.77 mmol) was dissolved in 7 mL DCM, then 270 μΐ DAST (1.16 mmol) was added. The mixture was stirred at r.t. until no further conversion was observed. The mixture was then diluted with DCM and washed with water, then with NaHC0₃ solution and brine. The organic phase was dried over Na₂S0₄, filtered and concentrated under reduced pressure. The crude product was purified via flash chromatography using heptane and EtOAc as eluents to obtain Preparation 4r. 1H NMR (500 MHz, CDC1₃) δ: 8.97 (s, 1H), 8.04 (d, 1H), 7.97 (d, 1H), 7.62-7.54 (m, 2H), 7.49-7.43 (m, 2H), 7.28 (d, 1H), 6.47 (t, 1H)

MS (M+H): 347.0

Preparation 4s: 4-chloro-6-iodo-5-(l-naphthyl)thieno [2,3-i ] pyrimidine

Using General Procedure IVa and iodine as the appropriate electrophilic reagent, Preparation 4s was obtained.

1H NMR (400 MHz, DMSO-d₆) δ: 8.94 (s, 1H), 8.10 (dm, 1H), 8.05 (dm, 1H), 7.66 (dm, 1H), 7.56 (tm, 1H), 7.48 (dd, 1H), 7.44 (tm, 1H), 7.31 (dm, 1H) HRMS calculated for Ci₆H₈N₂SClI: 421.9141 ; found: 422.921 1 (M+H)

Preparation 4t: 4-chloro-5-(3-chloro-2-methyl-phenyl)-6-iodo-thieno [2,3-i/] yrimidine

Step A: 4-chloro-5- ( 3-chloro-2-methyl-phenyl) thienof 2, 3 -ά] pyrimidine

Using General Procedure lib and Preparation lc as the appropriate 5-iodo-thieno[2,3-<i] pyrimidine derivative and (3-chloro-2-methyl-phenyl)boronic acid as the appropriate boronic acid derivative 4-chloro-5-(3-chloro-2-methyl-phenyl)thieno[2,3-<i]pyrimidine was obtained. 1H NMR (400 MHz, CDC1₃) δ: 8.89 (s, 1H), 7.47 (dd, 1H), 7.43 (s, 1H), 7.20 (t, 1H), 7.14 (dd, lH), 2.14 (s, 3H)

Step B: Preparation 4t

Using General Procedure IVa and 4-chloro-5-(3-chloro-2-methyl-phenyl)thieno[2,3-<i] pyrimidine instead of Preparation 4i and iodine as the appropriate electrophilic reagent, Preparation 4t was obtained. 1H NMR (400 MHz, CDC1₃) δ: 8.82 (s, 1H), 7.52 (dd, 1H), 7.25 (t, 1H), 7.05 (dd, 1H), 2.09 (s, 3H)

Preparation 4u: 4-chloro-5-(3-chloro-2-methyl-phenyl)-6-isopropyl-thieno[2,3-i/] pyrimidine

Using General Procedure lib and Preparation 2d as the appropriate 5-iodo-thieno[2,3-<i] pyrimidine derivative and (3-chloro-2-methyl-phenyl)boronic acid as the appropriate boronic acid derivative, Preparation 4u was obtained.

1H NMR (400 MHz, DMSO-d₆) δ: 8.90 (s, 1H), 7.56 (dd, 1H), 7.34 (t, 1H), 7.29-7.22 (m, 1H), 2.94 (septet, 1H), 2.04 (s, 3H), 1.26 (d, 3H), 1.22 (d, 3H)

HRMS calculated for C16H14N2SCI2: 336.0255; found: 337.0335 (M+H)

Preparation 4v: 4-chloro-6-ethyl-5-(lH-indol-4-yl)thieno [2,3-i/] pyrimidine

The mixture of 0.664 g Preparation 2a (2.0 mmol), 0.400 g lH-indol-4-ylboronic acid (1.2 eq, 2.4 mmol), 44.9 mg Pd(OAc)₂ (10 mol%, 0.2 mmol), 152 mg PCy₃xHBF₄ (20 mol%, 0.4 mmol), 1.96 g Cs₂C0₃ (3.0 eq, 6.0 mmol) in 7.3 mL dimethoxyethane and 7.3 mL water was heated in microwave reactor at 100 °C until no further conversion was observed. The crude reaction mixture was filtered through a pad of Celite, washed with 2 x 10 mL MTBE and 2 x 10 mL water. The two layers of the filtrate were separated and the organic layer was washed with brine, then dried over Na₂SC"4, filtered and concentrated in vacuo. The residue was purified via preparative reversed phase chromatography using water (containing 0.1 % TFA) and acetonitrile as eluents to obtain Preparation 4v.

1H NMR (400 MHz, DMSO-d₆) δ: 11.22 (br s, 1H), 8.87 (s, 1H), 7.49 (dm, 1H), 7.32 (m, 1H), 7.19 (dd, 1H), 6.95 (dm, 1H), 5.96 (m, 1H), 2.67 (m, 2H), 1.14 (t, 3H)

HRMS calculated for Ci₆Hi₂ClN₃S: 313.0440; found 314.0508 (M+H)

Preparation 4w: 4-chloro-5-(l-naphthyl)-6-vinyl-thieno[2,3-i |pyrimidine

Using General Procedure lie and Preparation 4s as the appropriate 6-iodo-thieno[2,3-<i] pyrimidine derivative and vinylboronic acid pinacol ester as the appropriate boronic acid derivative, Preparation 4w was obtained.

1H NMR (500 MHz, DMSO-d₆) δ: 8.95 (s, 1H), 8.09 (d, 1H), 8.05 (d, 1H), 7.65 (dd, 1H), 7.56 (t, 1H), 7.52 (dd, 1H), 7.45 (t, 1H), 7.35 (d, 1H), 6.34 (dd, 1H), 5.90 (d, 1H), 5.45 (d, 1H)

HRMS calculated for Ci₈HnClN₂S: 322.0331; found 323.0415 (M+H)

Preparation 4x: 4-chloro-5-(l-naphthyl)-6-[(£'/Z)-prop-l-enyl]thieno[2,3-i ]pyrimidine

Step A: 5,5-dimethyl-2-[ ( /E)-prop- 1-enyl] - 1 ,3 ,2-dioxaborinane

To a solution of 0.172 g (Z)-prop-l-en-l-yl boronic acid (2.0 mmol, 9: 1 ZIE isomer mixture) and 0.208 g neopentyl glycol (2.0 mmol) in 6 mL 2-Me-THF 20 mg Amberlyst 15H⁺ ionic exchange resin was added and it was stirred at r.t. until no further conversion was observed. The conversion was followed by 1H-NMR measurement in CDC1₃ solution. The mixture was filtered through a pad of celite, washed with 2 x 3 mL 2-Me-THF and the filtrate was concentrated in vacuo. The resulting crude material was sufficiently pure for the next step as a 87: 13 mixture of ZIE isomers according to NMR measurement. 1H NMR (400 MHz, CDC1₃) δ: 6.57-6.43 (m, 1H), 5.39-5.27 (dd, 1H), 3.67 (s, 4H), 1.95-1.83 (dd, 3H), 0.97 (s, 6H)

Step B: Preparation 4x Using General Procedure lie and Preparation 4s as the appropriate 6-iodo-thieno[2,3-<i] pyrimidine derivative and 5,5-dimethyl-2-[(Z/E)-prop-l-enyl]-l,3,2-dioxaborinane (Z/E- mixture, Step A) as the appropriate boronic acid derivative, Preparation 4x was obtained as a 63:37 mixture of ZIE isomers.

1H NMR (500 MHz, DMSO-d₆) δ: 8.95-8.90 (s, 1H), 8.11-8.06 (m, 1H), 8.06-8.01 (m, 1H), 7.67-7.60 (m, 1H), 7.58-7.52 (m, 1H), 7.52-7.48 (m, 1H), 7.46-7.40 (m, 1H), 7.36- 7.29 (m, 1H), 6.45-5.90 (m, 1H), 6.10-6.04 (m, 1H), 2.06-1.72 (dd, 3H)

HPvMS calculated for Ci₉Hi₃ClN₂S: 336.0488; found 337.0541 (M+H)

Preparation 4y: 4-chloro-6-isopropenyl-5-(l-naphthyl)thieno [2,3-i j pyrimidine

Using General Procedure lie and Preparation 4s as the appropriate 6-iodo-thieno[2,3-<i] pyrimidine derivative and 2-isopropenyl-4,4,5,5-tetramethyl-l,3,2-dioxaborolane as the appropriate boronic acid derivative, Preparation 4y was obtained.

1H NMR (500 MHz, DMSO-d₆) δ: 8.83 (s, 1H), 7.96 (d, 1H), 7.92 (d, 1H), 7.55-7.37 (m, 5H), 5.23 (m, 1H), 5.12 (m, 1H), 1.65 (dd, 3H)

HRMS calculated for Ci₉Hi₃ClN₂S: 336.0488; found 337.0551 (M+H)

Preparation 4z: 4-chloro-5-(l-naphthyl)-6- [(£)-prop-l-enyl] thieno [2,3-i j pyrimidine

Step A: 5,5-dimethyl-2-[ (E)-prop-l-enyl]-l,3,2-dioxaborinane

To a solution of 0.172 g (E)-prop-l-en-l-yl boronic acid (2.0 mmol) and 0.208 g neopentyl glycol (2.0 mmol) in 6 mL 2-Me-THF 20 mg Amberlyst 15H⁺ ionic exchange resin was added and it was stirred at r.t. until no further conversion was observed. The conversion was followed by 1H-NMR measurement in CDC1₃ solution. The mixture was filtered through a pad of celite, washed with 2 x 3 mL 2-Me-THF and the filtrate was concentrated in vacuo. The resulting crude material was sufficiently pure for the next step. It contained only the E-stereoisomer. 1H NMR (400 MHz, CDC1₃) δ: 6.57 (m, 1H), 5.39 (dd, 1H), 3.63 (s, 4H), 1.83 (dd, 3H), 0.97 (s, 6H)

Step B: Preparation 4z Using General Procedure IlcIIIb and Preparation 4s as the appropriate 6-iodo-thieno [2,3-d]pyrimidine derivative and 5,5-dimethyl-2-[(E)-prop-l-enyl]-l ,3,2-dioxaborinane (Step A) as the appropriate boronic acid derivative, Preparation 4z was obtained.

1H NMR (500 MHz, DMSO-d₆) δ: 8.90 (s, 1H), 8.09 (d, 1H), 8.04 (d, 1H), 7.64 (dd, 1H), 7.58-7.53 (m, 1H), 7.50 (dd, 1H), 7.44 (m, 1H), 7.34 (d, 1H), 6.45 (m, 1H), 6.10-6.03 (m, 1H), 1.72 (dd, 3H)

HRMS calculated for Ci₉Hi₃ClN₂S: 336.0488; found 337.0550 (M+H)

Preparation 5a: (2R)-2- [ [5-(3-chloro-2-methyl-phenyl)-6-iodo-thieno [2,3-i/] pyrimidin- 4-yl] amino] -3-phenyl-propanoic acid

Using General Procedure lb and Preparation 4t as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and D-phenylalanine as the appropriate amino acid derivative, Preparation 5a was synthesized. The crude product was purified via preparative reversed phase chromatography using 0.1 % TFA solution and acetonitrile as eluents and Preparation 5a was obtained as a 1 : 1 mixture of diastereoisomers.

1H NMR (500 MHz, DMSO-d₆) δ: 13.15 (br s, 1H), 8.42-8.41 (s, 1H), 7.62-7.54 (d, 1H), 7.39-7.17 (t, 1H), 7.21-7.01 (m, d, 1H), 7.21 (m, 4H), 6.82-6.79 (d, 1H), 5.15-5.1 1 (d, 1H), 4.82-4.76 (q, 1H), 3.23-3.14 (dd, 1H), 2.73-2.67 (dd, 1H), 2.02-1.80 (s, 3H)

HRMS calculated for C22H17N2O2SCU: 548.9775; found 549.9842 and 549.9864 (M+H)

Preparation 5b: (2R)-2- [ [(5S_«)-5- [3-chloro-2-methyl-4- [2-(4-methylpiperazin- 1-yl) ethoxy] phenyl] -6-iodo-thieno [2,3-i ] pyrimidin-4-yl] amino] -3- [2- [(2-methylpyrazol-3- yl)methoxy] phenyl] propanoic acid

Using General Procedure lb and Preparation 4a as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and Preparation Al as the appropriate amino acid derivative, followed by HILIC purification, Preparation 5b was obtained as the later eluting diastereoisomer. MS: (M+H) = 802.0

Preparation 5c: (2R)-2- [ [5- [3-chloro-2-methyl-4- [2-(4-methylpiperazin- l-yl)ethoxy] phenyl] -6-iodo-thieno [2,3-i ] pyrimidin-4-yl] amino] -3- [2- [(2-ethylpyrazol-3- yl)methoxy] phenyl] propanoic acid Using General Procedure lb and Preparation 4a as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and Preparation A7 as the appropriate amino acid derivative, followed by HILIC purification, Preparation 5c was obtained as the later eluting diastereomer. MS: (M+H) = 816.0 Preparation 6a: (2R)-2- [ [5-bromo-6-(4-fluor ophenyl)thieno [2,3-i j pyrimidin-4-yl] amino] -3-(2-hydr oxyphenyl)propanoic acid

Using General Procedure lb and Preparation 2b as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative, and (2i?)-2-amino-3-(2-hydroxyphenyl)propanoic acid as the appropriate amino acid derivative, Preparation 6a was obtained, isolated by filtration. 1H NMR (400 MHz, DMSO-d₆) δ: 12.90 (br s, 1H), 9.65 (br s, 1H), 8.41 (s, 1H), 7.70 (m, 2H), 7.45-7.34 (m, 3H), 7.18 (dd, 1H), 7.04 (td, 1H), 6.80 (d, 1H), 6.72 (t, 1H), 4.96 (m, 1H), 3.31 (dd, 1H), 3.08 (dd, 1H)

MS (M+H): 488.0

Preparation 6b: (2R)-3-(2-hydroxyphenyl)-2-[(5-iodo-6-prop-l-ynyl-thieno[2,3-i ] pyrimidin-4-yl)amino] propanoic acid

Using General Procedure lb and Preparation 2c as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative, and (2i?)-2-amino-3-(2-hydroxyphenyl)propanoic acid as the appropriate amino acid derivative, Preparation 6b was obtained. The product was isolated by filtration instead of chromatography. MS: (M+H) = 480.0 Preparation 6c: methyl (2R)-2-[(6-ethyl-5-iodo-thieno[2,3-i |pyrimidin-4-yl)amino]-3- phenyl-propanoate

3.246 g Preparation 2a (10 mmol), 3.70 g [(li?)-l-benzyl-2-methoxy-2-oxo-ethyl] ammonium chloride (17 mmol) and 13.03 g CS₂CO₃ (40 mmol) were dissolved in 15 mL DMSO and stirred at r.t. under N₂ atmosphere until no further conversion was observed. The mixture was then acidified with 2M HCl solution to pH=l and extracted with 2 x 300 mL EtOAc. The combined organic phases were washed with NaHC0₃ solution, dried over Na₂S0₄, filtered and concentrated under reduced pressure. The crude product was purified via flash chromatography using heptane and EtOAc as eluents to obtain Preparation 6c. 1H NMR (500 MHz, DMSO-d₆) δ: 8.39 (s, 1H), 7.33 (d, 1H), 7.30 (m, 2H), 7.25-7.22 (m, 3H), 5.1 1 (m, 1H), 3.69 (s, 3H), 3.33 (dd, 1H), 3.18 (dd, 1H), 2.82 (q, 2H), 1.23 (t, 3H) HRMS calculated for Ci₈Hi₈IN₃0₂S: 467.0164; found 468.0242 (M+H)

Preparation 7a: ethyl (2R)-2- [ [5- [3-chloro-2-methyl-4- [2-(4-methylpiperazin- 1-yl) ethoxy] phenyl] -6-(4-fluor ophenyl)thieno [2,3-i j pyrimidin-4-yl] amino] -3-(2- hydroxyphenyl)propanoate

Step A: (2J )-2-[ [5- [3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl] -6-(4- fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]amino]-3-(2-hydroxyphenyl)propanoic acid Using General Procedure lid and Preparation 6a as the appropriate 5-iodo-thieno[2,3-<i] pyrimidine derivative and Preparation B4 as the appropriate boronic acid derivative, (2R)- 2-[[5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin- l-yl)ethoxy]phenyl]-6-(4-fluorophenyl) thieno[2,3-(i]pyrimidin-4-yl]amino]-3-(2-hydroxyphenyl)propanoic acid was obtained. HRMS calculated for C₃₅H₃₅C1FN₅0₄S: 675.2082; found 676.2097 (M+H)

Step B: Preparation 7a

2.3 g (2i?)-2-[[5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy]phenyl]- 6-(4-fluorophenyl)thieno[2,3- ]pyrimidin-4-yl]amino]-3-(2-hydroxyphenyl)propanoic acid (3.4 mmol) was dissolved in 20 mL 1.25 M HC1 in EtOH and stirred at 40°C overnight. The mixture was then diluted with NaHCC>3 solution and extracted with DCM. The combined organic phases were dried over Na₂S0₄, filtered and concentrated in vacuo. The crude product was purified via flash chromatography using DCM and MeOH as eluents to obtain Preparation 7a. HRMS calculated for C₃₇H₃₉CIFN₅O₄S: 703.2395; found 704.2417 (M+H)

Preparation 7ad2: ethyl (2R)-2- [ [(5S_«)-5- [3-chloro-2-methyl-4- [2-(4-methylpiperazin- l-yl)ethoxy] phenyl] -6-(4-fluorophenyl)thieno [2,3-i ] pyrimidin-4-yl] amino] -3-(2- hydroxyphenyl)propanoate

Step A: (2R)-2-[[(5S^-5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxyj 'phenyl] '- 6- ( 4-fluorophenyl) thienof 2, 3-dJpyrimidin-4-ylj 'amino ] -3-(2-hydroxyphenyl)propanoic acid Using General Procedure lid and Preparation 6a as the appropriate 5-iodo-thieno[2,3-<i] pyrimidine derivative and Preparation B4 as the appropriate boronic acid derivative, (2R)- 2-[[5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy]phenyl]-6-(4-fluorophenyl) thieno[2,3-(i]pyrimidin-4-yl]amino]-3-(2-hydroxyphenyl)propanoic acid was obtained as a mixture of diastereomers. The mixture was separated via flash chromatography using HILIC eluents. The earlier eluting diastereoisomer was collected as Preparation 7al. MS (M+H): 676.2

The later eluting diastereoisomer was collected as Preparation 7a2. MS (M+H): 676.2

Step B: Preparation 7ad2

44.51 g of Preparation 7a2 (6.67 mmol) was dissolved in 85 mL 1.25 M HCl in EtOH and stirred at 40 °C overnight. The mixture was then cautiously diluted with NaHC0₃ solution and extracted with DCM. The combined organic phases were dried over Na₂S0₄, filtered and concentrated in vacuo. The crude product was purified via flash chromatography using DCM and MeOH as eluents to obtain Preparation 7ad2.

1H NMR (500 MHz, DMSO-d₆) δ: 9.49 (s, 1H), 8.40 (s, 1H), 7.34 (d, 1H), 7.27-7.21 (m, 3H), 7.20-7.14 (m, 2H), 7.00 (td, 1H), 6.71 (dd, 1H), 6.60 (td, 1H), 6.39 (dd, 1H), 5.03 (d, 1H), 4.92 (m, 1H), 4.26 (t, 2H), 4.03 (m, 2H), 3.03 (dd, 1H), 2.78 (t, 2H), 2.54 (br, 4H), 2.36 (dd, 1H), 2.30 (br, 4H), 2.12 (s, 3H), 1.83 (s, 3H), 1.10 (t, 3H)

HPvMS calculated for C₃₇H₃₉C1FN₅0₄S: 703.2395; found 704.2450 (M+H) Preparation 7b: ethyl (2R)-2-[[(5S_fl)-5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin-l- yl)ethoxy] phenyl] -6-prop- 1-ynyl-thieno [2,3-i j pyrimidin-4-yl] amino] -3-(2- hydroxyphenyl)propanoate

Step A: (2JL)-2-[[(5S^-5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl] - 6-prop- 1-ynyl-thieno [2, 3-d]pyrimidin-4-yl] amino] -3-(2-hydroxy phenyl)propanoic acid Using General Procedure lib and Preparation 6b as the appropriate 5-iodo-thieno[2,3-<i] pyrimidine derivative and Preparation B4 as the appropriate boronic acid derivative, Ataphos as catalyst and THF: water 3: 1 as solvent a mixture diastereoisomers was obtained. They were separated via flash chromatography using HILIC eluents. The diastereoisomer eluting later was collected as (2i?)-2-[[(55'_iJ)-5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl]-6-prop- 1 -ynyl-thieno[2,3-(i]pyrimidin-4-yl]amino]-3-(2-hydroxy phenyl)propanoic acid. MS: (M+H): 620.2

Step B: Preparation 7b

2.3 g (2i?)-2-[[(55'_iJ)-5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl] -6-prop-l-ynyl-thieno[2,3- ]pyrimidin-4-yl]amino]-3-(2-hydroxyphenyl)propanoic acid (3.71 mmol) was dissolved in 20 mL 1.25M HC1 in EtOH and stirred at 40 °C overnight. The mixture was then diluted with NaHC0₃ solution and extracted with DCM. The combined organic phases were dried over Na₂S0₄, filtered and concentrated in vacuo. The crude product was purified via flash chromatography using EtOAc or DCM and MeOH as eluents to obtain Preparation 7b.

1H NMR (500 MHz, DMSO-d₆) δ: 9.47 (s, IH), 8.41 (s, IH), 7.21 (s, IH), 7.21 (s, IH), 7.00 (td, IH), 6.70 (dd, IH), 6.60 (td, IH), 6.34 (d, IH), 5.11 (d, IH), 4.89 (m, IH), 4.27 (t, 2H), 4.03 (m, 2H), 3.06 (dd, IH), 2.79 (t, 2H), 2.55 (br, 4H), 2.40 (dd, IH), 2.30 (br, 4H), 2.12 (s, 3H), 2.00 (s, 3H), 1.97 (s, 3H), 1.11 (t, 3H)

HRMS calculated for C₃₄H₃₈C1N₅0₄S: 647.2333; found 648.2385 (M+H)

Preparation 7c: ethyl (2R)-2- [ [5- [3-chloro-4-(2-dimethylaminoethyloxy)-2-methyl- phenyl] -6-prop- 1-ynyl-thieno [2,3-i ] pyrimidin-4-yl] amino] -3-(2-hydroxyphenyl) propanoate

Step A: (2R)-2-[[ (5Sa)-5-[ 3-chloro-4-(2-dimethylaminoethyloxy)-2-methyl-phenylJ-6-prop- 1-ynyl-thieno [2, 3-d]pyrimidin-4-yl] amino] -3-(2-hydroxyphenyl)propanoic acid

Using General Procedure lid and Preparation 6b as the appropriate 5-iodo-thieno[2,3-<i] pyrimidine derivative and Preparation B5 as the appropriate boronic acid derivative, a mixture diastereoisomers was obtained. They were separated via flash chromatography using HILIC eluents. The diastereoisomer eluting later was collected as (2R)-2-[[(5S_a)-5- [3-chloro-4-(2-dimethylaminoethyloxy)-2-methyl-phenyl]-6-prop- 1 -ynyl-thieno[2,3-<i] pyrimidin-4-yl]amino]-3-(2-hydroxyphenyl)propanoic acid. MS (M+H): 565.2

Step B: Preparation 7c 2.3 g (2i?)-2-[[(55'_a)-5-[3-chloro-4-(2-dimethylaminoethyloxy)-2-methyl-phenyl]-6-prop-l- ynyl-thieno[2,3- ]pyrimidin-4-yl]amino]-3-(2-hydroxyphenyl)propanoic acid (4.07 mmol) was dissolved in 20 mL 1.25M HCl in EtOH and stirred at 40 °C overnight. The mixture was then diluted with NaHC0₃ solution and extracted with DCM. The combined organic phases were dried over Na₂S0₄, filtered and concentrated in vacuo. The crude product was purified via flash chromatography using DCM and MeOH as eluents to obtain Preparation 7c.

1H NMR (500 MHz, DMSO-d₆) δ: 9.45 (s, 1H), 8.41 (s, 1H), 7.21 (s, 1H), 7.21 (s, 1H), 7.00 (td, 1H), 6.70 (dd, 1H), 6.60 (td, 1H), 6.34 (d, 1H), 5.12 (d, 1H), 4.89 (m, 1H), 4.26 (m, 2H), 4.03 (m, 2H), 3.06 (dd, 1H), 2.74 (t, 2H), 2.39 (dd, 1H), 2.27 (s, 6H), 2.01 (s, 3H), 1.97 (s, 3H), 1.1 1 (t, 3H)

HRMS calculated for C₃iH₃₃ClN₄0₄S: 592.191 1 ; found 593.1954 (M+H)

Preparation 7d: ethyl (2R)-2- [ [5-bromo-6-(4-fluor ophenyl)thieno [2,3-i/] pyrimidin-4- yl] amino] -3-(2-hydr oxyphenyl)propanoate

2.5 g of Preparation 6a (5.1 mmol) was dissolved in 20 mL 1.25M HCl in EtOH and stirred at 40 °C overnight. The resulting mixture was diluted with aq. NaHC0₃ solution and extracted with DCM. The combined organic phases were dried over Na₂S0₄, filtered and concentrated in vacuo. The crude product was purified via flash chromatography using heptane and EtOAc as eluents to obtain Preparation 7d. 1H NMR (400 MHz, DMSO-d₆) δ: 9.67 (s, 1H), 8.42 (s, 1H), 7.70 (m, 2H), 7.43-7.37 (m, 3H), 7.14 (dd, 1H), 7.05 (td, 1H), 6.80 (dd, 1H), 6.72 (td, 1H), 5.01 (m, 1H), 4.12 (q, 2H), 3.26 (dd, 1H), 3.14 (dd, 1H), 1.17 (t, 3H)

Preparation 7e: methyl (2R)-2- [ [6-ethyl-5-(4-hydroxy-2-methyl-phenyl)thieno [2,3-i ] pyrimidin-4-yl] amino] -3-phenyl-propanoate

934 mg Preparation 6c (2 mmol), 903 mg Preparation B6 (2.4 mmol), 231 mg Pd(PPh₃)₄ (0.2 mmol), 662 mg Ag₂C0₃ (2.4 mmol) and 81 methanol (2 mmol) were dissolved in 20 mL 2-Me-THF and stirred in MW reactor at 1 10 °C until no further conversion was observed. The mixture was filtered through Celite, diluted with 100 mL EtOAc then 2.5 mL TBAF (1M solution in THF) was added and the mixture was stirred at r.t. until no further conversion was observed. The mixture was then washed with NH₄C1 solution and brine, dried over Na₂SC"4, filtered and concentrated and purified via flash chromatography using heptane and EtOAc as eluents to obtain Preparation 7e as a mixture of diastereoisomers.

1H NMR (400 MHz, CDC1₃) δ: 8.43-8.43 (s, 1H), 7.26-6.80 (m, 7H), 6.76-6.64 (m, 2H), 5.18 (m, 1H), 5.03 (m, 1H), 3.66-3.65 (s, 3H), 3.16-3.13 (dd, 1H), 2.73 (dd, 1H), 2.57 (m, 2H), 2.07-1.80 (s, 3H), 1.18-1.17 (t, 3H)

MS (M+H): 448.2

Preparation 7f: methyl (2R)-2-[[5-(3,5-dichloro-4-hydroxy-2-methyl-phenyl)-6-ethyl- thieno [2,3-i/] pyrimidin-4-yl] amino] -3-phenyl-propanoate

402 mg Preparation 7e (0.898 mmol) and 300 mg NCS (2.245 mmol) were dissolved in 5 mL THF and stirred at 60 °C until no further conversion was observed. The volatiles were removed in vacuo, the residue was purified via flash chromatography using heptane and EtOAc as eluents to obtain the title product as a mixture of diastereoisomers.

1H NMR (500 MHz, DMSO-d₆) δ: 10.46-10.44 (s, 1H), 8.40-8.38 (s, 1H), 7.29-7.24 (s, 1H), 7.20 (m, 3H), 6.80-6.78 (d, 2H), 5.09-5.01 (d, 1H), 4.95 (m, 1H), 3.59-3.58 (s, 3H), 3.15-3.13 (dd, 1H), 2.78-2.61 (dd, 1H), 2.53 (q, 2H), 2.02-1.84 (s, 3H), 1.11 (t, 3H) HRMS calculated for C₂5H2₃C1₂N₃0₃S: 515.0837; found 516.0908 (M+H)

Preparation 7g: methyl (2R)-2- [ [5-(3-chloro-4-hydroxy-2-methyl-phenyl)-6-ethyl- thieno [2,3-i ] pyrimidin-4-yl] amino] -3-phenyl-propanoate

Using General Procedure lie and Preparation 6c as the appropriate 5-iodo-thieno[2,3-<i] pyrimidine derivative and Preparation B2 as the appropriate boronic acid derivative, Preparation 7g was obtained as a mixture of diastereoisomers. MS (M+H): 482.1

Preparation 7gdl: methyl (2R)-2- [ [(5S_fl)-5-(3-chloro-4-hydroxy-2-methyl-phenyl)-6- ethyl-thieno [2,3-i ] pyrimidin-4-yl] amino] -3-phenyl-propanoate The diastereoisomers of Preparation 7g were separated via flash chromatography using heptane and EtOAc as eluents. The diastereoisomer eluting later was collected as Preparation 7gdl. 1H NMR (500 MHz, DMSO-d₆) δ: 10.53 (s, 1H), 8.36 (s, 1H), 7.23 (m, 2H), 7.20 (m, 1H), 7.04 (d, 1H), 6.98 (d, 1H), 6.80 (m, 2H), 5.11 (d, 1H), 4.90 (m, 1H), 3.57 (s, 3H), 3.10 (dd, 1H), 2.63 (dd, 1H), 2.51-2.46 (m, 2H), 1.86 (s, 3H), 1.10 (t, 3H)

HRMS calculated for C25H24CIN3O3S : 481.1227; found 482.1313 (M+H) Preparation 7h: (2R)-2- [ [6-ethyl-5-(lH-indol-4-yl)thieno [2,3-d\ yrimidin-4-yl] amino] - 3-phenyl-propanoic acid

Using General Procedure lb and Preparation 4v as the the appropriate 4-chloro- thieno[2,3-d]pyrimidine derivative and (2i?)-2-amino-3-(2-hydroxyphenyl)propanoic acid as the appropriate amino acid derivative, Preparation 7h was obtained as a mixture of diastereoisomers .

1H NMR (500 MHz, DMSO-d₆) δ: 12.71-12.59 (br s, 1H), 11.48-11.37 (s, 1H), 8.35-8.30 (s, 1H), 7.64-7.53 (d, 1H), 7.45-7.39 (dd, 1H), 7.30-7.08 (t, 1H), 7.17-6.33 (m, 6H), 6.07- 6.01 (s, 1H), 5.27 (d, 1H), 4.59/4.50 (m, 1H), 2.98-2.83 (dd, 1H), 2.56 (m, 2H), 2.35-2.15 (dd, 1H), 1.11-1.09 (t, 3H)

HRMS calculated for C25H22N4O2S: 442.1463; found 443.1529 and 443.1538 (M+H)

Preparation 7i: methyl (2R)-2- [ [5-(3-chloro- lH-indol-4-yl)-6-ethyl-thieno [2,3-d\ pyrimidin-4-yl] amino] -3-phenyl-propanoate

Step A: methyl (2R)-2-ff6-ethyl-5-(lH-indol-4-yl)thienof2 -dJpyrimidin-4-ylJaminoJ-3- phenyl-propanoate

8.87 g Preparation 7h (20 mmol) was dissolved in 60 mL MeOH and 5.88 mL cc. H₂S0₄ (60 mmol) was added. The mixture was stirred at r.t. under N2 atmosphere for 2 hours. The mixture was then poured into icy water, the precipitate was filtered to obtain methyl (2R)- 2- [ [6-ethyl-5 -( lH-indo l-4-yl)thieno [2,3 - ]pyrimidin-4-yl]amino] -3 -phenyl-propanoate as a mixture of diastereoisomers.

1H NMR (400 MHz, DMSO-d₆) δ: 11.52-11.43 (s, 1H), 8.39-8.34 (s, 1H), 7.65-7.57 (d, 1H), 7.47-7.42 (t, 1H), 7.30-7.11 (dd, 1H), 7.18-6.79 (m, 2H), 7.02 (m, 1H), 6.93 (m, 1H), 6.65 (m, 1H), 6.34 (m, 1H), 6.05 (dt, 1H), 5.28 (m, 1H), 4.71-4.62 (m, 1H), 3.55-3.41 (s, 3H), 2.91-2.77 (dd, 1H), 2.57 (m, 2H), 2.37-2.23 (dd, 1H), 1.11-1.10 (t, 3H)

MS (M+H): 457.2 and 457.2 Step B: Preparation 7i

8.477 g methyl (2i?)-2-[[6-ethyl-5-(lH-indol-4-yl)thieno[2,3- ]pyrimidin-4-yl]amino]-3- phenyl-propanoate (18.5 mmol), 2.47 g NCS (18.5 mmol) and 30 mL abs. THF were stirred at r.t. until no further conversion was observed. Then the mixture was poured into icy water and was extracted with EtOAc. The combined organic phases were dried over Na₂S0₄, filtered and concentrated under reduced pressure. The crude product was purified via flash chromatography using heptane and EtOAc as eluents to obtain Preparation 7i as a mixture of diastereoisomers.

1H NMR (500 MHz, DMSO-d₆) δ: 11.73-11.65 (d, 1H), 8.35-8.31 (s, 1H), 7.63-7.56 (d, 1H), 7.62-7.54 (d, 1H), 7.44-7.15 (dd, 1H), 7.20-7.03 (m, 3H), 7.04-6.84 (d, 1H), 6.70-6.44 (dm, 2H), 5.09-4.98 (d, 1H), 4.80-4.72 (m, 1H), 3.51-3.38 (s, 3H), 2.93-2.81 (dd, 1H), 2.52 (m, 2H), 2.46-2.29 (dd, 1H), 1.10-1.09 (t, 3H)

HRMS calculated for C₂6H₂3C1N₄0₂S: 490.1230; found 491.1282 and 491.1316 (M+H)

Preparation 7j: 4-chloro-5-(3-chloro- lH-indol-4-yl)-6-ethyl-thieno [2,3-i j pyrimidine The mixture of 1.099 g Preparation 4v (3.5 mmol) and 0.572 g NCS (4.2 mmol) in 20 mL CC was stirred at r.t. until no further conversion was observed. The mixture was then poured onto crushed ice, and it was extracted with DCM. The combined organic layers were dried over Na₂S0₄, filtered and concentrated under reduced pressure. The crude product was purified via flash chromatography using heptane and EtOAc as eluents to obtain 4-chloro-5-(3-chloro-lH-indol-4-yl)-6-ethyl-thieno[2,3-<i]pyrimidine Preparation 7j. 1H NMR (400 MHz, CDC1₃) δ: 8.79 (s, 1H), 8.33 (br s, 1H), 7.47 (dd, 1H), 7.31 (t, 1H), 7.18 (d, 1H), 7.03 (dd, 1H), 2.73 (m, 2H), 1.24 (t, 3H)

Preparation 8a: (£)-4-(Dimethylamino)- 1 , l-dimethoxy-but-3-en-2-one

502.1 g l,l-dimethoxypropan-2-one (4.25 mol) and 506.4 g 1 ,1-dimethoxy-NN-dimethyl- methanamine (4.25 mol) were mixed in a 2 L flask and stirred at 105 °C for 3 hours. The formed MeOH was removed continuously via distillation. When MeOH formation stopped (at 65 °C head temperature) the reaction mixture was vacuum distilled (decreasing the pressure slowly to 30 mbar) to remove side products and unreacted starting materials. The crude product was distilled at 0.1 mbar. Fractions were collected between 107-118 °C head temperature (bath temperature 160-165 °C) to give a yellow oil. 1H NMR (500 MHz, DMSO-de) δ: 7.59 (d, 1H), 5.17 (d, 1H), 4.42 (s, 1H), 3.25 (s, 6H), 3.09 (s, 3H), 2.78 (s, 3H)

Preparation 8b: 4-(Dimethoxymethyl)-2-methylsulfonyl-pyrimidine Step A: 4-(Dimethoxymethyl)-2-methylsulfanyl-pyrimidine

198 g sodium methoxide (3.67 mmol) was dissolved in 3 L MeOH and cooled to 0 °C. 322 g thiocarbamide (4.23 mol) was added portionwise and the mixture was stirred for 1 hour. Then 488 g Preparation 8a (2.82 mol) was added dropwise at 0 °C, then it was heated to 70°C until no further conversion was observed. It was cooled to r.t., 237 mL methyl iodide (3.81 mol) was added dropwise, keeping the temperature below 28 °C, and the resulting mixture was stirred overnight at r.t. It was filtered, the filtrate was concentrated under reduced pressure, diluted with EtOAc, washed with water and brine. The combined aqueous layers were extracted with EtOAc. The combined organic layers were dried over Na₂S0₄, filtered and concentrated under reduced pressure. The residue was dissolved in 500 mL Et₂0, filtered through a pad of silica, using Et₂0 as eluent. The filtrate was concentrated under reduced pressure to give a light brown oil. 1H NMR (400 MHz, DMSO-de) δ: 8.69 (d, 1H), 7.23 (d, 1H), 5.22 (s, 1H), 3.33 (s, 6H), 2.52 (s, 3H)

Step B: Preparation 8b

To a solution of 180 g 4-(dimethoxymethyl)-2-methylsulfanyl-pyrimidine (940 mmol) in 1.5 L methanol and 1.5 L water 752 g Oxone® (potassium peroxymonosulfate, 1220 mmol) was added portionwise at -5 °C, then stirred at 0 °C overnight. The reaction mixture was concentrated under reduced pressure to half volume using a 30 °C bath and then the mixture was filtered, and the precipitate was washed with DCM. The filtrate was extracted with DCM. The combined organic layers were dried over MgS0₄, filtered and concentrated under reduced pressure to give a light brown oil. 1H NMR (400 MHz, CDCI3) δ: 8.98 (d, 1H), 7.97 (d, 1H), 5.36 (s, 1H), 3.47 (s, 6H), 3.39 (s, 3H)

Preparation 9a: methyl (2R)-2-amino-3-(2-hydroxyphenyl)propanoate hydrochloride 24.6 g (2i?)-2-amino-3-(2-hydroxyphenyl)propanoic acid (136 mmol) was stirred at r.t. in 900 mL solution of 3M HC1 in methanol for 40 hours. The reaction mixture was concentrated under reduced pressure keeping the bath temperature below 40 °C. The residue was triturated with diethyl ether to give the product as a cream colored shining powder. HRMS calculated for CnHi₅N0₃ (free base): 209.1052; found 210.1128 (M+H)

Preparation 9b: methyl (2R)-2-(terf-butoxycarbonylamino)-3-(2-hydroxyphenyl) propanoate

16.7 g Preparation 9a (73.0 mmol) was suspended in 180 mL DCM. 30.5 mL (219 mmol) TEA was added and the solution was cooled using a water-ice bath. A solution of 15.6 g di-tert-butyl bicarbonate (73.0 mmol) in 75 mL DCM was added slowly (2.5 hours). The mixture was stirred overnight at r.t. Then 100 mL water was added and the organic phase was separated, washed with water, 1M HC1 solution and finally with water again. The organic phase was dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure to obtain the product as an oil. Preparation Al: (2R)-2-amino-3- [2- [(2-methylpyrazol-3-yl)methoxy] phenyl] propanoic acid

Using General procedure IXa and (2-methylpyrazol-3-yl)methanol as the appropriate alcohol derivative, Preparation Al was obtained. MS (M+H): 276.2

Preparation A2: (2R)-2-amino-3- [2- [(2-ethoxypyrimidin-4-yl)methoxy] phenyl] propanoic acid

Using General procedure IXa and Preparation CI as the appropriate alcohol derivative, Preparation A2 was obtained. MS (M+H): 318.1

Preparation A3: (2R)-2-amino-3- [2- [(2-butylpyrazol-3-yl)methoxy] phenyl] propanoic acid

Using General procedure IXa and Preparation C2 as the appropriate alcohol derivative, Preparation A3 was obtained. MS (M+H): 318.2 Preparation A4: (2R)-2-amino-3- [2- [ [2-(2-methoxyphenyl)pyrimidin-4-yl] methoxy] phenyl] propanoic acid

Using General procedure IXa and Preparation C3 as the appropriate alcohol derivative, Preparation A4 was obtained. MS (M+H): 380.2 Preparation A5: (2R)-2-amino-3-[2-(2-pyridylmethoxy)phenyl] propanoic acid

Using General procedure IXa and 2-pyridylmethanol as the appropriate alcohol derivative, Preparation A5 was obtained. MS (M+H): 273.1

Preparation A6: (2R)-2-amino-3- [2-(2,2,2-trifluoroethoxy)phenyl] propanoic acid

Using General procedure IXb and 2,2,2-trifluoroethyl trifluoromethanesulfonate as the appropriate alkylating reagent, Preparation A6 was obtained. MS (M+H): 264.1

Preparation A7: (2R)-2-amino-3- [2- [(2-ethylpyrazol-3-yl)methoxy] phenyl] propanoic acid

Using General procedure IXa and (2-ethylpyrazol-3-yl)methanol as the appropriate alcohol derivative, Preparation A7 was obtained. HRMS calculated for C15H19N3O3 : 289.1426, found: 290.1512 (M+H)

Preparation A8: (2R)-2-amino-3- [2- [ [2-(2,2,2-trifluoroethoxy)pyrimidin-4-yl] methoxy] phenyl] propanoic acid

Using General procedure IXa and Preparation C8 as the appropriate alcohol derivative, Preparation A8 was obtained. MS (M+H): 372.1 Preparation A9: (2R)-2-amino-3- [2- [2-(dimethylamino)-2-oxo-ethoxy] phenyl] propanoic acid

Using General procedure IXb and 2-chloro-N,N-dimethylacetamide as the appropriate alkylating reagent, Preparation A9 was obtained. MS (M+H): 267.1

Preparation A10: (2R)-2-amino-3-[2-(2-cyclopentylethoxy)phenyl] propanoic acid

Using General procedure IXa and 2-cyclopentylethanol as the appropriate alcohol derivative, Preparation A10 was obtained. MS (M+H): 278.2 Preparation All: (2R)-2-amino-3-(2-phenethyloxyphenyl)propanoic acid

hydrochloride

Using General procedure IXa and 2-phenylethanol as the appropriate alcohol derivative, Preparation All was obtained. MS (M+H): 286.1 Preparation A12: (2R)-2-amino-3-[2-(3-phenylpropoxy)phenyl] propanoic acid

Using General procedure IXa and 3-phenylpropan-l-ol as the appropriate alcohol derivative, Preparation A12 was obtained. MS (M+H): 300.2

Preparation A13: (2R)-2-amino-3- [2- [(3-chlorophenyl)methoxy] phenyl] propanoic acid

Using General procedure IXa and (3-chlorophenyl)methanol as the appropriate alcohol derivative, Preparation A13 was obtained. MS (M+H): 306.1

Preparation A14: (2R)-2-amino-3- [2- [2-(4-methylpiperazin- l-yl)ethoxy] phenyl] propanoic acid

Using General procedure IXa and 2-(4-methylpiperazin-l-yl)ethanol as the appropriate alcohol derivative, Preparation A14 was obtained. MS (M+H): 308.2

Preparation A15: (2R)-2-amino-3- [2-(2-dimethylaminoethyloxy)phenyl] propanoic acid

Using General procedure IXa and 2-(dimethylamino)ethanol as the appropriate alcohol derivative, Preparation A15 was obtained. MS (M+H): 253.2 Preparation A16: (2R)-2-amino-3- [2- [3-(dimethylamino)propoxy] phenyl] propanoic acid

Using General procedure IXa and 3-(dimethylamino)propan-l-ol as the appropriate alcohol derivative, Preparation A16 was obtained. MS (M+H): 267.2

Preparation Bl: 3-methyl-4-(3,3,4,4-tetramethylborolan-l-yl)-lH-indole 1.87 g 4-bromo-3-methyl-lH- indole (8.9 mmol), 5.028 g bis(pinacolato)diboron (19.6 mmol), and 2.65 g potassium acetate (26.7 mmol) were dissolved in 35 mL dry DMF under Argon, then 652 mg [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.89 mmol) was added. The reaction mixture was heated to 85 °C and stirred until no further conversion was observed. Then it was concentrated under reduced pressure and purified via flash chromatography using heptane and EtOAc as eluents to obtain Preparation Bl.

1H NMR (400 MHz, CDC1₃) δ: 7.92 (br s, 1H), 7.56 (d, 1H), 7.42 (dd, 1H), 7.16 (t, 1H), 7.01 (d, 1H), 2.47 (d, 3H), 1.40 (s, 12H)

HRMS calculated for Ci₅H₂oN0₂B: 257.1587; found 258.1665 (M+H)

Preparation B2: 2-Chloro-3-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl) phenol

Step A: (4-Bromo-2-chloro-phenoxy)-trimethyl-silane

20.8 g 4-bromo-2-chloro-phenol (100 mmol) was dissolved in 150 mL dry THF then 24.2 g HMDS (150 mmol) was added. The reaction mixture was stirred at 85 °C under argon atmosphere for 1.5 hours then concentrated under reduced pressure. The resulted crude product was used without further purification. 1H NMR (200 MHz, CDC1₃) δ: 7.49 (d, 1H), 7.23 (dd, 1H), 6.75 (d, 1H), 0.26 (s, 9H)

Step B: 4-Bromo-2-chloro-3-methyl-phenol

48 mL ⁿBuLi solution (120 mmol, 2.5 M in hexanes) was added dropwise to a solution of 12.1 g dry DIPA (120 mmol) in 250 mL dry THF at -78 °C under argon atmosphere. The mixture was stirred for 30 minutes at the same temperature then 28.0 g (4-bromo-2-chloro- phenoxy)-trimethyl-silane (100 mmol) was added dropwise. After 2.5 hours 21.3 g Mel (150 mmol) was added dropwise then the cooling bath was removed and the mixture was stirred overnight. The reaction was quenched with 100 mL NH₄OH solution and 200 mL NH₄CI solution then extracted with EtOAc. The organic phase was dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. The resulting dark mass was refluxed with pure hexane several times (150-150 mL aliquots) and decanted leaving a black tar behind. The combined organic phases were concentrated under reduced pressure affording 19.0 g crude product, which was used without further purification. 1H NMR (200 MHz, CDCI₃) δ: 7.32 (d, 1H), 6.76 (d, 1H), 5.62 (s, 1H), 2.49 (s, 3H)

Step C: ( 4-Bromo-2-chloro-3-methyl-phenoxy)-trimethyl-silane

20.8 g HMDS (129 mmol) was added to the solution of 19.0 g 4-bromo-2-chloro-3-methyl- phenol (86.0 mmol) in 150 mL dry THF. The mixture was stirred at 85 °C under argon balloon for 1.5 hours and then concentrated under reduced pressure. The obtained product was used without further purification. 1H NMR (200 MHz, CDC1₃) δ: 7.30 (d, 1H), 6.63 (d, 1H), 2.50 (s, 3H), 0.28 (s, 9H)

Step D: Preparation B2

A solution of 25.2 g (4-bromo-2-chloro-3-methyl-phenoxy)-trimethyl-silane (86.0 mmol) in 250 mL dry THF was cooled to -78 °C under argon and then 38 mL ⁿBuLi solution (94.6 mmol, 2.5M in hexanes) was added dropwise. After 5 minutes 19.2 g 2-isopropoxy- 4,4,5, 5-tetramethyl-l,3,2-dioxaborolane (103 mmol) was added dropwise. The cooling bath was removed and the mixture was slowly allowed to warm up to r.t. Then the mixture was added to 200 mL NH₄CI solution and extracted with EtOAc. The combined organic layers were concentrated under reduced pressure and passed through a pad of silica gel using hexane and EtOAc as eluents. The crude product was recrystallized from a mixture of EtOAc and hexane to obtain Preparation B2. 1H NMR (500 MHz, DMSO-d₆) δ: 10.40 (s, 1H), 7.42 (d, 1H), 6.80 (d, 1H), 2.49 (s, 3H), 1.27 (s, 12H) Preparation B3: [2-Chloro-3-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl) phenoxy] -triisopropyl-silane

Step A: (4-Bromo-2-chloro-phenoxy)-triisopropyl-silane

200 g 4-bromo-2-chloro-phenol (0.97 mol) and 126 mL TIPSC1 (1.18 mol) were dissolved in 1.6 L DCM. 167 g imidazole (2.45 mol) was added and the mixture was stirred at r.t. for 2 hours. Then the volatiles were evaporated under reduced pressure and the residue was dissolved in 1.5 L EtOAc. The mixture was washed with brine, dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. The triisopropylsilyl hydroxide impurity was removed by distillation (120 °C at 0.01 mmHg). The residue was filtered through a short pad of silica with hexane and concentrated under reduced pressure. The product (colourless oil) was used in the next step without further purification.

1H NMR (400 MHz, CDC1₃) δ: 7.49 (d, 1H), 7.21 (dd, 1H), 6.78 (d, 1H), 1.31 (septet, 3H), 1.14 (d, 18H)

MS (EI, 70 eV) m/z (% relative intensity, [ion]): 63 (30), 79 (24), 93 (41), 170 (17), 235 (19), 251 (16), 265 (24), 293 (23), 319 (77), 321 (100), 323 (28), 362 (1, [M⁺]).

Step B: ( 4-Bromo-2-chloro-3-methyl-phenoxy)-triisopropyl-silane

76.0 mL dry DIPA (0.54 mol) was dissolved in 1.2 L dry THF under argon atmosphere and 51.2 mL ⁿBuLi solution (0.512 mol, 10M in hexanes) was added dropwise at -78 °C. The mixture was stirred for 45 minutes at the same temperature. Then 178 g (4-bromo-2- chloro-phenoxy)-triisopropyl-silane (0.488 mol) was added dropwise at -78 °C and the white suspension was stirred until no further conversion was observed. Then 36.5 mL Mel (0.586 mmol) was added at this temperature and the reaction mixture was stirred overnight without further cooling. The volatiles were evaporated under reduced pressure. The residue was dissolved in 1.5 L EtOAc, washed with brine. The organic phase was dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. The crude product was filtered through a short pad of silica using hexane as eluent and concentrated under reduced pressure to obtain the product as pale yellow oil. 1H NMR (400 MHz, CDC1₃) δ: 7.30 (d, 1H), 6.68 (d, 1H), 2.53 (s, 3H), 1.32 (septet, 3H), 1.14 (d, 18H) Step C: Preparation B3

178 g (4-bromo-2-chloro-3-methyl-phenoxy)-triisopropyl-silane (0.472 mol) was dissolved in 1.4 L dry THF under argon atmosphere and 52 mL ⁿBuLi solution (0.52 mol, 10M in hexanes) was added dropwise at -78 °C. The mixture was stirred for 5 minutes at this temperature. Then 116 mL 2-isopropoxy-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (0.569 mol) was added and the mixture was allowed to warm up to r.t. The volatiles were evaporated under reduced pressure. The residue was dissolved in 1.5 L EtOAc, washed with brine. The organic phase was dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. The 2-isopropoxy-4,4,5,5-tetramethyl-l,3,2- dioxaborolane impurity was removed by distillation (80 °C at 0.01 mmHg). The crude product was triturated in MeOH affording Preparation B3 as a white solid. 1H NMR (400 MHz, CDCls) δ: 7.53 (d, 1H), 6.74 (d, 1H), 2.60 (s, 3H), 1.34 (s, 12H), 1.32 (m, 3H), 1.12 (d, 18H)

Preparation B4: l-[2-[2-Chloro-3-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)phenoxy] ethyl] -4-methyl-piperazine

10.0 g Preparation B2 (37.2 mmol), 8.7 g 2-(4-methylpiperazin-l-yl)ethanol (60.3 mmol) and 15.8 g PPI13 (60.3 mmol) were dissolved in 100 mL dry toluene and then 27 mL diethyl azodicarboxylate (60.3 mmol, 40 % solution in toluene) was added dropwise. The mixture was stirred at 50 °C under argon until no further conversion was observed. The volatiles were evaporated under reduced pressure and 100 mL Et₂0 was added. The precipitated white crystals were filtered off and washed with Et₂0. The filtrate was concentrated under reduced pressure and purified via flash chromatography using CHCI₃ and MeOH as eluents. The resulting light brown oil was crystallized from hexane to give Preparation B4 as an off-white solid. 1H NMR (500 MHz, DMSO-d₆) δ: 7.56 (d, 1H), 6.99 (d, 1H), 4.15 (t, 2H), 2.72 (t, 2H), 2.51 (s, 3H), 2.50 (br s, 4H), 2.29 (br s, 4H), 2.13 (s, 3H), 1.29 (s, 12H)

Preparation B5: l-[2-[2-Chloro-3-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)phenoxy] ethyl] -4-methyl-piperazine

10.0 g Preparation B2 (37.2 mmol), 5.366 g N,N-dimethylethanolamine (60.3 mmol) and 15.8 g PPI13 (60.3 mmol) were dissolved in 100 mL dry toluene and then 27 mL diethyl azodicarboxylate (60.3 mmol, 40 % solution in toluene) was added dropwise. The mixture was stirred at 50 °C under argon until no further conversion was observed. The volatiles were evaporated under reduced pressure and 100 mL Et₂0 was added. The precipitated white crystals were filtered off and washed with Et₂0. The filtrate was concentrated under reduced pressure and purified via flash chromatography using CHCI₃ and MeOH as eluents. The resulting light brown oil was crystallized from hexane to give Preparation B5. 1H NMR (400 MHz, DMSO-d₆) δ: 7.56 (d, 1H), 6.99 (d, 1H), 4.13 (t, 2H), 2.66 (t, 2H), 2.51 (s, 3H), 2.23 (s, 6H), 1.29 (s, 12H)

Preparation B6: [4-(5,5-dimethyl-l,3,2-dioxaborinan-2-yl)-3-methyl-phenoxy]- triisopropyl-silane Step A: 4- ( 5, 5-dimethyl-l, 3, 2-dioxaborinan-2-yl)-3-methyl-phenol

4.675 g (4-hydroxy-2-methyl-phenyl)boronic acid (30.76 mmol), 3.204 neopentyl glycol (32.9 mmol), Amberlyst 15H⁺ and 150 mL 2-Me-THF were stirred at r.t. under N₂ atmosphere until no further conversion was observed. The mixture was then filtered through Celite and the filtrate was concentrated under reduced pressure to obtain 4-(5,5-dimethyl-l,3,2-dioxaborinan-2-yl)-3-methyl-phenol. 1H NMR (400 MHz, CDC1₃) δ: 7.64 (m, 1H), 6.60 (m, 2H), 5.23 (br s, 1H), 3.75 (s, 4H), 2.47 (s, 3H), 1.01 (s, 6H)

Step B: Preparation B6

30.76 mmol 4-(5, 5-dimethyl-l, 3, 2-dioxaborinan-2-yl)-3 -methyl-phenol, 8.56 mL TIPSC1 (40 mmol) and 4.19 g imidazole (61.52 mmol) were dissolved in 100 mL DCM and stirred at r.t. under N₂ atmosphere until no further conversion was observed. Imidazolium hydrochloride was removed by filtration, the filtrate was concentrated under reduced pressure and purified via flash chromatography using heptane and EtOAc as eluents to obtain Preparation B6. 1H NMR (400 MHz, CDC1₃) δ: 7.62 (d, 1H), 6.68-6.66 (m, 2H), 3.76 (s, 4H), 2.47 (s, 3H), 1.32-1.21 (m, 3H), 1.11 (d, 18H), 1.03 (s, 6H)

Preparation B7: 2-(3-bromo-2-methyl-phenyl)-4,4,5,5-tetramethyl-l,3,2- dioxaborolane

2.362 g 2,6-dibromo-toluene (9.45 mmol) was dissolved in 10 mL dry THF under N₂ atmosphere and the mixture was cooled to -78 °C. Then 5.2 mL nBuLi (2.0M in pentane, 10.4 mmol) was added dropwise and the mixture was stirred for 15 minutes. Then 2.31 mL 2-isopropoxy-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (11.3 mmol) was added dropwise and the mixture was allowed to warm up to r.t.. It was stirred until no further conversion was observed. Then the mixture was quenched with aqueous NH₄C1 solution, then extracted with EtOAc. The combined organic layer was dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via flash chromatography using heptane and EtOAc as eluents to obtain Preparation B7. 1H NMR (400 MHz, CDC1₃) δ: 7.67 (d, 1H), 7.62 (d, 1H), 7.10 (t, 1H), 2.53 (s, 3H), 1.29 (s, 12H)

Preparation CI: (2-ethoxypyrimidin-4-yl)methanol Step A: 4-(dimethoxymethyl)-2-ethoxy-pyrimidine

1500 mg Preparation 8b (6.46 mmol) was dissolved in 60 mL ethanol, then 527 mg sodium ethoxide (7.75 mmol) was added and the mixture was stirred at r.t. for 1 hour. The volatiles were evaporated under reduced pressure and the residue was purified via flash chromatography using heptane and EtOAc as eluents to give 4-(dimethoxymethyl)-2- ethoxy-pyrimidine. MS (M+H): 199.2

Step B: Preparation CI

Using General Procedure Va and 4-(dimethoxymethyl)-2-ethoxy-pyrimidine as the appropriate acetal, Preparation CI was obtained. MS (M+H): 155.2 Preparation C2: (l-Butyl-lH-pyrazol-5-yl)methanol

Using General Procedure Vb and 1-butylpyrazole as the appropriate alkyl pyrazole, Preparation C2 was obtained.

1H NMR (400 MHz, DMSO-d₆) δ: 7.30 (d, 1H), 6.12 (d, 1H), 5.23 (t, 1H), 4.49 (d, 2H), 4.06 (t, 2H), 1.72 (m, 2H), 1.26 (m, 2H), 0.88 (t, 3H)

MS (M+H): 155.2

Preparation C3: [2-(2-methoxyphenyl)pyrimidin-4-yl] methanol

Step A: 4-(dimethoxymethyl)-2-(2-methoxyphenyl)pyrimidine

Using General Procedure Vc and 2-methoxybenzamidine acetic acid salt as the appropriate amidine salt, 4-(dimethoxymethyl)-2-(2-methoxyphenyl)pyrimidine was obtained. 1H NMR (400 MHz, DMSO-d₆) δ: 8.93 (d, 1H), 7.55-7.44 (m, 3H), 7.16 (d, 1H), 7.06 (m, 1H), 5.31 (s, 1H), 3.76 (s, 3H), 3.37 (s, 6H)

Step B: Preparation C3

261 mg 4-(dimethoxymethyl)-2-(2-methoxyphenyl)pyrimidine (1.0 mmol) was dissolved in 2 mL HC1 in dioxane (4M solution), then 2 mL water was added and this mixture was stirred at 50 °C for 16 hours. The reaction mixture was cooled to 0 °C, then 320 mg NaOH (8.0 mmol) was added portionwise. The pH was adjusted to 8 using 10 % K₂CO₃ solution, then 76 mg sodium boro hydride (2.0 mmol) was added and the mixture was stirred for 30 minutes at 0 °C. The reaction mixture was diluted with 5 mL water and extracted with EtOAc. The combined organic phases were dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via flash chromatography using heptane and EtOAc as eluents to give Preparation C3. 1H NMR (400 MHz, DMSO-dg) δ: 8.84 (d, 1H), 7.50-7.42 (m, 3H), 7.14 (d, 1H), 7.03 (m, 1H), 5.66 (t, 1H), 4.58 (d, 2H), 3.75 (s, 3H)

Preparation C4: (l-tef"f-Butyl-lH-pyrazol-5-yl)methanol

Step A: l-tert-butyl-5-(dimethoxymethyl)-lH-pyrazole

Using General Procedure Vd and tert-butylhydrazine hydrochloride as the appropriate hydrazine hydrochloride, l-tert-butyl-5-(dimethoxymethyl)-lH-pyrazole was obtained. 1H NMR (400 MHz, DMSO-dg) δ: 7.34 (d, 1H), 6.34 (d, 1H), 5.74 (s, 1H), 3.24 (s, 6H), 1.57 (s, 9H)

Note: l-tert-butyl-3-(dimethoxymethyl)-lH-pyrazole was also obtained. 1H NMR (400 MHz, DMSO-dg) δ: 7.75 (d, 1H), 6.18 (d, 1H), 5.34 (s, 1H), 3.24 (s, 6H), 1.50 (s, 9H)

Step B: Preparation C4

Using General Procedure Ve and l-tert-butyl-5-(dimethoxymethyl)-lH-pyrazole as the appropriate acetal, Preparation C4 was obtained.1H NMR (400 MHz, DMSO-dg) δ: 7.27 (d, 1H), 6.19 (d, 1H), 5.31 (t, 1H), 4.61 (d, 2H), 1.56 (s, 9H) Preparation C5: [2-(2-methoxyethyl)pyrimidin-4-yl] methanol

Step A: 4-(dimethoxymethyl)-2-(2-methoxyethyl)pyrimidine

Using General Procedure Vc and 3-methoxypropanamidine hydrochloride as the appropriate amidine hydrochloride, 4-(dimethoxymethyl)-2-(2-methoxyethyl)pyrimidine was obtained. 1H NMR (400 MHz, DMSO-dg) δ: 8.78 (d, 1H), 7.38 (d, 1H), 5.25 (s, 1H), 3.80 (t, 2H), 3.33 (s, 6H), 3.22 (s, 3H), 3.11 (t, 2H)

Note: 2-[4-(dimethoxymethyl)pyrimidin-2-yl]-N,N-dimethyl-ethanamine was also obtained. MS (M+H): 226.2 Step B: Preparation C5

Using General Procedure Va and 4-(dimethoxymethyl)-2-(2-methoxyethyl)pyrimidine as the appropriate acetal, Preparation C5 was obtained. 1H NMR (400 MHz, DMSO-d₆) δ: 8.70 (d, 1H), 7.39 (d, 1H), 5.60 (t, 1H), 4.52 (d, 2H), 3.78 (t, 2H), 3.22 (s, 3H), 3.06 (t, 2H) Preparation C6: [l-(2,2,2-Trifluoroethyl)-lH-pyrazol-5-yl] methanol

Step A: 5-(dimethoxymethyl)-l-(2,2,2-trifluoroethyl)-4,5-dihydro-lii-pyrazol-5-ol

Using General Procedure Vd in the absence of sodium methoxide and using ethanol instead of methanol and 2,2,2-trifluoroethylhydrazine (70 w/w% in water) as the appropriate hydrazine, 5-(dimethoxymethyl)- 1 -(2,2,2-trifluoroethyl)-4,5-dihydro- 1H- pyrazol-5-ol was obtained. 1H NMR (400 MHz, DMSO-d₆) δ: 6.83 (t, 1H), 6.03 (s, 1H), 4.30 (s, 1H), 3.95 (m, 1H), 3.47 (m, 1H), 3.40 (d, 6H), 2.88 (m, 1H), 2.50 (m, 1H)

Step B: Preparation C6

Using General Procedure Ve and 5-(dimethoxymethyl)-l-(2,2,2-trifluoroethyl)-4,5- dihydro-lH-pyrazol-5-ol as the appropriate acetal, Preparation C6 was obtained. 1H NMR (400 MHz, DMSO-dg) δ: 7.48 (d, 1H), 6.27 (d, 1H), 5.46 (t, 1H), 5.08 (q, 2H), 4.56 (d, 2H)

Preparation C7: (2-(Morpholin-4-yl)pyrimidin-4-yl)methanol

Step A: 4-f 4-(dimethoxymethyl)pyrimidin-2-ylJmorpholine

25.0 g Preparation 8b (107.6 mmol) was dissolved in 161 mL morpholine and the mixture was stirred at r.t. until no further conversion was observed. Then it was concentrated under reduced pressure and the crude product was purified via flash chromatography using heptane and EtOAc as eluents to obtain 4-[4-(dimethoxymethyl)pyrimidin-2- yljmorpholine.

Step B: Preparation C7 Using General Procedure Va and 4-[4-(dimethoxymethyl)pyrimidin-2-yl]morpholine as the appropriate acetal, Preparation C7 was obtained. 1H NMR (400 MHz, DMSO-d₆) δ: 8.35 (d, 1H), 6.75 (dm, 1H), 5.431 (t, 1H), 4.36 (dm, 2H), 3.67 (m, 4H), 3.63 (m, 4H)

Preparation C8: [2-(2,2,2-trifluoroethoxy)pyrimidin-4-yl] methanol Step A: 4- ( dimethoxymethyl)-2- ( 2, 2, 2-trifluoroethoxy)pyrimidine

5.00 g Preparation 8b (21.5 mmol) was dissolved in 54 mL dry acetonitrile, then 5.95 g K₂CO₃ (43.1 mmol) and 3.24 g 2,2,2-trifluoroethanol (32.3 mmol) were added, and the mixture was stirred at 60 °C until no further conversion was observed. The reaction mixture was cooled, filtered, the solid was washed with EtOAc, then the filtrate was concentrated under reduced pressure. The crude product was purified via flash chromatography using heptane and EtOAc as eluents to give 4-(dimethoxymethyl)-2- (2,2,2-trifiuoroethoxy) pyrimidine. 1H NMR (400 MHz, DMSO-d₆) δ: 8.74 (d, 1H), 7.32 (d, 1H), 5.25 (s, 1H), 5.05 (q, 2H), 3.34 (s, 6H)

Step B: Preparation C8

Using General Procedure Va and 4-(dimethoxymethyl)-2-(2,2,2-trifluoroethoxy) pyrimidine as the appropriate acetal, Preparation C8 was obtained. 1H NMR (400 MHz, DMSO-de) δ: 8.65 (d, 1H), 7.32 (d, 1H), 5.69 (t, 1H), 5.02 (q, 2H), 4.51 (d, 2H)

Preparation C9: [2-(2-Fluorophenyl)pyrimidin-4-yl] methanol

Step A: 2-Fluoro-N '-hydroxy-benzamidine

The mixture of 11.48 g hydroxylamine hydrochloride (165 mmol), 13.87 g NaHC0₃ (165 mmol) and 120 mL MeOH was stirred at r.t. for 30 minutes. Then 10 g 2-fluorobenzonitrile (82.6 mmol) was added and the mixture was stirred at 75 °C until no further conversion was observed. The solvent was partially evaporated under reduced pressure, the residue was filtered, washed with MeOH. The filtrate was concentrated under reduced pressure, then diluted with water and extracted with EtOAc. The combined organic phases were dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure to give 2-fluoro-N'-hydroxy-benzamidine. Step B: 2-Fluorobenzamidine

12.67 g 2-fluoro-A/"-hydroxy-benzamidine (81.55 mmol) was dissolved in 300 mL AcOH at 0 °C and 9.24 mL Ac₂0 (97.86 mmol) was added. The mixture was stirred at r.t. until no further conversion was observed. Then 630 mg 10 % Pd/C was added and the mixture was stirred under H₂ atmosphere (4 bars) until no further conversion was observed. The mixture was filtered through celite and the filtrate was concentrated under reduced pressure to obtain 2-fluorobenzamidine acetate. MS (M(free base)+H): 139.4

Step C: 4-(Dimethoxymethyl)-2-(2-fluorophenyl)pyrimidine

Using General Procedure Vc and 2-fluorobenzamidine as the appropriate amidine, 4-(dimethoxymethyl)-2-(2-fluorophenyl)pyrimidine was obtained. MS (M+H): 249.2

Step D: Preparation C9

Using General Procedure Va and 4-(dimethoxymethyl)-2-(2-fluorophenyl)pyrimidine as the appropriate acetal, Preparation C9 was obtained. MS (M+H): 205.2

Preparation CIO: [2- [2-(2-methoxyethoxy)phenyl] yrimidin-4-yl] methanol Step A : N '-Hydroxy-2-methoxyethoxy-benzamidine

2 eq. hydroxylamine hydrochloride was dissolved in MeOH (lmL/mmol), then 2 eq.

NaHC0₃ was added. The mixture was stirred at r.t. for 20 minutes, then 1 eq.

2-methoxyethoxy-benzonitrile was added and the mixture was stirred at reflux until no further conversion was observed. MeOH was partially evaporated, the residue was filtered and the filtrate was concentrated under reduced pressure. The obtained N"-hydroxy-2-(2- methoxyethoxy)benzamidine was used without further purification.

1H NMR (400 MHz, CDC1₃) δ: 9.48 (s, 1H), 7.45 (m, 1H), 7.34 (m, 1H), 7.08 (d, 1H), 6.94 (td, 1H), 5.65 (br s, 2H), 4.17 (m, 2H), 3.67 (m, 2H), 3.31 (s, 3H)

MS (M+H): 211.2 Step B: 2-methoxyethoxy-benzamidine 8.22 g N'-hydroxy-2-(2-methoxyethoxy)benzamidine (39.1 mmol) was dissolved in 80 mL AcOH at 0 °C, then 4.43 mL Ac₂0 (46.92 mmol) was added dropwise. The mixture was stirred at r.t. until no further conversion was observed. 575 mg 10 % Pd/C was added and the mixture was stirred under H₂ atmosphere (4 bars) until no further conversion was observed. The mixture was filtered through celite and the filtrate was concentrated under reduced pressure to obtain 2-(2-methoxyethoxy)benzamidine acetate. MS (M+H): 195.2

Step C: 4-(Dimethoxymethyl)-2- [2-methoxyethoxy-phenyl] pyrimidine

Using General procedure Vc and 2-(2-methoxyethoxy)benzamidine acetate as the appropriate amidine salt, 4-(dimethoxymethyl)-2-[2-methoxyethoxy-phenyl]pyrimidine was obtained.

1H NMR (400 MHz, CDC1₃) δ: 8.92 (d, 1H), 7.55 (m, 1H), 7.47 (m, 1H), 7.45 (m, 1H), 7.17 (d, 1H), 7.08 (m, 1H), 5.29 (s, 1H), 4.12 (m, 2H), 3.57 (m, 2H), 3.36 (s, 6H), 3.20 (s, 3H)

MS (M+H): 305.0 Step D: Preparation CIO

Using General Procedure Va and 4-(dimethoxymethyl)-2-[2-methoxyethoxy- phenyljpyrimidine as the appropriate acetal, Preparation CIO was obtained.

1H NMR (400 MHz, CDC1₃) δ: 8.84 (d, 1H), 7.53 (m, 1H), 7.47 (m, 1H), 7.43 (m, 1H), 7.14 (d, 1H), 7.05 (td, 1H), 5.64 (t, 1H), 4.58 (d, 2H), 4.1 1 (m, 2H), 3.57 (m, 2H), 3.21 (s, 3H)

MS (M+H): 261.0

Example 1: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]-2-methoxy-Z⁾-phenylalanine and

Example 2: V-[(5R_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]-2-methoxy-Z⁾-phenylalanine Using General Procedure VI and Preparation 7a as the appropriate phenol derivative and methanol as the appropriate alcohol, then hydro lyzing the formed intermediate according to General Procedure VII, Example 1 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₃₆H₃₇C1FN₅0₄S: 689.2240, found: 345.6182 (M+2H)

Example 2 was obtained as the later eluting diastereoisomer. HRMS calculated for C₃₆H₃₇C1FN₅0₄S: 689.2240, found: 345.6185 (M+2H)

Example 3 : TV- [(5S_fl)-5-{3-chloro-2-methyl-4- [2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]-2-[(l-methyl-lH-pyrazol-5-yl) methoxy] -D-phenylalanine Using General Procedure VI and Preparation 7ad2 as the appropriate phenol derivative and (2-methylpyrazol-3-yl)methanol as the appropriate alcohol, then hydro lyzing the formed intermediate according to General Procedure VII, Example 3 was obtained. HRMS calculated for C₄₀H₄iClFN₇O₄S: 769.2613, found: 385.6378 (M+2H)

Example 4: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluor ophenyl)thieno [2,3-i j pyrimidin-4-yl] -2- [(2-ethoxypyrimidin-4-yl) methoxy] -D-phenylalanine

and

Example 5: V-[(5R_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]-2-[(2-ethoxypyrimidin-4-yl) methoxy] -D-phenylalanine

Using General Procedure VI and Preparation 7a as the appropriate phenol derivative and Preparation CI as the appropriate alcohol, then hydro lyzing the formed intermediate according to General Procedure VII, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 40 mM aqueous NH₄OAc solution (pH = 4, adjusted with AcOH) and acetonitrile as eluents, Example 4 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₄₂H₄₃C1FN₇0₅S: 811.2719, found: 406.6417 (M+2H) Example 5 was obtained as the later eluting diastereoisomer. HRMS calculated for C₄₂H₄₃C1FN₇0₅S: 811.2719, found: 406.6436 (M+2H)

Example 6: 2-[(l-butyl-lH-pyrazol-5-yl)methoxy]- V-[(5S_«)-5-{3-chloro-2-methyl-4-[2- (4-methylpiperazin-l-yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-i ]pyrimidin-4- yl]-D-phenylalanine

Using General Procedure VI and Preparation 7ad2 as the appropriate phenol derivative and Preparation C2 as the appropriate alcohol, then hydro lyzing the formed intermediate according to General Procedure VII, Example 6 was obtained. HRMS calculated for C₄₃H₄₇C1FN₇0₄S: 811.3082, found: 406.6616 (M+2H) Example 7: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluor ophenyl)thieno [2,3-i j pyrimidin-4-yl] -2- { [2-(2-methoxyphenyl) pyrimidin-4-yl]methoxy}-D-phenylalanine

Using General Procedure VI and Preparation 7ad2 as the appropriate phenol derivative and Preparation C3 as the appropriate alcohol, then hydro lyzing the formed intermediate according to General Procedure VII, Example 7 was obtained. HRMS calculated for C₄₇H₄₅C1FN₇0₅S: 873.2875, found: 437.6498 (M+2H)

Example 8: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(furan-2-yl)thieno[2,3-i ]pyrimidin-4-yl]-2-methoxy-Z⁾-phenylalanine and

Example 9: V-[(5R_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(furan-2-yl)thieno[2,3-i ]pyrimidin-4-yl]-2-methoxy-Z⁾-phenylalanine

Using General Procedure Ic and Preparation 4b as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(2-methoxyphenyl)propanoic acid as the appropriate amino acid derivative, Example 8 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₃4H₃₆C1N50₅S: 661.2126, found: 662.2203 (M+H) Example 9 was obtained as the later eluting diastereoisomer. HRMS calculated for C₃4H3₆C1N₅0₅S: 661.2126, , found: 662.2203 (M+H)

Example 10 : 2-chloro- V- [5- {3-chloro-2-methyl-4- [2-(4-methylpiperazin- l-yl)ethoxy] phenyl}-6-(furan-2-yl)thieno [2,3-i/] pyrimidin-4-yl] -D-phenylalanine,

diastereoisomer 1

Using General Procedure Ic and Preparation 4b as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(2-chlorophenyl)propanoic acid as the appropriate amino acid derivative, Example 10 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C3₃H₃₃C1₂N50₄S: 665.1630, found: 666.1670 (M+H)

Example 11 : 2-carbamoykV- [5- {3-chloro-2-methyl-4- [2-(4-methylpiperazin- 1-yl) ethoxy] phenyl}-6-(furan-2-yl)thieno [2,3-i/] pyrimidin-4-yl] -D-phenylalanine

Step A: 5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl] -4-fluoro-6-(2- furyl)thieno [2, 3 -ά] pyrimidine

A mixture of 150 mg Preparation 4b (0.3 mmol) and 380 mg silver fluoride (3.0 mmol) in 6 mL toluene was heated at reflux temperature for 3 hours. Then it was cooled to r.t., and the inorganic components were filtered off. The filtrate was concentrated under reduced pressure to obtain the crude product which was used in the next step without further purification. Step B: Example 11

A mixture of 316 mg 5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy]phenyl]- 4-fluoro-6-(2-furyl)thieno[2,3-(i]pyrimidine (0.65 mmol), 271 mg (2i?)-2-amino-3-(2- carbamoylphenyl)propanoic acid (1.30 mmol) and 424 mg Cs₂C0₃ (1.30 mmol) in 6 mL DMSO was stirred at 40 °C for 30 minutes. The mixture was diluted with water, the pH was adjusted to 5 using 1M HC1 solution and extracted with DCM. The organic phase was dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via preparative reversed phase chromatography using 0.1 % aqueous TFA solution solution and acetonitrile as eluents. The diastereoisomer eluting earlier was collected as Example 11. HRMS calculated for C34H35CI 6O5S : 674.2078, found: 675.2146 (M+H)

Example 12: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(furan-2-yl)thieno[2,3-i ]pyrimidin-4-yl]-2-(pyridin-2-ylmethoxy)-Z⁾- phenylalanine

and

Example 13 : TV- [(5R_fl)-5-{3-chloro-2-methyl-4- [2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(furan-2-yl)thieno[2,3-i ]pyrimidin-4-yl]-2-(pyridin-2-ylmethoxy)-Z⁾- phenylalanine

Using General Procedure Ic and Preparation 4b as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and Preparation A5 as the appropriate amino acid derivative, Example 12 was obtained as the later eluting diastereoisomer. HRMS calculated for C39H₃9C1N₆0₅S: 738.2391, found: 370.1269 (M+2H)

Example 13 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₃9H₃₉C1N₆0₅S: 738.2391, found: 370.1263 (M+2H)

Example 14: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(5-fluorofuran-2-yl)thieno[2,3-i |pyrimidin-4-yl]-2-hydroxy-Z⁾- phenylalanine Step A: (2R)-2-ff(5S_a)-5-f3-chloro-2-methyl-4-f2-(4-methylpiperazin-l-yl)ethoxyJphenylJ- 6-iodo-thieno[2,3-d]pyrimidin-4-yl]amino]-3-(2-hydroxyphenyl)propanoic acid

Using General Procedure Ic and Preparation 4a as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(2-hydroxyphenyl)propanoic acid a mixture of diastereoisomers was obtained. They were separated via HILIC chromatography. (2i?)-2-[[(55'_iJ)-5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl]-6-iodo- thieno[2,3-(i]pyrimidin-4-yl]amino]-3-(2-hydroxyphenyl)propanoic acid was obtained as the later eluting diastereoisomer. MS (M+H): 708.0 Step B: Example 14

Using General procedure Illb and (2i?)-2-[[(55'_iJ)-5-[3-chloro-2-methyl-4-[2-(4-methyl piperazin- 1 -yl)ethoxy]phenyl]-6-iodo-thieno

phenyl)propanoic acid as the appropriate 6-iodo-thieno[2,3-d]pyrimidine derivative and 2-(5-fluoro-2-furyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane as the appropriate boronic ester derivative, Example 14 was obtained. HRMS calculated for C₃₃H₃₃CIFN₅O₅S: 665.1875, found: 333.6012 (M+2H)

Example 15: V-[(5R_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(5-fluorofuran-2-yl)thieno[2,3-i |pyrimidin-4-yl]-2-methoxy-Z⁾- phenylalanine

and

Example 16: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(5-fluorofuran-2-yl)thieno[2,3-i |pyrimidin-4-yl]-2-methoxy-Z⁾- phenylalanine Using General Procedure lb and Preparation 4c as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(2-methoxyphenyl)propanoic acid as the appropriate amino acid derivative, Example 15 was obtained as the later eluting diastereoisomer. HRMS calculated for C₃₄H₃₅CIFN₅O₅S: 679.2031, found: 680.2100 (M+H)

Example 16 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₃₄H₃₅C1FN₅0₅S: 679.2031, found: 680.2092 (M+H)

Example 17: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(5-fluorofuran-2-yl)thieno [2,3-i j pyrimidin-4-yl] -2-(2,2,2-trifluoroethoxy)- D-phenylalanine Step A: ethyl (2R)-2-ff(5S_a)-5-f3-chloro-2-methyl-4-f2-(4-methylpiperazin-l-yl)ethoxyJ phenyl] -6-iodo-thieno[ 2, 3-d]pyrimidin-4-yl] amino] -3-(2-hydroxyphenyl)propanoate 876 mg (2i?)-2-[[(55'_iJ)-5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl]- 6-iodo-thieno[2,3-(i]pyrimidin-4-yl]amino]-3-(2-hydroxyphenyl)propanoic acid (1.24 mmol) was dissolved in 5 mL ethanol then 0.05 mL concentrated sulfuric acid was added and the mixture was stirred at 70 °C for 2 hours. Then the mixture was diluted with water, the pH was set to 5 using 1M NaHC0₃ solution and extracted with DCM. The organic phase was dried over Na₂S0₄, filtrated and the filtrate was concentrated under reduced pressure. The crude product was purified via flash chromatography using DCM and MeOH as eluents to obtain ethyl (2i?)-2-[[(5¾)-5-[3-chloro-2-methyl-4-[2-(4- methylpiperazin-l-yl)ethoxy]phenyl]-6-iodo-thieno[2,3-(i]pyrimidin-4-yl]amino]-3-(2- hydroxyphenyl) propanoate. MS (M+H): 736.1

Step B: ethyl (2R)-2-[[ (5Sa)-5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl] -6-iodo-thienof 2, 3-d]pyrimidin-4-yl] amino J-3-f 2- ( 2, 2, 2 -trifluoroethoxy) phenyl] propanoate

648 mg ethyl (2i?)-2-[[(55'_ii)-5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl]-6-iodo-thieno[2,3-(i]pyrimidin-4-yl]amino]-3-(2-hydroxyphenyl)propanoate (0.88 mmol) was dissolved in 10 mL DMF then 415 mg K₂C0₃ (3.00 mmol) and 348 mg 2,2,2-trifluoroethyl trifluoromethanesulfonate (1.50 mmol) were added at r.t. The mixture was stirred at 50 °C for 5 hours. The reaction mixture was diluted with brine, extracted with DCM. The organic phase was dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. The crude material was purified via flash chromatography using DCM and methanol as eluents to obtain ethyl (2R)-2-[[(5S_a)-5-[3- chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl]-6-iodo-thieno[2,3-<i] pyrimidin-4-yl]amino]-3-[2-(2,2,2-trifluoroethoxy)phenyl]propanoate. MS (M+H): 818.1

Step C: Example 17

Ethyl (2i?)-2-[[(55'_iJ)-5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl]-6- iodo-thieno[2,3- ]pyrimidin-4-yl]amino]-3-[2-(2,2,2-trifluoroethoxy)phenyl]propanoate was hydrolyzed according to General procedure VII to give (2i?)-2-[[(55'_iJ)-5-[3-chloro-2- methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy]phenyl]-6-iodo-thieno[2,3-(i]pyrimidin-4-yl] amino]-3-[2-(2,2,2-trifluoroethoxy)phenyl]propanoic acid. This compound was used as the appropriate 6-iodo-thieno[2,3-d]pyrimidine derivative and converted to Example 17 according to General Procedure Illb, using 2-(5-fluoro-2-furyl)-4,4,5,5-tetramethyl-l,3,2- dioxaborolane as the appropriate boronic acid derivative. HRMS calculated for C35H3₄C1F₄N₅0₅S: 747.1905, found: 374.6006 (M+2H)

Example 18: V-[(5R_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(5-fluorofuran-2-yl)thieno[2,3-i |pyrimidin-4-yl]-2-(pyridin-2-ylmethoxy)- D-phenylalanine

and

Example 19: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(5-fluorofuran-2-yl)thieno [2,3-i j pyrimidin-4-yl] -2-(pyridin-2-ylmethoxy)- D-phenylalanine Using General Procedure Ic and Preparation 4c as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and Preparation A5 as the appropriate amino acid derivative, Example 18 was obtained as the earlier eluting diastereoisomer. HRMS calculated for CsgHssClFNgOsS: 756.2296, found: 379.1230 (M+2H)

Example 19 was obtained as the later eluting diastereoisomer. HRMS calculated for CsgHssClFNgOsS: 756.2296, found: 379.1230 (M+2H)

Example 20: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(5-fluorofuran-2-yl)thieno[2,3-i |pyrimidin-4-yl]-2-[(l-methyl-lH-pyrazol- 5-yl)methoxy] -D-phenylalanine

Using General Procedure Illb and Preparation 5b as the appropriate 6-iodo-thieno[2,3-<i] pyrimidine derivative and 2-(5-fluoro-2-furyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane as the appropriate boronic acid derivative, Example 20 was obtained. HRMS calculated for CssHsgClFNyOsS: 759.2406, found: 380.6271 (M+2H)

Example 21: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(5-fluorofuran-2-yl)thieno[2,3-i |pyrimidin-4-yl]-2-[(l-ethyl-lH-pyrazol-5- yl)methoxy] -D-phenylalanine Using General Procedure Illb and Preparation 5c as the appropriate 6-iodo-thieno[2,3-<i] pyrimidine derivative and 2-(5-fluoro-2-furyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane as the appropriate boronic acid derivative, Example 21 was obtained. HRMS calculated for C₃9H₄iClFN₇0₅S: 773.2562, found: 387.6358 (M+2H) Example 22: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(5-fluorofuran-2-yl)thieno [2,3-i j pyrimidin-4-yl] -2- [(2-ethoxypyrimidin-4- yl)methoxy] -D-phenylalanine

Using General Procedure Ic and Preparation 4c as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and Preparation A2 as the appropriate amino acid derivative, Example 22 was obtained as the later eluting diastereoisomer. HRMS calculated for C₄oH₄iClFN₇0₆S: 801.2512, found: 401.6326 (M+2H)

Example 23 : 2- [(1-butyl- lH-pyrazol-5-yl)methoxy] -TV- [(5R«)-5- {3-chloro-2-methyl-4- [2-(4-methylpiperazin-l-yl)ethoxy]phenyl}-6-(5-fluorofuran-2-yl)thieno[2,3-i ] pyrimidin-4-yl] -D-phenylalanine

and

Example 24: 2-[(l-butyl-lH-pyrazol-5-yl)methoxy]-iV-[(5S_fl)-5-{3-chloro-2-methyl-4-

[2-(4-methylpiperazin-l-yl)ethoxy]phenyl}-6-(5-fluorofuran-2-yl)thieno[2,3- d\ pyrimidin-4-yl] -D-phenylalanine

Using General Procedure Ic and Preparation 4c as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and Preparation A3 as the appropriate amino acid derivative, Example 23 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₄iH₄₅ClFN₇0₅S: 801.2875, found: 401.6502 (M+2H)

Example 24 was obtained as the later eluting diastereoisomer. HRMS calculated for C₄iH₄₅ClFN₇0₅S: 801.2875, found: 401.6505 (M+2H) Example 25: V-[(5R_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(5-fluorofuran-2-yl)thieno [2,3-d\ pyrimidin-4-yl] -2- { [2-(2,2,2-trifluoro ethoxy)pyrimidin-4-yl]methoxy}-D-phenylalanine and

Example 26: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(5-fluorofuran-2-yl)thieno [2,3-d\ pyrimidin-4-yl] -2- { [2-(2,2,2-trifluoro ethoxy)pyrimidin-4-yl]methoxy}-D-phenylalanine Using General Procedure Ic and Preparation 4c as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and Preparation A8 as the appropriate amino acid derivative, Example 25 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₄₀H₃₈CIF₄N₇O₆S: 855.2228, found: 428.6181 (M+2H)

Example 26 was obtained as the later eluting diastereoisomer. HRMS calculated for C₄₀H₃₈CIF₄N₇O₆S: 855.2228, found: 428.6193 (M+2H)

Example 27: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(5-fluorofuran-2-yl)thieno [2,3-i j pyrimidin-4-yl] -2- { [2-(2-methoxyphenyl) pyrimidin-4-yl]methoxy}-D-phenylalanine

Step A: ethyl (2R)-2-[[ (5S_a)-5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl] -6- ( 5-fluoro-2-furyl)thieno[ 2, 3-d]pyrimidin-4-yl] amino ]-3-(2-hydroxyphenyl) propanoate

0.97 g Example 14 (1.46 mmol) was dissolved in 15 mL HC1 solution (1.25M in EtOH) and stirred at 40 °C overnight. The mixture was cooled to r.t., neutralized with aqueous NaHCC"3 solution and the mixture was extracted with DCM. The organic phase was dried over Na₂S04, filtered and the filtrate was concentrated under reduced pressure. The residue was purified via flash chromatography using DCM and MeOH as eluents to obtain ethyl (2i?)-2-[[(55'_iJ)-5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl) ethoxy]phenyl]-6-(5- f uoro-2-furyl)thieno[2,3-(i]pyrimidin-4-yl]amino]-3-(2-hydroxy phenyl)propanoate.

1H NMR (400 MHz, DMSO-d₆) δ: 9.48 (br s, 1H), 8.39 (s, 1H), 7.30 (s, 2H), 7.01 (td, 1H), 6.72 (d, 1H), 6.64 (t, 1H), 6.41 (d, 1H), 5.83 (m, 1H), 5.56 (t, 1H), 5.08 (d, 1H), 4.94 (m, 1H), 4.30 (t, 2H), 4.03 (m, 2H), 3.07 (dd, 1H), 2.81 (t, 2H), 2.56 (br, 4H), 2.36 (dd, 1H), 2.32 (br, 4H), 2.14 (s, 3H), 1.91 (s, 3H)

MS (M+H): 694.2 Step B: Example 27

Using General Procedure VI and ethyl (2R)-2-[[(5S_e)-5-[3-chloro-2-methyl-4-[2-(4-methyl piperazin- 1 -yl)ethoxy]phenyl] -6-(5 -fluoro-2-furyl)thieno [2,3 - ]pyrimidin-4-yl] amino] -3 - (2-hydroxyphenyl)propanoate as the appropriate phenol derivative and Preparation C3 as the appropriate alcohol derivative, then hydrolyzing the formed intermediate according to General Procedure VII, Example 27 was obtained. HRMS calculated for C₄₅H₄₃CIFN₇O₆S: 863.2668, found: 432.6414 (M+2H)

Example 28: TV- [(5S_fl)-5- {3-chloro-4- [2-(dimethylamino)ethoxy] -2-methylphenyl}-6-(5- fluorofuran-2-yl)thieno [2,3-i/] pyrimidin-4-yl] -2-hydroxy-D-phenylalanine Step A: 2-[2-chloro-4-[4-chloro-6-(5-fluoro-2-furyl)thieno[2,3-d]pyrimidin-5-yl]-3- methyl-phenoxyJ-N^-dimethyl-ethanamine

Using General Procedure Illb and Preparation 4e as the appropriate 6-iodo-thieno[2,3-<i] pyrimidine derivative and 2-(5-fluoro-2-furyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane as the appropriate boronic acid derivative, 2-[2-chloro-4-[4-chloro-6-(5-fluoro-2-furyl) thieno[2,3-(i]pyrimidin-5-yl]-3-methyl-phenoxy]-N,N-dimethyl-ethanamine was obtained.

Step B: Example 28

Using General Procedure lb and 2-[2-chloro-4-[4-chloro-6-(5-fluoro-2-furyl)thieno[2,3-(i] pyrimidin-5-yl]-3-methyl-phenoxy]-N,N-dimethyl-ethanamine as the appropriate 4-chloro- thieno[2,3-<i]pyrimidine derivative and 2-hydroxy-D-phenylalanine as the appropriate amino acid derivative, Example 28 was obtained as the later eluting diastereoisomer. HRMS calculated for C₃oH₂₈ClFN₄0₅S: 610.1453, found: 611.1503 (M+H)

Example 29: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(thiophen-3-yl)thieno [2,3-i ] pyrimidin-4-yl] -3-pyridin-2-yl-D-alanine and

Example 30: V-[(5R_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(thiophen-3-yl)thieno [2,3-i ] pyrimidin-4-yl] -3-pyridin-2-yl-D-alanine Using General Procedure Ic and Preparation 4g as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(2-pyridyl)propanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 40 mM aqueous NH₄OAc solution (pH = 4, adjusted with AcOH) and acetonitrile as eluents. Example 29 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₃₂H₃₃CIN₆O₃S₂: 648.1744, found: 649.1811 (M+H)

Example 30 was obtained as the later eluting diastereoisomer. HRMS calculated for C32H33CIN6O3S2: 648.1744, found: 649.1816 (M+H) Example 31: V-[(5R_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(thiophen-3-yl)thieno[2,3-i ]pyrimidin-4-yl]-3-cyclohexyl-Z⁾-alanine

and

Example 32: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(thiophen-3-yl)thieno[2,3-i ]pyrimidin-4-yl]-3-cyclohexyl-Z⁾-alanine Using General Procedure Ic and Preparation 4g as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-cyclohexyl-propanoic acid as the appropriate amino acid derivative, Example 31 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₃₃H₄oClN₅0₃S₂: 653.2261, found: 327.6194 (M+2H)

Example 32 was obtained as the later eluting diastereoisomer. HRMS calculated for C₃3H₄oClN₅0₃S2: 653.2261, found: 327.6195 (M+2H)

Example 33 : TV- [(5R_fl)-5-{3-chloro-2-methyl-4- [2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(thiophen-3-yl)thieno [2,3-i/] pyrimidin-4-yl] -2-fluoro-D-phenylalanine and

Example 34: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(thiophen-3-yl)thieno [2,3-i ] pyrimidin-4-yl] -2-fluoro-D-phenylalanine

Using General Procedure Ic and Preparation 4g as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(2-fluorophenyl)propanoic acid as the appropriate amino acid derivative, Example 33 was obtained as the later eluting diastereoisomer. HRMS calculated for C₃₃H₃₃CIFN₅O₃S₂: 665.1697, found: 666.1776 (M+H)

Example 34 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₃3H33C1FN₅03S₂: 665.1697, found: 666.1776 (M+H) Example 35: V-[(5R_fl)-5-{3-chloro-2-methyl-4-[2-(morpholin-4-yl)ethoxy]phenyl}-6- (thiophen-3-yl)thieno [2,3-i j pyrimidin-4-yl] -3-pyridin-2-yl-D- alanine

and

Example 36: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(morpholin-4-yl)ethoxy]phenyl}-6- (thiophen-3-yl)thieno [2,3-i j pyrimidin-4-yl] -3-pyridin-2-yl-D- alanine Using General Procedure Ic and Preparation 4h as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(2-pyridyl)propanoic acid as the appropriate amino acid derivative, Example 35 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C3iH3₀ClN₅O₄S2 : 635.1428, found: 636.1499 (M+H)

Example 36 was obtained as the later eluting diastereoisomer. HRMS calculated for C₃iH3oClN₅0₄S₂: 635.1428, found: 636.1508 (M+H)

Example 37: 2-(aminomethyl)- V-[(5R_fl)-5-{3-chloro-2-methyl-4-[2-(morpholin-4-yl) ethoxy] phenyl}-6-(thiophen-3-yl)thieno [2,3-i/] pyrimidin-4-yl] -D-phenylalanine and

Example 38 : 2-(aminomethyl)-7V- [(5S_fl)-5- {3-chloro-2-methyl-4- [2-(morpholin-4-yl) ethoxy] phenyl}-6-(thiophen-3-yl)thieno [2,3-i ] pyrimidin-4-yl] -D-phenylalanine

Using General Procedure Ic and Preparation 4h as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-[2-(aminomethyl)phenyl]propanoic acid as the appropriate amino acid derivative, Example 37 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₃3H₃₄C1 ₅0₄S₂: 663.1741, found: 664.1808 (M+H)

Example 38 was obtained as the later eluting diastereoisomer. HRMS calculated for C33H₃₄C1N₅0₄S₂: 663.1741, found: 664.1825 (M+H) Example 39: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(prop-l-yn-l-yl)thieno[2,3-i ]pyrimidin-4-yl]-2-methoxy-Z⁾-phenylalanine

Using General Procedure VI and Preparation 7b as the appropriate phenol derivative and methanol as the appropriate alcohol derivative, then hydro lyzing the formed intermediate according to General Procedure VII, Example 39 was obtained. HRMS calculated for C₃₃H₃₆C1N₅0₄S: 633.2176, found: 317.6163 (M+2H)

Example 40: 2-[(l-tei-i-butyl-lH-pyrazol-5-yl)methoxy]- V-[(5S_fl)-5-{3-chloro-2- methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy]phenyl}-6-(prop-l-yn-l-yl)thieno[2,3-i ] pyrimidin-4-yl] -D-phenylalanine Using General Procedure VI and Preparation 7b as the appropriate phenol derivative and Preparation C4 as the appropriate alcohol derivative, then hydro lyzing the formed intermediate according to General Procedure VII, Example 40 was obtained. HRMS calculated for C₄₀H₄₆ClN₇O₄S: 755.3021 found: 378.6573 (M+2H)

Example 41: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(prop- 1-yn- l-yl)thieno [2,3-i/] pyrimidin-4-yl] -2- { [2-(2-methoxy ethyl) pyrimidin-4-yl]methoxy}-D-phenylalanine

Using General Procedure VI and Preparation 7b as the appropriate phenol derivative and Preparation C5 as the appropriate alcohol derivative, then hydrolyzing the formed intermediate according to General Procedure VII, Example 41 was obtained. HRMS calculated for C₄₀H₄₄ClN₇O₅S: 769.2813, found: 385.6476 (M+2H).

Example 42: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(prop- 1-yn- l-yl)thieno [2,3-i ] pyrimidin-4-yl] -2- { [ l-(2,2,2-trifluoroethyl)- lH-pyrazol-5-yl]methoxy}-D-phenylalanine

Using General Procedure VI and Preparation 7b as the appropriate phenol derivative and Preparation C6 as the appropriate alcohol derivative, then hydrolyzing the formed intermediate according to General Procedure VII, Example 42 was obtained. HRMS calculated for C₃₈H₃₉CIF₃N₇O₄S: 781.2425, found: 391.6300 (M+2H)

Example 43 : TV- [(5S_fl)-5-{3-chloro-2-methyl-4- [2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(prop- 1-yn- l-yl)thieno [2,3- \ pyrimidin-4-yl] -2- { [2-(morpholin-4-yl) pyrimidin-4-yl]methoxy}-D-phenylalanine

Using General Procedure VI and Preparation 7b as the appropriate phenol derivative and Preparation C7 as the appropriate alcohol derivative, then hydrolyzing the formed intermediate according to General Procedure VII, Example 43 was obtained. HRMS calculated for C₄iH4₅ClN₈0₅S: 796.2922, found: 399.1546 (M+2H) Example 44: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(prop- 1-yn- l-yl)thieno [2,3- \ pyrimidin-4-yl] -2- { [2-(2,2,2-trifluoroethoxy) pyrimidin-4-yl]methoxy}-D-phenylalanine

Using General Procedure VI and Preparation 7b as the appropriate phenol derivative and Preparation C8 as the appropriate alcohol derivative, then hydrolyzing the formed intermediate according to General Procedure VII, Example 44 was obtained. HRMS calculated for CsgHsgClFsNyOsS: 809.2374, found: 405.6262 (M+2H)

Example 45: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(prop- 1-yn- l-yl)thieno [2,3- \ pyrimidin-4-yl] -2- { [2-(2-methoxyphenyl) pyrimidin-4-yl]methoxy}-D-phenylalanine Using General Procedure VI and Preparation 7b as the appropriate phenol derivative and Preparation C3 as the appropriate alcohol derivative, then hydrolyzing the formed intermediate according to General Procedure VII, Example 45 was obtained. HRMS calculated for C₄₄H₄₄C1N₇0₅S: 817.2813, found: 409.6494 (M+2H) Example 46: TV- [(5S_fl)-5-{3-chloro-4- [2-(dimethylamino)ethoxy] -2-methylphenyl}-6- (prop- 1-yn- l-yl)thieno [2,3-</] pyrimidin-4-yl] -2- { [ l-(2,2,2-trifluoroethyl)- lH-pyrazol- 5-yl]methoxy}-D-phenylalanine

Using General Procedure VI and Preparation 7c as the appropriate phenol derivative and Preparation C6 as the appropriate alcohol derivative, then hydrolyzing the formed intermediate according to General Procedure VII, Example 46 was obtained. HRMS calculated for C₃₅H₃₄CIF₃N₆O₄S: 726.2003, found: 727.2092 (M+H)

Example 47: TV- [(5S_fl)-5-{3-chloro-4- [2-(dimethylamino)ethoxy] -2-methylphenyl}-6- (prop- 1-yn- l-yl)thieno [2,3-i ] pyrimidin-4-yl] -2- { [2-(morpholin-4-yl)pyrimidin-4-yl] methoxy}-D-phenylalanine

Using General Procedure VI and Preparation 7c as the appropriate phenol derivative and Preparation C7 as the appropriate alcohol derivative, then hydrolyzing the formed intermediate according to General Procedure VII, Example 47 was obtained. HRMS calculated for

741.2500, found: 371.6331 (M+2H) Example 48: 7V-[(5S_fl)-5-{3-chloro-4-[2-(dimethylamino)ethoxy]-2-methylphenyl}-6- (prop- 1-yn- l-yl)thieno [2,3-i ] pyrimidin-4-yl] -2- { [2-(2,2,2-trifluoroethoxy)pyrimidin-4- yl]methoxy}-D-phenylalanine

Using General Procedure VI and Preparation 7c as the appropriate phenol derivative and Preparation C8 as the appropriate alcohol derivative, then hydrolyzing the formed intermediate according to General Procedure VII, Example 48 was obtained. HRMS calculated for

754.1952, found: 755.1971 (M+H)

Example 49: N- [(5S_fl)-5-{3-chloro-4- [2-(dimethylamino)ethoxy] -2-methylphenyl}-6- (prop- 1-yn- l-yl)thieno [2,3-i/] pyrimidin-4-yl] -2- { [2-(2-methoxyphenyl)pyrimidin-4-yl] methoxy}-D-phenylalanine Using General Procedure VI and Preparation 7c as the appropriate phenol derivative and Preparation C3 as the appropriate alcohol derivative, then hydro lyzing the formed intermediate according to General Procedure VII, Example 49 was obtained. HRMS calculated for C₄iH₃₉ClN₆0₅S: 762.2391, found: 371.6323 (M+2H) Example 50: V-[(5S_fl)-5-{3-chloro-4-[2-(dimethylamino)ethoxy]-2-methylphenyl}-6-(4- fluor ophenyl)thieno [2,3-i j pyrimidin-4-yl] -2- { [2-(2-fluorophenyl)pyrimidin-4-yl] methoxy}-D-phenylalanine

Step A: ethyl (2 )-2-[[5-bromo-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]amino]-3- [2-[[2-(2-fluorophenyl)pyrimidin-4-yl]methoxy]phenyl]propanoate

Using General Procedure VI and Preparation 7d as the appropriate phenol derivative and Preparation C9 as the appropriate alcohol derivative, ethyl (2i?)-2-[[5-bromo-6-(4- fluorophenyl)thieno [2,3 - ]pyrimidin-4-yl]amino] -3 - [2- [ [2-(2-fluorophenyl)pyrimidin-4-yl] methoxy]phenyl]propanoate was obtained. 1H NMR (400 MHz, DMSO-d₆) δ: 8.84 (d, 1H), 8.39 (s, 1H), 7.95 (td, 1H), 7.58-7.52 (m, 3H), 7.39-7.24 (m, 8H), 7.13 (d, 1H), 6.95 (t, 1H), 5.29-5.15 (m, 3H), 4.16 (q, 2H), 3.63 (dd, 1H), 3.25 (dd, 1H), 1.19 (t, 3H)

Step B: ethyl (2R)-2-[[5-[3-chloro-4-(2-dimethylaminoethyloxy)-2-methyl-phenyl]-6-(4- fluorophenyl) thienof 2, 3-d]pyrimidin-4-yl] amino J-3-f 2-f f 2-(2-fluorophenyl)pyrimidin-4- yljmethoxy] phenyl] propanoate

1 eq. ethyl (2i?)-2-[[5-bromo-6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]amino]-3-[2- [[2-(2-fluorophenyl)pyrimidin-4-yl]methoxy]phenyl]propanoate and 1.2 eq. Preparation B5 were dissolved in dioxan (5 mL/mmol), then 5 mol% AtaPhos, 3 eq. Cs₂C0₃ and water(5 mL/mmol) were added and the mixture was stirred at 70 °C under argon atmosphere until no further conversion was observed. Then the mixture was diluted with EtOAc and was washed with brine. The organic phase was dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via flash chromatography using DCM and MeOH as eluents to obtain ethyl (2i?)-2-[[5-[3- chloro-4-(2-dimethylaminoethyloxy)-2-methyl-phenyl]-6-(4-fluorophenyl)thieno[2,3-(i] pyrimidin-4-yl]amino] -3 - [2- [ [2-(2-fluorophenyl)pyrimidin-4-yl]methoxy]phenyl] propanoate as a mixture of diastereoisomers. MS (M+H): 834.6 Step C: Example 50

Using General Procedure VII and ethyl (2i?)-2-[[5-[3-chloro-4-(2-dimethylaminoethyl oxy)-2-methyl-phenyl]-6-(4-fluorophenyl)thieno[2,3- ]pyrimidin-4-yl]amino]-3-[2-[[2-(2- fluorophenyl)pyrimidin-4-yl]methoxy]phenyl]propanoate as the appropriate ester derivative, Example 50 was obtained as the later eluting diastereoisomer. HRMS calculated for C₄₃H₃₇CIF₂N₆O₄S: 806.2254, found: 807.2343 (M+H)

Example 51: TV- [(5S_fl)-5- {3-chloro-4- [2-(dimethylamino)ethoxy] -2-methylphenyl}-6-(4- fluor ophenyl)thieno [2,3-i j pyrimidin-4-yl] -2-({2- [2-(2-methoxyethoxy)phenyl] pyrimidin-4-yl}methoxy)-Z⁾-phenylalanine

Step A: ethyl (2R)-2-[[5-bromo-6-(4-fluorophenyl)thieno[2, 3-d]pyrimidin-4-yl]amino]-3- [2-[[2-[2-(2-methoxyethoxy)phenyl]pyrimidin-4-yl]methoxy]phenyl]propanoate

Using General Procedure VI and Preparation 7d as the appropriate phenol derivative and Preparation CIO as the appropriate alcohol derivative, ethyl (2i?)-2-[[5-bromo-6-(4- fluorophenyl)thieno [2,3 - ]pyrimidin-4-yl]amino] -3 - [2- [ [2- [2-(2-methoxyethoxy)phenyl] pyrimidin-4-yl]methoxy]phenyl]propanoate was obtained. 1H NMR (400 MHz, DMSO-d₆) δ: 8.80 (d, 1H), 8.41 (s, 1H), 7.57-7.53 (m, 3H), 7.46-7.23 (m, 7H), 7.16 (d, 1H), 7.07 (d, 1H), 7.03 (t, 1H), 6.94 (t, 1H), 5.28-5.23 (m, 1H), 5.19 (dd, 2H), 4.18-4.1 1 (m, 4H), 3.61- 3.57 (m, 3H), 3.27 (dd, 1H), 3.21 (s, 3H), 1.19 (t, 3H)

Step B: ethyl (2R)-2-[[5-[3-chloro-4-(2-dimethylaminoethyloxy)-2-methyl-phenyl]-6-(4- fluorophenyl) thienof 2, 3-d]pyrimidin-4-yl] amino J-3-f 2-f f 2-f 2-(2-methoxyethoxy)phenyl] pyrimidin-4-yl]methoxy] phenyl] propanoate

1 eq. ethyl (2i?)-2-[[5-bromo-6-(4-fluorophenyl)thieno[2,3- ]pyrimidin-4-yl]amino]-3-[2- [[2-[2-(2-methoxyethoxy)phenyl]pyrimidin-4-yl]methoxy]phenyl]propanoate and 1.2 eq. Preparation B5 were dissolved in dioxan (5 mL/mmol), then 5 mol% AtaPhos, 3 eq. CS₂CO₃ and water(5 mL/mmol) were added and the mixture was stirred at 70°C under argon atmosphere until no further conversion was observed. Then the mixture was diluted with EtOAc and was washed with brine. The organic phase was dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via flash chromatography using DCM and MeOH as eluents to obtain ethyl (2i?)-2-[[5-[3-chloro-4-(2-dimethylaminoethyloxy)-2-methyl-phenyl]-6-(4-fluorophenyl) thieno [2,3 - ]pyrimidin-4-yl] amino] -3 - [2- [ [2-[2-(2-methoxyethoxy)phenyl]pyrimidin-4-yl] methoxy]phenyl]propanoate as a mixture of diastereoisomers. MS (M+H): 890.6 Step C: Example 51

Using General Procedure VII and ethyl (2i?)-2-[[5-[3-chloro-4-(2-dimethylaminoethyl oxy)-2-methyl-phenyl]-6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]amino]-3-[2-[[2-[2- (2-methoxyethoxy)phenyl]pyrimidin-4-yl]methoxy]phenyl]propanoate as the appropriate ester derivative, Example 51 was obtained as the later eluting diastereoisomer. HRMS calculated for C46H44CIFN6O6S : 862.2716, found: 432.1442 (M+2H)

Example 52: V-[(5R_fl)-5-(3,5-dichloro-4-hydroxy-2-methylphenyl)-6-ethylthieno[2,3-i | pyrimidin-4-yl] -D-phenylalanine

and

Example 53 : N- [(5S_fl)-5-(3,5-dichloro-4-hydroxy-2-methylphenyl)-6-ethylthieno [2,3-i j pyrimidin-4-yl] -D-phenylalanine

Using General Procedure VII and Preparation 7f as the appropriate ester derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 52 was obtained as the earlier eluting diastereomer. HRMS calculated for C24H21CI2N3O3S : 501.0681, found: 502.0755 (M+H)

Example 53 was obtained as the later eluting diastereomer. HRMS calculated for C24H21CI2N3O3S : 501.0681, found: 502.0772 (M+H)

Example 54: V-((5S_fl)-5-{3,5-dichloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-ethylthieno[2,3-i ]pyrimidin-4-yl)-Z⁾-phenylalanine

and

Example 55: V-((5R_fl)-5-{3,5-dichloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-ethylthieno[2,3-i ]pyrimidin-4-yl)-Z⁾-phenylalanine Using General Procedure VI and Preparation 7f as the appropriate phenol derivative and 2-(4-methylpiperazin-l-yl)ethanol as the appropriate alcohol derivative, then hydro lyzing the formed intermediate according to General Procedure VII, Example 54 was obtained as the later eluting diastereoisomer. HRMS calculated for C31H35CI2N5O3S : 627.1838, found: 628.1935 (M+H)

Example 55 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₃iH₃₅Cl₂N₅0₃S: 627.1838, found: 628.1932 (M+H)

Example 56 : TV- {(5S_fl)-5- [3-chloro-4-(2-hydroxyethoxy)-2-methylphenyl] -6-ethyl thieno[2,3-i/]pyrimidin-4-yl}-D-phenylalanine Using General Procedure VI and Preparation 7gdl as the appropriate phenol derivative and 10 eq. ethylene glycol as the appropriate alcohol derivative, then hydro lyzing the formed intermediate according to General Procedure VII, Example 56 was obtained. HRMS calculated for C₂₆H₂₆C1N₃0₄S: 511.1333, found: 512.1390 (M+H)

Example 57: iV-{(5S_fl)-5-[4-(carboxymethoxy)-3-chloro-2-methylphenyl]-6-ethylthieno

[2,3-i/l pyrimidin-4-yl}-D-phenylalanine

Using General Procedure VI and Preparation 7gdl as the appropriate phenol derivative and 2-hydroxy-N,N-dimethylacetamide as the appropriate alcohol derivative, then hydrolyzing the formed intermediate according to General Procedure VII, Example 57 was obtained. HRMS calculated for C₂₆H₂₄C1N₃0₅S: 525.1125, found: 526.1217 (M+H) Example 58: V-((5R_fl)-5-{3-chloro-4-[2-(dimethylamino)ethoxy]-2-methylphenyl}-6- ethylthieno [2,3-i j pyrimidin-4-yl)-L-phenylalanine

and

Example 59: V-((5S_fl)-5-{3-chloro-4-[2-(dimethylamino)ethoxy]-2-methylphenyl}-6- ethylthieno [2,3-i j pyrimidin-4-yl)-L-phenylalanine Using General Procedure VI and Preparation 7g as the appropriate phenol derivative and 2-(dimethylamino)ethanol as the appropriate alcohol derivative, then hydrolyzing the formed intermediate according to General Procedure VII, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 40 mM aqueous NH₄OAc solution (pH = 4, adjusted with AcOH) and acetonitrile as eluents. Example 58 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂8H₃iClN₄0₃S: 538.1805, found: 539.1869 (M+H)

Example 59 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₈H₃iClN₄0₃S: 538.1805, found: 539.1866 (M+H)

Example 60: V-((5S_fl)-5-{3-chloro-4-[3-(dimethylamino)propoxy]-2-methylphenyl}-6- ethylthieno [2,3-i j pyrimidin-4-yl)-D-phenylalanine Using General Procedure VI and Preparation 7gdl as the appropriate phenol derivative and 3-(dimethylamino)propanol as the appropriate alcohol derivative, then hydrolyzing the formed intermediate according to General Procedure VII, Example 60 was obtained. HRMS calculated for C₂₉H₃₃C1N₄0₃S: 552.1962, found: 553.2036 (M+H)

Example 61: V-((5S_fl)-5-{3-chloro-2-methyl-4-[2-(morpholin-4-yl)ethoxy]phenyl}-6- ethylthieno [2,3-i j pyrimidin-4-yl)-D-phenylalanine

Using General Procedure VI and Preparation 7gdl as the appropriate phenol derivative and 2-morpholinoethanol as the appropriate alcohol derivative, then hydrolyzing the formed intermediate according to General Procedure VII, Example 61 was obtained. HRMS calculated for C₃₀H₃₃ClN₄O₄S: 580.1911, found: 581.1981 (M+H) Example 62: V-((5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-ethylthieno[2,3-i ]pyrimidin-4-yl)-Z⁾-phenylalanine

and

Example 63 V-((5R_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-ethylthieno[2,3-i ]pyrimidin-4-yl)-Z⁾-phenylalanine Using General Procedure VI and Preparation 7g as the appropriate phenol derivative and 2-(4-methylpiperazin-l-yl)ethanol as the appropriate alcohol derivative, then hydrolyzing the formed intermediate according to General Procedure VII, Example 62 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₃₁H₃₆CIN₅O₃S: 593.2227, found: 594.2313 (M+H)

Example 63 was obtained as the later eluting diastereoisomer. HRMS calculated for C₃iH₃₆ClN₅0₃S: 593.2227, found: 594.2304 (M+H)

Example 64 : V-((5S_fl)-5- {3-chloro-2-methyl-4- [3-(4-methylpiperazin- l-yl)propoxy] phenyl}-6-ethylthieno[2,3-i ]pyrimidin-4-yl)-Z⁾-phenylalanine

Using General Procedure VI and Preparation 7gdl as the appropriate phenol derivative and 3-(4-methylpiperazin-l-yl)propan-l-ol as the appropriate alcohol derivative, then hydrolyzing the formed intermediate according to General Procedure VII, Example 64 was obtained. HRMS calculated for C3₂H₃₈C1N₅0₃S: 607.2384, found: 608.2444 (M+H)

Example 65: V-((5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-[5-(methoxycarbonyl)-4-methylfuran-2-yl]thieno[2,3-i ]pyrimidin-4-yl)-2- methoxy-D-phenylalanine

and

Example 66: V-((5R_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-[5-(methoxycarbonyl)-4-methylfuran-2-yl]thieno[2,3-i ]pyrimidin-4-yl)-2- methoxy-D-phenylalanine

Step A: [4-chloro-5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl] thieno[2, 3-d]pyrimidin-6-yl]-trimethyl-stannane

1.97 g 4-chloro-5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy]phenyl]thieno [2,3- ]pyrimidine (4.50 mmol, from Step A of Preparation 4a) was dissolved in 40 mL dry THF under N₂ atmosphere, and the mixture was cooled to -78 °C. Then 4.5 mL LDA (9 mmol, 2M solution in heptane, THF and ethyl benzene) was added and the mixture was stirred at -78 °C for 1 hour. Then 13.5 mL Me₃SnCl solution (13.5 mmol, 1M in hexane) was added and the mixture was allowed to warm up to r.t. The mixture was then diluted with cc. NH₄CI solution and extracted with diethyl ether. The organic phase was dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. Then it was dissolved in 60 mL EtOAc, and 40 mL saturated NaF solution was added, and it was stirred at r.t. overnight. Then it was filtered, the phases of the filtrate were separated. The aqueous phase was extracted with EtOAc. The combined organic phases were dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via flash chromatography using DCM and MeOH as eluents to obtain [4-chloro-5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy] phenyl]thieno[2,3-<i] pyrimidin-6-yl]-trimethyl-stannane. HRMS calculated for C₂₃H₃₀N₄OSCl₂Sn: 600.0539, found: 601.0584 (M+H)

Step B: methyl 5-[4-chloro-5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl] thieno [2, 3-d]pyrimidin-6-yl]-3-methyl-furan-2-carboxylate

900 mg [4-chloro-5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl] thieno[2,3-(i]pyrimidin-6-yl]-trimethyl-stannane (1.50 mmol), 657 mg methyl 5-bromo-3- methyl-furan-2-carboxylate (3 mmol), 29 mg Cul (0.15 mmol), 29 mg Pd(PhCN)₂Cl₂ (0.075 mmol), 46 mg Ph₃As (0.15 mmol) and 2 mL NMP were stirred at 100 °C until no further conversion was observed. Then the mixture was diluted with EtOAc and washed with saturated NaF solution. The aqueous phase was extracted with EtOAc. The combined organic phases were dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via flash chromatography using DCM and MeOH as eluents to obtain methyl 5-[4-chloro-5-[3-chloro-2-methyl-4- [2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl]thieno[2,3-<i]pyrimidin-6-yl]-3-methyl-furan-2- carboxylate. HRMS calculated for C₂7H₂8C1₂N₄0₄S: 574.1208, found: 575.1263 (M+H)

Step C: Example 65

Using General Procedure lb and methyl 5-[4-chloro-5-[3-chloro-2-methyl-4-[2-(4-methyl piperazin-l-yl)ethoxy]phenyl]thieno[2,3-(i]pyrimidin-6-yl]-3-methyl-furan-2-carboxylate as the appropriate 4-chloro-thieno[2,3-d]pyrimidine derivative and (2i?)-2-amino-3-(2- methoxyphenyl)propanoic acid as the appropriate amino acid derivative Example 65 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₃₇H₄oClN50₇S: 733.23369, found: 367.6263 (M+2H)

Example 66 was obtained as the later eluting diastereoisomer. HRMS calculated for C₃₇H₄oClN₅0₇S: 733.23369, found: 367.6223 (M+2H) Example 67: TV- [6-ethyl-5-(3-hydroxy-2-methylphenyl)thieno [2,3-i/] pyrimidin-4-yl] -D- phenylalanine

Using General Procedure lid and Preparation 3a as the appropriate 5-iodo-thieno[2,3-<i] pyrimidine derivative and 2-methyl-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenol as the appropriate boronic acid derivative, Example 67 was obtained as a mixture of diastereoisomers. HRMS calculated for C24H23N3O3S : 433.1460, found: 434.1545 and 434.1535 (M+H)

Example 68 : TV- [6-ethyl-5-(3-fluoro-2-methylphenyl)thieno [2,3-i ] pyrimidin-4-yl] -D- phenylalanine Using General Procedure Ila and Preparation 3a as the appropriate 5-iodo-thieno[2,3-<i] pyrimidine derivative and (3-fluoro-2-methyl-phenyl)boronic acid as the appropriate boronic acid derivative, Example 68 was obtained as a mixture of diasteromeres. HRMS calculated for C24H22FN3O2S : 435.1417, found: 436.1489 and 436.1484 (M+H)

Example 69: V-[6-ethyl-(5S_fl)-5-(3-fluoro-2-methylphenyl)thieno[2,3-i |pyrimidin-4- yl]-D-phenylalanine

and

Example 70 : TV- [6-ethyl-(5R«)-5-(3-fluoro-2-methylphenyl)thieno [2,3-i ] pyrimidin-4- yl] -D-phenylalanine

Diastereoisomers of Example 68 were separated by preparative reversed phase chromatography using 25 mM aqueous NH₄HCO₃ solution and acetonitrile as eluents. Example 69 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₄H₂₂FN₃O₂S: 435.1417, found: 436.1481 (M+H)

Example 70 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₄H₂₂FN₃O₂S: 435.1417, found: 436.1498 (M+H) Example 71: TV- [6-ethyl-5-(lH-indol-7-yl)thieno [2,3-d\ yrimidin-4-yl] -D- phenylalanine, diastereoisomer 1

and

Example 72 : TV- [6-ethyl-5-(lH-indol-7-yl)thieno [2,3-i J pyrimidin-4-yl] -D- phenylalanine, diastereoisomer 2

Using General Procedure Ila and Preparation 3a as the appropriate 5-iodo-thieno[2,3-<i] pyrimidine derivative and 7-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)-lH-indole as the appropriate boronic acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 71 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₅H₂₂N₄O₂S: 442.1463, found: 443.1540 (M+H) Example 72 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₅H₂₂N₄O₂S: 442.1463, found: 443.1537 (M+H)

Example 73 : N- [6-ethyl-(5S«)-5-(lH-indol-4-yl)thieno [2,3-*/] pyrimidin-4-yl] -D- phenylalanine

and

Example 74 : N- [6-ethyl-(5R«)-5-(lH-indol-4-yl)thieno [2,3-*/] pyrimidin-4-yl] -D- phenylalanine

The diastereoisomers of Preparation 7h were separated by preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 73 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₅H₂₂N₄O₂S: 442.1463, found: found: 443.1529 (M+H)

Example 74 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₅H₂₂N₄O₂S: 442.1463, found: 443.1538 (M+H) Example 75: 7V-[6-ethyl-(5S_fl)-5-(3-methoxy-2-methylphenyl)thieno[2,3-i |pyrimidin-4- yl] -D-phenylalanine

and Example 76 : TV- [6-ethyl-(5R_fl)-5-(3-methoxy-2-methylphenyl)thieno [2,3-</] pyrimidin- 4-yl] -D-phenylalanine

Using General Procedure lib and Preparation 3a as the appropriate 5-iodo-thieno[2,3-<i] pyrimidine derivative and 2-(3-methoxy-2-methyl-phenyl)-4,4,5,5-tetramethyl-l,3,2- dioxaborolane as the appropriate boronic acid derivative, using DME: water 5: 1 instead of 2-Me-THF, and separating the diastereoisomers by preparative reversed phase chromatography using 25 mM aqueous NH₄HCO₃ solution and acetonitrile as eluents, Example 75 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂5H₂₅N₃0₃S: 447.1617, found: 448.1701 (M+H)

Example 76 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂5H2₅N30₃S: 447.1617, found: 448.1672 (M+H)

Example 77: TV- [(5R_fl)-5-(2-chloro-3-methylpyridin-4-yl)-6-ethylthieno [2,3-i ] pyrimidin-4-yl] -D-phenylalanine

and

Example 78 N- [(5S_fl)-5-(2-chloro-3-methylpyridin-4-yl)-6-ethylthieno [2,3-i ] pyrimidin-4-yl] -D-phenylalanine

Using General Procedure lib and Preparation 3a as the appropriate 5-iodo-thieno[2,3-<i] pyrimidine derivative and 2-chloro-3-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)pyridine as the appropriate boronic acid derivative, using DME: water 5: 1 instead of 2-Me-THF, and separating the diastereoisomers by preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents, Example 77 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C23H21CIN4O2S : 452.1074, found: 453.1158 (M+H)

Example 78 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₃H₂iClN₄0₂S: 452.1074, found: 453.1165 (M+H)

Example 79 : N- [6-ethyl-5-(naphthalen- l-yl)thieno [2,3-i/] pyrimidin-4-yl] -D- phenylalanine Using General Procedure lib and Preparation 3a as the appropriate 5-iodo-thieno[2,3-<i] pyrimidine derivative and 4,4,5,5-tetramethyl-2-(l-naphthyl)-l,3,2-dioxaborolane as the appropriate boronic acid derivative, a mixture of diastereoisomers was obtained. It was purified via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents, Example 79 was obtained as the mixture of diastereoisomers. HPvMS calculated for C₂₇H₂₃N₃O₂S: 453.1511, found: 454.1580 and 454.1580 (M+H)

Example 80 : TV- [6-ethyl-5-(quinolin-5-yl)thieno [2,3-i/] pyrimidin-4-yl] -D- phenylalanine

Using General Procedure Ila and Preparation 3a as the appropriate 5-iodo-thieno[2,3-<i] pyrimidine derivative and 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)quinolone as the appropriate boronic acid derivative, a mixture of diastereoisomers was obtained. It was purified via preparative reversed phase chromatography using 40 mM aqueous NH₄OAc solution (pH = 4, adjusted with AcOH) and acetonitrile as eluents. Example 80 was obtained as amixture of diastereoisomers. HRMS calculated for C26H22N4O2S : 454.1463, found: 455.1554 and 455.1518 (M+H)

Example 81 : TV- [6-ethyl-(5S_fl)-5-(isoquinolin-4-yl)thieno [2,3-i/] pyrimidin-4-yl] -D- phenylalanine

and

Example 82 : N- [6-ethyl-(5R«)-5-(isoquinolin-4-yl)thieno [2,3-i/] pyrimidin-4-yl] -D- phenylalanine

Step A: 4-chloro-6-ethyl-5-(4-isoquinolyl)thieno[2,3-d]pyrimidine

Using General Procedure lie and Preparation 2a as the appropriate 5-iodo-thieno[2,3-<i] pyrimidin and 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)isoquinoline as the appropriate boronic acid derivative, 4-chloro-6-ethyl-5-(4-isoquinolyl)thieno[2,3-<i] pyrimidine was obtained.

1H NMR (500 MHz, DMSO-d₆) δ: 9.46 (s, 1H), 8.93 (s, 1H), 8.50 (s, 1H), 8.26 (m, 1H),

7.74 (m, 2H), 7.42 (m, 1H), 2.65 (q, 2H), 1.14 (t, 3H)

HRMS calculated for C17H12CIN3S : 325.0440; found 326.0502 (M+H) Step B: N-/^" 6-ethyl-5- ( isoquinolin-4-yl) thienof 2, 3-d]pyrimidin-4-yl]-D-phenylalanine Using General Procedure la, the product of Step A as the appropriate 4-chloro-thieno [2,3- ]pyrimidine derivative and D-phenylalanine as the appropriate amino acid derivative N- [6-ethyl-5 -(isoquino lin-4-yl)thieno [2,3 - ]pyrimidin-4-yl] -D-phenylalanine was obtained as a mixture of diastereoisomers. They were separated via preparative reversed phase chromatography using water and acetonitrile as eluents. Example 81 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C26H22N4O2S: 454.1463, found: 455.1526 (M+H)

Example 82 was obtained as the later eluting diastereoisomer. HRMS calculated for C26H22N4O2S : 454.1463, found: 455.1538 (M+H)

Example 83 : TV- [6-ethyl-(5S_«)-5-(l-methyl- lH-indol-7-yl)thieno [2,3-d\ pyrimidin-4-yl] - D-phenylalanine

and

Example 84: V-[6-ethyl-(5R_fl)-5-(l-methyl-lH-indol-7-yl)thieno[2,3-i ]pyrimidin-4-yl]- D-phenylalanine

Using General Procedure lib and Preparation 3a as the appropriate 5-iodo-thieno[2,3-<i] pyrimidine derivative and l-methyl-7-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)indole as the appropriate boronic acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 40 mM aqueous NH4OAC solution (pH = 4, adjusted with AcOH) and acetonitrile as eluents. Example 83 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C26H24N4O2S: 456.1620, found: 457.1671 (M+H)

Example 84 was obtained as the later eluting diastereoisomer. HRMS calculated for C26H22N4O2S : 456.1620, found: 457.1701 (M+H) Example 85: V-[6-ethyl-(5S_«)-5-(3-methyl-lH-indol-4-yl)thieno[2,3-i ]pyrimidin-4-yl]- D-phenylalanine

and Example 86: TV- [6-ethyl-(5R_fl)-5-(3-methyl- lH-indol-4-yl)thieno [2,3-d\ pyrimidin-4-yl] - D-phenylalanine

Using General Procedure lie and Preparation 3a as the appropriate 5-iodo-thieno[2,3-<i] pyrimidine derivative and 3-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- indole as the appropriate boronic acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 40 mM aqueous NH₄OAc solution (pH = 4, adjusted with AcOH) and acetonitrile as eluents. HRMS calculated for C₂6H2₄N₄0₂S: 456.1620, found: 457.1691 (M+H)

Example 86 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₆H₂₄N₄0₂S: 456.1620, found: 457.1688 (M+H)

Example 87: V-[6-ethyl-5-(l-methyl-lH-indazol-4-yl)thieno[2,3-i |pyrimidin-4-yl]-Z)- phenylalanine

Using General Procedure Ila and Preparation 3a as the appropriate 5-iodo-thieno[2,3-<i] pyrimidine derivative and l-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)indazole as the appropriate boronic acid derivative, Example 87 was obtained as a mixture of diastereoisomers. HRMS calculated for C₂5H₂3N₅0₂S: 457.1572, found: 458.1646 and 458.1648 (M+H)

Example 88: V-[6-ethyl-(5S_fl)-5-(l-methyl-lH-indazol-7-yl)thieno[2,3-i |pyrimidin-4- yl] -D-phenylalanine

and

Example 89: V-[6-ethyl-(5R_fl)-5-(l-methyl-lH-indazol-7-yl)thieno[2,3-i |pyrimidin-4- yl] -D-phenylalanine

Using General Procedure Ila and Preparation 3a as the appropriate 5-iodo-thieno[2,3-<i] pyrimidine derivative and (l-methylindazol-7-yl)boronic acid as the appropriate boronic acid derivative, Example 88 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₅H₂₃N₂0₂S: 457.1572, found: 458.1641 (M+H) Example 89 was obtained as the later eluting diastereoisomer. HRMS calculated for C25H23N2O2S : 457.1572, found: 458.1634 (M+H)

Example 90: V-[(5S_fl)-5-(3-chloro-4-hydroxy-2-methylphenyl)-6-ethylthieno[2,3-i | pyrimidin-4-yl] -D-phenylalanine

and

Example 91: TV- [(5R_fl)-5-(3-chloro-4-hydroxy-2-methylphenyl)-6-ethylthieno [2,3- \ pyrimidin-4-yl] -D-phenylalanine

500 mg Preparation 7e (1.12 mmol) and 157 mg NCS (1.173 mmol) were dissolved in 30 mL THF and the mixture was stirred at 60 °C overnight. The solvent was evaporated under reduced pressure and the residue was purified via flash chromatography using heptane and EtOAc as eluents to obtain methyl 2-[[5-(3-chloro-4-hydroxy-2-methyl- phenyl)-6-ethyl-thieno[2,3-<i] pyrimidin-4-yl]amino]-3-phenyl-propanoate as a mixture of diastereoisomers (along with other regio isomers). The crude mixture was hydrolysed according to General Procedure VII. The diastereoisomers were purified and separated via preparative reversed phase chromatography using 25 mM aqueous NH₄HCO₃ solution and acetonitrile as eluents. Example 90 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₄H₂₂CIN₃O₃S: 467.1070, found: 468.1153 (M+H)

Example 91 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₄H₂₂CIN₃O₃S: 467.1070, found: 468.1143 (M+H) Example 92: V-[(5R_fl)-5-(2,3-dichlorophenyl)-6-ethylthieno[2,3-i ]pyrimidin-4-yl]-Z)- phenylalanine

and

Example 93 : TV- [(5S«)-5-(2,3-dichlorophenyl)-6-ethylthieno [2,3-d\ pyrimidin-4-yl] -D- phenylalanine Using General Procedure Ila and Preparation 3a as the appropriate 5-iodo-thieno[2,3-<i] pyrimidine derivative and (2,3-dichlorophenyl)boronic acid as the appropriate boronic acid derivative, using Xantphos instead of "BuPAd₂, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents, Example 92 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C23H19CI2N3O2S : 471.0575, found: 472.0667 (M+H)

Example 93 was obtained as the later eluting diastereoisomer. HRMS calculated for C23H19CI2N3O2S : 471.0575, found: 472.0654 (M+H)

Example 94 : TV- [(5R_fl)-5-(3,4-dichloro-2-methylphenyl)-6-ethylthieno [2,3-</] pyrimidin- 4-yl] -D-phenylalanine

and

Example 95 : N- [(5S_fl)-5-(3,4-dichloro-2-methylphenyl)-6-ethylthieno [2,3-i ] pyrimidin- 4-yl] -D-phenylalanine

Using General Procedure lib and Preparation 3a as the appropriate 5-iodo-thieno[2,3-<i] pyrimidine derivative and (3,4-dichloro-2-methyl-phenyl)boronic acid as the appropriate boronic acid derivative, using Xantphos as ligand instead of Q-Phos and DME: water 4: 1 instead of 2-Me-THF, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents, Example 94 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C24H21CI2N3O2S : 485.0731, found: 486.0816 (M+H)

Example 95 was obtained as the later eluting diastereoisomer. HRMS calculated for C24H21CI2N3O2S : 485.0731, found: 486.0797 (M+H) Example 96: N- [(5R_fl)-5-(3-bromo-2-methylphenyl)-6-ethylthieno [2,3-i ] pyrimidin-4- yl] -D-phenylalanine

and

Example 97: N- [(5S_fl)-5-(3-bromo-2-methylphenyl)-6-ethylthieno [2,3-i/] pyrimidin-4- yl] -D-phenylalanine Using General Procedure Ila and Preparation 3a as the appropriate 5-iodo-thieno[2,3-<i] pyrimidine derivative and Preparation B7 as the appropriate boronic acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 40 mM aqueous NH₄OAc solution (pH = 4, adjusted with AcOH) and acetonitrile as eluents. Example 96 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₄H₂₂BrN₃0₂S: 495.0616, found: 496.0673 (M+H) Example 97 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₄H₂₂BrN₃0₂S: 495.0616, found: 496.0687 (M+H) Example 98: V-[6-ethyl-5-(lH-indazol-4-yl)thieno[2,3-i |pyrimidin-4-yl]-Z)- phenylalanine

Using General Procedure Ila and Preparation 3a as the appropriate 5-iodo-thieno[2,3-<i] pyrimidine derivative and lH-indazol-4-ylboronic acid as the appropriate boronic acid derivative, then purifying the crude product viapreparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents, gave Example 98 as a mixture of diastereoisomers. HRMS calculated for C₂₄H₂iN₅0₂S: 443.1416, found: 444.1485 and 444.1481 (M+H)

Example 99: TV- [6-ethyl-5-(quinolin-8-yl)thieno [2,3-d] pyrimidin-4-yl] -D- phenylalanine Using General Procedure lid and Preparation 3a as the appropriate 5-iodo-thieno[2,3-<i] pyrimidine derivative and 8-quinolylboronic acid as the appropriate boronic acid derivative, Example 99 was obtained as a mixture of diastereoisomers. HRMS calculated for C₂6H₂₈N₄0₂S: 454.1463, found: 455.1558 (M+H)

Example 100: TV- [6-ethyl-(5R«)-5-(naphthalen- l-yl)thieno [2,3-i J pyrimidin-4-yl] -D- phenylalanine

and

Example 101: N- [6-ethyl-(5S«)-5-(naphthalen- l-yl)thieno [2,3-i J pyrimidin-4-yl] -D- phenylalanine

Separating the diastereoisomers of Example 79, using preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents, Example 100 was obtained as the earlier eluting diastereoisomer. HRMS calculated for HRMS calculated for C27H23N3O2S : 453.1511, found: 454.1596 (M+H)

Example 101 was obtained as the later eluting diastereoisomer. HRMS calculated for HRMS calculated for C27H23N3O2S : 453.1511, found: 454.1577 (M+H)

Example 102 : TV- [6-ethenyl-(5S_«)-5-(naphthalen- l-yl)thieno [2,3-d\ pyrimidin-4-yl] -D- phenylalanine

and

Example 103 : TV- [6-ethenyl-(5R_«)-5-(naphthalen- l-yl)thieno [2,3-i J pyrimidin-4-yl] -D- phenylalanine

Using General Procedure la and Preparation 4w as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and D-phenylalanine as the appropriate amino acid derivative, Example 102 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C27H21N3O2S : 451.1354, found: 452.1411 (M+H)

Example 103 was obtained as the later eluting diastereoisomer. HRMS calculated for C27H21N3O2S : 451.1354, found: 452.1412 (M+H)

Example 104 : N- [(5S«)-5-(naphthalen- l-yl)-6-((lZ)-prop- 1-en- l-yl)thieno [2,3-i ] pyrimidin-4-yl] -D-phenylalanine

and

Example 105: V-[(5R«)-5-(naphthalen-l-yl)-6-((lZ)-prop-l-en-l-yl)thieno[2,3-i ] pyrimidin-4-yl] -D-phenylalanine

Using General Procedure lb and Preparation 4x as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and D-phenylalanine as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 40 mM aqueous NH₄OAc solution (pH = 4, adjusted with AcOH) and acetonitrile as eluents. Example 104 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C28H23N3O2S : 465.1511, found: 466.1577 (M+H) Example 104 also contains 55 % of Example 108. Example 105 was obtained as the later eluting diastereoisomer. HRMS calculated for C28H23N3O2S : 465.1511, found: 466.1578 (M+H)

Example 105 also contains 55 % Example 109.

Example 106: N- [(5S_fl)-5-(naphthalen- l-yl)-6-(prop- l-en-2-yl)thieno [2,3- \ pyrimidin- 4-yl] -D-phenylalanine

and

Example 107: V-[(5R_fl)-5-(naphthalen-l-yl)-6-(prop-l-en-2-yl)thieno[2,3-i ]pyrimidin- 4-yl] -D-phenylalanine

Using General Procedure la and Preparation 4y as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and D-phenylalanine as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 40 mM aqueous NH₄OAc solution (pH = 4, adjusted with AcOH) and acetonitrile as eluents. Example 106 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C28H23N3O2S : 465.1511, found: 466.1581 (M+H) Example 107 was obtained as the later eluting diastereoisomer. HRMS calculated for C28H23N3O2S : 465.1511, found: 466.1597 (M+H)

Example 108: TV- {(5S«)-5-(naphthalen- l-yl)-6- [(LE)-prop- 1-en- 1-yl] thieno [2,3-d\ pyrimidin-4-yl}-D-phenylalanine

and

Example 109: ν-{(5¾)-5-(η3ρ1ι11ΐ3ΐ6η-1^1)-6-[(1£)-ρΓορ-1-6η-1^1]11ιΪ6ηο[2,3-ί | pyrimidin-4-yl}-D-phenylalanine

Using General Procedure la and Preparation 4z as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and D-phenylalanine as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 40 mM aqueous NH₄OAc solution (pH = 4, adjusted with AcOH) and acetonitrile as eluents. Example 108 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C28H23N3O2S : 465.1511, found: 466.1593 (M+H) Example 109 was obtained as the later eluting diastereoisomer. HRMS calculated for C28H23N3O2S : 465.1511, found: 466.1581 (M+H)

Example 110: TV- [5-(3-chloro-2-methylphenyl)-6-ethylthieno [2,3-</] pyrimidin-4-yl] -3- (lH-pyrazol-l-yl)alanine Using General Procedure Ic and Preparation 4j as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and methyl 2-amino-3-pyrazol-l-yl-propanoate hydrochloride as the appropriate amino acid derivative, then hydrolyzing the formed intermediate according to General Procedure VII, a mixture of diastereoisomers was obtained. It was purified via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents, and Example 110 was obtained as the mixture of diastereoisomers. HRMS calculated for C21H20CIN5O2S : 441.1026, found: 442.1120 and 442.1123 (M+H)

Example 111: TV- [(5R_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno [2,3-i ] pyrimidin-4- yl] -3-cyclopentyl-D- alanine

and

Example 112: N- [(5S_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno [2,3-i ] pyrimidin-4- yl] -3-cyclopentyl-D- alanine

Using General Procedure lb and Preparation 4j as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-cyclopentyl-propanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 111 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C23H26CIN3O2S : 443.1434, found: 444.1519 (M+H)

Example 112 was obtained as the later eluting diastereoisomer. HRMS calculated for C23H26CIN3O2S : 443.1434, found: 444.1518 (M+H) Example 113: N- [(5S_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno [2,3-i/] pyrimidin-4- yl] -D-phenylalanine

and Example 114: V-[(5R_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno[2,3-i ]pyrimidin-4- yl] -D-phenylalanine

Using General Procedure Ila and Preparation 3a as the appropriate 5-iodo-thieno[2,3-<i] pyrimidine derivative and (3-chloro-2-methyl-phenyl)boronic acid as the appropriate boronic acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 40 mM aqueous NH₄OAc solution (pH = 4, adjusted with AcOH) and acetonitrile as eluents. Example 113 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C24H22CIN3O2S : 451.1121, found: 452.1192 (M+H)

Example 114 was obtained as the later eluting diastereoisomer. HRMS calculated for C24H22CIN3O2S : 451.1121, found: 452.1174 (M+H)

Example 115: TV- [(5S_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno [2,3-i/] pyrimidin-4- yl] -L-phenylalanine

and

Example 116: TV- [(5R_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno [2,3-i ] pyrimidin-4- yl] -L-phenylalanine

Using General Procedure lb and Preparation 4j as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and ^-phenylalanine as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 115 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C24H22CIN3O2S : 451.1121, found: 452.1207 (M+H)

Example 116 was obtained as the later eluting diastereoisomer. HRMS calculated for C24H22CIN3O2S : 451.1121, found: 452.1183 (M+H)

Example 117: N- [(5R_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno [2,3-i ] pyrimidin-4- yl] -3-cyclohexyl-D- alanine

and - I l l -

Example 118: TV- [(5S_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno [2,3-</] pyrimidin-4- yl] -3-cyclohexyl-D- alanine

Using General Procedure lb and Preparation 4j as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and 2i?)-2-amino-3-cyclohexyl-propanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 117 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C24H28CIN3O2S : 457.1591, found: 458.1672 (M+H)

Example 118 was obtained as the later eluting diastereoisomer. HRMS calculated for C24H28CIN3O2S : 457.1591, found: 458.1663 (M+H)

Example 119: TV- [5-(3-chloro-2-methylphenyl)-6-ethylthieno [2,3-i ] pyrimidin-4-yl] - alpha-methyl-D-phenylalanine

Using General Procedure lb and Preparation 4j as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-2-methyl-3-phenyl-propanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. It was purified via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 119 was obtained as a mixture of diastereoisomers. HRMS calculated for C25H24CIN3O2S : 465.1278, found: 466.1372 and 466.1356 (M+H)

Example 120: N- [(5R_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno [2,3-i ] pyrimidin-4- yl]-2-hydroxy-D-phenylalanine

and

Example 121: N- [(5S_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno [2,3-i/] pyrimidin-4- yl] -2-hydroxy-D-phenylalanine

Using General Procedure lb, Preparation 4j as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative, and (2i?)-2-amino-3-(2-hydroxyphenyl)propanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 120 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₄H₂₂CIN₃O₃S: 467.1070, found: 468.1135 (M+H) Example 121 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₄H₂₂CIN₃O₃S: 467.1070, found: 468.1162 (M+H) Example 122: (PS)- V-[(5R_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno[2,3-i | pyrimidin-4-yl]-beta-hydroxy-Z⁾-phenylalanine

and

Example 123 : (PS)- V- [(5S«)-5-(3-chloro-2-methylphenyl)-6-ethylthieno [2,3-d\ pyrimidin-4-yl]-beta-hydroxy-Z⁾-phenylalanine Using General Procedure lb and Preparation 4j as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?,35)-3-phenylserine as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 122 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₄H₂₂CIN₃O₃S: 467.1070, found: 468.1151 (M+H)

Example 123 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₄H₂₂CIN₃O₃S: 467.1070, found: 468.1133 (M+H)

Example 124: (PR)- V-[(5R_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno[2,3-i | pyrimidin-4-yl]-beta-hydroxy-L-phenylalanine

and

Example 125: (PR)- V-[(5S«)-5-(3-chloro-2-methylphenyl)-6-ethylthieno[2,3-i | pyrimidin-4-yl]-beta-hydroxy-L-phenylalanine

Using General Procedure lb and Preparation 4j as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (25',3i?)-2-amino-3-hydroxy-3-phenylpropionic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 124 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₄H₂₂CIN₃O₃S: 467.1070, found: 468.1144 (M+H) Example 125 was obtained as the later eluting diastereoisomer. HRMS calculated for C24H22CIN3O3S : 467.1070, found: 468.1153 (M+H)

Example 126: V-[(5R_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno[2,3-i ]pyrimidin-4- yl] -2-cyano-D-phenylalanine

and

Example 127 TV- [(5S«)-5-(3-chloro-2-methylphenyl)-6-ethylthieno [2,3-d\ pyrimidin-4- yl] -2-cyano-D-phenylalanine

Using General Procedure lb and Preparation 4j as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(2-cyanophenyl)propanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 126 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C25H21CIN4O2S : 476.1074, found: 477.1129 (M+H) Example 127 was obtained as the later eluting diastereoisomer. HRMS calculated for C25H21CIN4O2S : 476.1074, found: 477.1134 (M+H)

Example 128: iV-[(5R_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno[2,3-i ]pyrimidin-4- yl] -2-methoxy-D-phenylalanine

and

Example 129: V-[(5S_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno[2,3-i ]pyrimidin-4- yl] -2-methoxy-D-phenylalanine

Using General procedure Ic and Preparation 4j as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(2-methoxyphenyl)propanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 128 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C25H24CIN3O3S : 481.1227, found: 482.1320 (M+H) Example 129 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₅H₂₄C1N₃0₃S: 481.1227, found: 482.1319 (M+H) Example 130: V-[(5R_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno[2,3-i ]pyrimidin-4- yl] -2,6-difluoro-D-phenylalanine

and

Example 131: TV- [(5S_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno [2,3-i/] pyrimidin-4- yl] -2,6-difluoro-D-phenylalanine

Using General Procedure lb and Preparation 4j as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(2,6-difluorophenyl)propanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 130 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₄H₂₀CIF₂N₃O₂S: 487.0933, found: 488.1009 (M+H)

Example 131 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₄H₂₀CIF₂N₃O₂S: 487.0933, found: 488.1020 (M+H) Example 132: (2R)-2-{[(5R«)-5-(3-chloro-2-methylphenyl)-6-ethylthieno[2,3-i | pyrimidin-4-yl] amino}-3-(lH-indol-4-yl)propanoic acid

and

Example 133 : (2R)-2- { [(5S«)-5-(3-chloro-2-methylphenyl)-6-ethylthieno [2,3-i/] pyrimidin-4-yl] amino}-3-(lH-indol-4-yl)propanoic acid Using General Procedure lb and Preparation 4j as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(lH-indol-4-yl)propanoic acid hydrochloride as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 132 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₆H₂₃CIN₄O₂S: 490.1230, found: 491.1289 (M+H) Example 133 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₆H₂₃CIN₄O₂S: 490.1230, found: 491.1309 (M+H) Example 134: 2-carbamoyl- V-[(5S_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno[2,3-i | pyrimidin-4-yl] -D-phenylalanine

Using General Procedure lb and Preparation 4j as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(2-carbamoylphenyl)propanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 134 was obtained as the later eluting diastereoisomer. HRMS calculated for C25H23CIN4O3S : 494.1179, found: 495.1255 (M+H)

Example 135: V-[(5R_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno[2,3-i ]pyrimidin-4- yl] -2-nitro-D-phenylalanine

and

Example 136: V-[(5S_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno[2,3-i ]pyrimidin-4- yl] -2-nitro-D-phenylalanine

Using General Procedure lb and Preparation 4j as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(2-nitrophenyl)propanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 135 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C24H21CIN4O4S : 496.0972, found: 497.1026 (M+H)

Example 136 was obtained as the later eluting diastereoisomer. HRMS calculated for C24H21CIN4O4S : 496.0972, found: 497.1045 (M+H)

Example 137: TV- [(5R_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno [2,3-i ] pyrimidin-4- yl]-2-(trifluoromethyl)-Z⁾-phenylalanine

and

Example 138: TV- [(5S_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno [2,3-i ] pyrimidin-4- yl]-2-(trifluoromethyl)-Z⁾-phenylalanine Using General Procedure lb and Preparation 4j as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-[2-(trifluoromethyl)phenyl]propanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 137 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₅H₂₁CIF₃N₃O₂S: 519.0995, found: 520.1068 (M+H)

Example 138 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₅H₂₁CIF₃N₃O₂S: 519.0995, found: 520.1047 (M+H) Example 139: 2-bromo- V-[(5R_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno[2,3-i | pyrimidin-4-yl] -D-phenylalanine

and

Example 140: 2-bromo- V-[(5S_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno[2,3-i | pyrimidin-4-yl] -D-phenylalanine Using General Procedure lb and Preparation 4j as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-[2-bromophenyl]propanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 139 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₄H₂iClBrN₃0₂S: 529.0226, found: 530.0312 (M+H)

Example 140 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₄H₂iClBrN₃0₂S: 529.0226, found: 530.0294 (M+H)

Example 141: V-[(5R_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno[2,3-i ]pyrimidin-4- yl] -2- [2-(dimethylamino)-2-oxoethoxy] -D-phenylalanine

and

Example 142: V-[(5S_«)-5-(3-chloro-2-methylphenyl)-6-ethylthieno[2,3-i ]pyrimidin-4- yl] -2- [2-(dimethylamino)-2-oxoethoxy] -D-phenylalanine Using General Procedure lb and Preparation 4j as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and Preparation A9 as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 141 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C28H29CIN4O4S : 552.1598, found: 553.1694 (M+H)

Example 142 was obtained as the later eluting diastereoisomer. HRMS calculated for C28H29CIN4O4S : 552.1598, found: 553.1673 (M+H)

Example 143 : TV- [(5R_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno [2,3-</] pyrimidin-4- yl] -2-(2-cyclopentylethoxy)-D-phenylalanine

and

Example 144: TV- [(5S_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno [2,3-i ] pyrimidin-4- yl]-2-(2-cyclopentylethoxy)-D-phenylalanine

Using General Procedure lb and Preparation 4j as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and Preparation A10 as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents.

Example 143 was obtained as the earlier eluting diastereoisomer. HRMS calculated for

C₃₁H₃₄CIN₃O₃S: 563.2009, found: 564.2106 (M+H)

Example 144 was obtained as the later eluting diastereoisomer. HRMS calculated for

C₃₁H₃₄CIN₃O₃S: 563.2009, found: 564.2101 (M+H)

Example 145: 7V-[(5R_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno [2,3-i ] pyrimidin-4- yl]-2-(2-phenylethoxy)-D-phenylalanine

and

Example 146: N- [(5S_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno [2,3-i/] pyrimidin-4- yl]-2-(2-phenylethoxy)-D-phenylalanine

Using General Procedure lb and Preparation 4j as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and Preparation All as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 145 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₃₂H₃₀CIN₃O₃S: 571.1696, found: 572.1769 (M+H)

Example 146 was obtained as the later eluting diastereoisomer. HRMS calculated for C₃₂H₃₀CIN₃O₃S: 571.1696, found: 572.1763 (M+H)

Example 147: TV- [(5R_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno [2,3-d\ pyrimidin-4- yl]-2-(3-phenylpropoxy)-D-phenylalanine

and

Example 148: iV-[(5S_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno[2,3-i ]pyrimidin-4- yl]-2-(3-phenylpropoxy)-D-phenylalanine

Using General Procedure lb and Preparation 4j as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and Preparation A12 as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 147 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₃₃H₃₂CIN₃O₃S: 585.1853, found: 586.1917 (M+H)

Example 148 was obtained as the later eluting diastereoisomer. HRMS calculated for C₃₃H₃₂CIN₃O₃S: 585.1853, found: 586.1906 (M+H) Example 149: 2-[(3-chlorobenzyl)oxy]- V-[(5R_fl)-5-(3-chloro-2-methylphenyl)-6-ethyl thieno [2,3-i/] pyrimidin-4-yl] -D-phenylalanine

and

Example 150: 2- [(3-chlorobenzyl)oxy] -TV- [(5S_fl)-5-(3-chloro-2-methylphenyl)-6-ethyl thieno [2,3-i ] pyrimidin-4-yl] -D-phenylalanine Using General Procedure lb and Preparation 4j as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and Preparation A13 as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 149 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₃₁H₂₇CI₂N₃O₃S: 591.1150, found: 592.1211 (M+H)

Example 150 was obtained as the later eluting diastereoisomer. HRMS calculated for C₃₁H₂₇CI₂N₃O₃S: 591.1150, found: 592.1234 (M+H) Example 151: V-[(5R_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno[2,3-i ]pyrimidin-4- yl] -3-pyridin-2-yl-D- alanine

and

Example 152 : TV- [(5S_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno [2,3-i/] pyrimidin-4- yl] -3-pyridin-2-yl-D- alanine Using General Procedure lb and Preparation 4j as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(2-pyridyl)propanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 151 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₃H₂₁CIN₄O₂S: 452.1074, found: 453.1146 (M+H)

Example 152 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₃H₂₁CIN₄O₂S: 452.1074, found: 453.1135 (M+H)

Example 153 : N- [(5R_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno [2,3-i ] pyrimidin-4- yl] -2- [2-(4-methylpiperazin- l-yl)ethoxy] -D-phenylalanine

and

Example 154 : N- [(5S_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno [2,3-i ] pyrimidin-4- yl] -2- [2-(4-methylpiperazin- l-yl)ethoxy] -D-phenylalanine

Using General Procedure lb and Preparation 4j as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and Preparation A14 as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 153 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₃iH36ClN₅0₃S: 593.2227, found: 594.2297 (M+H) Example 154 was obtained as the later eluting diastereoisomer. HRMS calculated for CsiHseClNsOsS: 593.2227, found: 594.2289 (M+H)

Example 155: TV- [(5R_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno [2,3-</] pyrimidin-4- yl] -2- [2-(dimethylamino)ethoxy] -D-phenylalanine

and

Example 156: TV- [(5S_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno [2,3-i ] pyrimidin-4- yl] -2- [2-(dimethylamino)ethoxy] -D-phenylalanine

Using General Procedure lb and Preparation 4j as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and Preparation A15 as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 155 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₈H₃₁CIN₄O₃S: 538.1805, found: 539.1890 (M+H)

Example 156 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₈H₃₁CIN₄O₃S: 538.1805, found: 539.1887 (M+H)

Example 157: N- [(5R_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno [2,3-i ] pyrimidin-4- yl] -2- [3-(dimethylamino)propoxy] -D-phenylalanine

and

Example 158: N- [(5S_fl)-5-(3-chloro-2-methylphenyl)-6-ethylthieno [2,3-i/] pyrimidin-4- yl] -2- [3-(dimethylamino)propoxy] -D-phenylalanine

Using General Procedure lb and Preparation 4j as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and Preparation A16 as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 157 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₉H₃₃CIN₄O₃S: 552.1962, found: 553.2043 (M+H)

Example 158 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₉H₃₃CIN₄O₃S: 552.1962, found: 553.2053 (M+H). Example 159: 3-cyclopropykV- [6-ethyl-5-(naphthalen- l-yl)thieno [2,3-</] pyrimidin-4- yl]-D- alanine

Using General Procedure lb and Preparation 4k as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-cyclopropyl-propanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 159 was obtained as the mixture of diastereoisomers. HRMS calculated for C24H23N3O2S: 417.1511, found: 418.1570 (M+H)

Example 160: (2R)- { [6-ethyl-5-(naphthalen- l-yl)thieno [2,3-i/] pyrimidin-4-yl] amino} (phenyl)ethanoic acid, diastereoisomer 1

and

Example 161: (2R)- { [6-ethyl-5-(naphthalen- l-yl)thieno [2,3-i ] pyrimidin-4-yl] amino} (phenyl)ethanoic acid, diastereoisomer 2

Using General Procedure lb and Preparation 4k as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-2-phenyl-acetic acid as the appropriate amino acid derivative, using DMA as solvent instead of DMSO, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 160 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C26H21N3O2S : 439.1354, found: 440.1428 (M+H)

Example 161 was obtained as the later eluting diastereoisomer. HRMS calculated for C26H21N3O2S : 439.1354, found: 440.1412 (M+H)

Example 162 : TV- [6-ethyl-(5S«)-5-(naphthalen- l-yl)thieno [2,3-i ] pyrimidin-4-yl] -3- pyridin-3-yl-D-alanine

and

Example 163 : N- [6-ethyl-(5R«)-5-(naphthalen- l-yl)thieno [2,3-d] pyrimidin-4-yl] -3- pyridin-3-yl-D-alanine Using General Procedure lb and Preparation 4k as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(3-pyridyl)propanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 40 mM aqueous NH₄OAc solution (pH = 4, adjusted with AcOH) and acetonitrile as eluents. Example 162 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C26H22N4O2S : 454.1463, found: 455.1520 (M+H)

Example 163 was obtained as the later eluting diastereoisomer. HRMS calculated for C2₆H₂2N₄0₂S: 454.1463, found: 455.1536 (M+H) Example 164: 3-cyclohexyl- V-[6-ethyl-5-(naphthalen-l-yl)thieno[2,3-i ]pyrimidin-4- yl]-D- alanine

Using General Procedure la and Preparation 4k as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-cyclohexyl-propanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. It was purified via preparative reversed phase chromatography using 0.02 % aqueous HCOOH solution and acetonitrile as eluents. Example 164 was obtained as the mixture of diastereoisomers. HRMS calculated for C27H29N3O2S: 459.1980, found: 460.2042 (M+H)

Example 165: 3-cyclohexyl- V-[6-ethyl-(5R_fl)-5-(naphthalen-l-yl)thieno[2,3-i ] pyrimidin-4-yl] -D- alanine

and

Example 166: 3-cyclohexyl- V-[6-ethyl-(5S_fl)-5-(naphthalen-l-yl)thieno[2,3-i ] pyrimidin-4-yl] -D- alanine

Diastereoisomers of Example 164 were separated via preparative reversed phase chromatography using 40 mM aqueous NH₄OAc solution (pH = 4, adjusted with AcOH) and acetonitrile as eluents. Example 165 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C27H29N3O2S : 459.1980, found: 460.2043 (M+H) Example 166 was obtained as the later eluting diastereoisomer. HRMS calculated for C27H29N3O2S : 459.1980, found: 460.2058 (M+H)

Example 167: V-[6-ethyl-5-(naphthalen-l-yl)thieno[2,3-i |pyrimidin-4-yl]-2-methyl-Z⁾- phenylalanine, diastereoisomer 1

and

Example 168 : TV- [6-ethyl-5-(naphthalen- l-yl)thieno [2,3-d\ pyrimidin-4-yl] -2-methyl-Z⁾- phenylalanine, diastereoisomer 2

Using General Procedure lb and Preparation 4k as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and D-2'-methylphenylalanine as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 40 mM aqueous NH₄OAc solution (pH = 4, adjusted with AcOH) and acetonitrile as eluents. Example 167 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C28H25N3O2S : 467.1667, found: 468.1747 (M+H)

Example 168 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂8H2₅N₃0₂S: 467.1667, found: 468.1748 (M+H)

Example 169: (2R)-2- { [6-ethyl-5-(naphthalen- l-yl)thieno [2,3-d\ pyrimidin-4-yl] amino}-4-phenylbutanoic acid

Using General Procedure la and Preparation 4k as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-4-phenyl-butanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. It was purified via preparative reversed phase chromatography using 0.02 % aqueous HCOOH solution and acetonitrile as eluents. Example 169 was obtained as mixture of diastereoisomers. HRMS calculated for C₂8H2₅N₃0₂S: 467.1667, found: 468.1731 (M+H) Example 170: (2R)-2-{[6-ethyl-(5S_«)-5-(naphthalen-l-yl)thieno[2,3-i |pyrimidin-4-yl] amino}-4-phenylbutanoic acid

and Example 171: (2R)-2-{[6-ethyl-(5R_«)-5-(naphthalen-l-yl)thieno[2,3-i |pyrimidin-4-yl] amino}-4-phenylbutanoic acid

Diastereoisomers of Example 169 were separated via preparative reversed phase chromatography using 40 mM aqueous NH₄OAc solution (pH = 4, adjusted with AcOH) and acetonitrile as eluents. Example 170 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₈H₂₅N₃0₂S: 467.1667, found: 468.1733 (M+H) Example 171 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂8H2₅N30₂S: 467.1667, found: 468.1726 (M+H)

Example 172 : TV- [6-ethyl-(5R_«)-5-(naphthalen- l-yl)thieno [2,3-d\ pyrimidin-4-yl] -D- tyrosine

and

Example 173 : N- [6-ethyl-(5S_«)-5-(naphthalen- l-yl)thieno [2,3-i J pyrimidin-4-yl] -D- tyrosine

Using General Procedure lb and Preparation 4k as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(4-hydroxyphenyl)propanoic acid as the appropriate amino acid derivative, using DMA as solvent instead of DMSO, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 172 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₇H₂₃N₃0₃S: 469.1460, found: 470.1539 (M+H)

Example 173 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₇H₂₃N₃0₃S: 469.1460, found: 470.1534 (M+H)

Example 174 : N- [6-ethyl-(5S_«)-5-(naphthalen- l-yl)thieno [2,3-i/] pyrimidin-4-yl] -2- hydroxy-D-phenylalanine

and

Example 175 : N- [6-ethyl-(5R_«)-5-(naphthalen- l-yl)thieno [2,3-i ] pyrimidin-4-yl] -2- hydroxy-D-phenylalanine Using General Procedure lb and Preparation 4k as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(2-hydroxyphenyl)propanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 40 mM aqueous NH₄OAc solution (pH = 4, adjusted with AcOH) and acetonitrile as eluents. Example 174 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C27H23N3O3S: 469.1460, found: 470.1546 (M+H)

Example 175 was obtained as the later eluting diastereoisomer. HRMS calculated for C27H23N3O3S : 469.1460, found: 470.1520 (M+H) Example 176: V-[6-ethyl-(5R_fl)-5-(naphthalen-l-yl)thieno[2,3-i ]pyrimidin-4-yl]-4- fluoro-D-phenylalanine

and

Example 177: TV- [6-ethyl-(5S_«)-5-(naphthalen- l-yl)thieno [2,3-d] pyrimidin-4-yl] -4- fluoro-D-phenylalanine Using General Procedure lb and Preparation 4k as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(4-fluorophenyl)propanoic acid as the appropriate amino acid derivative, using DMA as solvent instead of DMSO, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 176 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₇H₂₂FN₃O₂S: 471.1417, found: 472.1493 (M+H)

Example 177 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₇H₂₂FN₃O₂S: 471.1417, found: 472.1494 (M+H)

Example 178 : N- [6-ethyl-(5R«)-5-(naphthalen- l-yl)thieno [2,3-d] pyrimidin-4-yl] -3- fluoro-D-phenylalanine

and

Example 179 : N- [6-ethyl-(5S«)-5-(naphthalen- l-yl)thieno [2,3-d] pyrimidin-4-yl] -3- fluoro-D-phenylalanine Using General Procedure lb and Preparation 4k as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(3-fluorophenyl)propanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 178 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₇H₂₂FN₃O₂S: 471.1417, found: 472.1486 (M+H) Example 179 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₇H₂₂FN₃O₂S: 471.1417, found: 472.1482 (M+H)

Example 180: TV- [6-ethyl-(5R_«)-5-(naphthalen- l-yl)thieno [2,3-d] pyrimidin-4-yl] -2- fluoro-D-phenylalanine

and

Example 181: N- [6-ethyl-(5S_«)-5-(naphthalen- l-yl)thieno [2,3-d] pyrimidin-4-yl] -2- fluoro-D-phenylalanine

Using General Procedure lb and Preparation 4k as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(2-fluorophenyl)propanoic acid as the appropriate amino acid derivative, using DMA as solvent instead of DMSO, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents.

Example 180 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₇H₂₂FN₃O₂S: 471.1417, found: 472.1501 (M+H)

Example 181 was obtained as the later eluting diastereoisomer. HRMS calculated for

C₂₇H₂₂FN₃O₂S: 471.1417, found: 472.1492 (M+H)

Example 182 : N- [6-ethyl-5-(naphthalen- l-yl)thieno [2,3-i j pyrimidin-4-yl] -2-methoxy- D-phenylalanine Using General Procedure lb and Preparation 4k as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(2-methoxyphenyl)propanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. It was purified via preparative reversed phase chromatography using 40 mM aqueous NH₄OAc solution ( H = 4, adjusted with AcOH) and acetonitrile as eluents. Example 182 was obtained as a mixture of diastereoisomers. HRMS calculated for C28H25N3O3S : 483.1617, found: 484.1682 and 484.1695 (M+H)

Example 183 : 2-chloro-iV- [6-ethyl-5-(naphthalen- l-yl)thieno [2,3-i j pyrimidin-4-yl] -D- phenylalanine

Using General Procedure lb and Preparation 4k as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(2-chlorophenyl)propanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. It was purified via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 183 was obtained as the mixture of diastereoisomers. HRMS calculated for C27H22CIN3O2S : 487.1121, found: 488.1198 and 488.1199 (M+H)

Example 184 : TV- [6-ethyl-(5R_fl)-5-(naphthalen- l-yl)thieno [2,3-i J pyrimidin-4-yl] -D- tryptophan

and

Example 185: V-[6-ethyl-(5S_fl)-5-(naphthalen-l-yl)thieno[2,3-i |pyrimidin-4-yl]-Z)- tryptophan

Using General Procedure lb and Preparation 4k as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(lH-indol-3-yl)propanoic acid as the appropriate amino acid derivative, using DMA as solvent instead of DMSO, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 184 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₉H₂₄N₄O₂S: 492.1620, found 493.1693 (M+H)

Example 185 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₉H₂₄N₄O₂S: 492.1620, found 493.1690 (M+H)

Example 186: TV- [6-ethyl-5-(naphthalen- l-yl)thieno [2,3-i ] pyrimidin-4-yl] -3- naphthalen-l-yl-D-alanine, diastereoisomer 1 and

Example 187: TV- [6-ethyl-5-(naphthalen- l-yl)thieno [2,3-d\ pyrimidin-4-yl] -3- naphthalen-l-yl-Z⁾-alanine, diastereoisomer 2

Using General Procedure lb and Preparation 4k as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(l-naphthyl)propanoic acid as the appropriate amino acid derivative, using DMA as solvent instead of DMSO, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 186 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₃iH2₅N₃0₂S: 503.1667, found: 504.1754 (M+H)

Example 187 was obtained as the later eluting diastereoisomer. HRMS calculated for C₃iH₂₅N₃0₂S: 503.1667, found: 504.1758 (M+H)

Example 188: (2R)-biphenyl-2-yl{ [6-ethyl-5-(naphthalen- l-yl)thieno [2,3-i/] pyrimidin- 4-yl]amino}ethanoic acid, diastereoisomer 2 Using General Procedure lb and Preparation 4k as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (i?)-amino-biphenyl-2-yl-acetic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 40 mM aqueous NH₄OAc solution (pH = 4, adjusted with AcOH) and acetonitrile as eluents. Example 188 was obtained as the later eluting diastereoisomer. HRMS calculated for C₃₂H₂₅N₃0₂S: 515.1667, found: 516.1747 (M+H)

Example 189: (2R)-biphenyl-3-yl{ [6-ethyl-5-(naphthalen- l-yl)thieno [2,3-i ] pyrimidin- 4-yl] amino} ethanoic acid, diastereoisomer 1

Using General Procedure lb and Preparation 4k as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (i?)-amino-biphenyl-3-yl-acetic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 40 mM aqueous NH₄OAc solution (pH = 4, adjusted with AcOH) and acetonitrile as eluents. Example 189 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C32H25N3O2S: 515.1667, found: 516.1743 (M+H)

Example 190 : TV- [6-ethyl-5-(naphthalen- l-yl)thieno [2,3-i j pyrimidin-4-yl] -D-histidine Using General Procedure la and Preparation 4k as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(lH-imidazol-4-yl)propanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. It was purified via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 190 was obtained as a mixture of diastereoisomers. HRMS calculated for C₂₄H₂₁N₅O₂S: 443.1416, found: 444.1462 and 444.1471 for the two diastereoisomers (M+H)

Example 191 : TV- [6-ethyl-5-(naphthalen- l-yl)thieno [2,3-i j pyrimidin-4-yl] -3-pyridin-2- yl-D-alanine Using General Procedure lb and Preparation 4k as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(2-pyridyl)propanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. It was purified via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 191 was obtained as a mixture of diastereoisomers. HRMS calculated for C₂₆H₂₂N₄O₂S: 454.1463, found: 455.1537 and 455.1558 for the two diastereoisomers (M+H)

Example 192 : N- [6-ethyl-5-(naphthalen- l-yl)thieno [2,3-i j pyrimidin-4-yl] -3-pyridin-3- yl-D-alanine

Using General Procedure lb and Preparation 4k as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and 3-(3-pyridyl)-D-alanine as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. It was purified via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 192 was obtained as a mixture of diastereoisomers. HRMS calculated for C26H22N4O2S : 454.1445, found: 455.1545 and 455.1553 for the two diastereoisomers (M+H)

Example 193 : TV- [6-ethyl-5-(naphthalen- l-yl)thieno [2,3-i j pyrimidin-4-yl] -3-pyridin-4- yl-D-alanine

Using General Procedure lb and Preparation 4k as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(4-pyridyl)propanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. It was purified via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 193 was obtained as a mixture of diastereoisomers. HRMS calculated for C26H22N4O2S : 454.1440, found: 455.1540 and 455.1545 for the two diastereoisomers (M+H)

Example 194 : TV- [6-ethyl-5-(naphthalen- l-yl)thieno [2,3-i j pyrimidin-4-yl] - 1-methykD- histidine Using General Procedure lb and Preparation 4k as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(l-methylimidazol-4-yl)propanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. It was purified via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 194 was obtained as a mixture of diastereoisomers. HRMS calculated for C₂5H23N₅0₂S: 457.1572, found: 458.1641 and 458.1654 for the two diastereoisomers (M+H)

Example 195: 1-benzykV- [6-ethyl-5-(naphthalen- l-yl)thieno [2,3-i j pyrimidin-4-yl] -D- histidine

Using General Procedure lb and Preparation 4k as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(l-benzylimidazol-4-yl)propanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. It was purified via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 195 was obtained as a mixture of diastereoisomers. HRMS calculated for C₃iH27N₅0₂S: 533.1885, found: 534.1934 and 534.1934 for the two diastereoisomers (M+H) Example 196: V-[6-methyl-5-(naphthalen-l-yl)thieno[2,3-i |pyrimidin-4-yl]-Z⁾- phenylalanine

Using General Procedure la and Preparation 41 as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and D-phenylalanine as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. It was purified via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 196 was obtained as a mixture of diastereoisomers. HRMS calculated for C₂6H2iN₃0₂S: 439.1354, found: 440.1421 and 440.1429 (M+H)

Example 197: V-[6-(hydroxymethyl)-(5R_fl)-5-(naphthalen-l-yl)thieno[2,3-i ] pyrimidin-4-yl] -D-phenylalanine

and

Example 198 : TV- [6-(hydr oxymethyl)-(5S_fl)-5-(naphthalen- l-yl)thieno [2,3-i/] pyrimidin- 4-yl] -D-phenylalanine

Using General Procedure la and Preparation 4m as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and D-phenylalanine as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 197 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₆H₂iN₃0₃S: 455.1304, found: 456.1356 (M+H)

Example 198 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₆H₂iN₃0₃S: 455.1304, found: 456.1390 (M+H)

Example 199: TV- [6-acetyl-(5S_«)-5-(naphthalen- l-yl)thieno [2,3-i/] pyrimidin-4-yl] -D- phenylalanine and

Example 200 : TV- [6-acetyl-(5R_«)-5-(naphthalen- l-yl)thieno [2,3-d\ pyrimidin-4-yl] -D- phenylalanine

Using General Procedure la and Preparation 4o as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and D-phenylalanine as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 40 mM aqueous NH₄OAc solution (pH = 4, adjusted with AcOH) and acetonitrile as eluents. Example 199 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C27H21N3O3S : 467.1304, found: 468.1379 (M+H) Example 200 was obtained as the later eluting diastereoisomer. HRMS calculated for C27H21N3O3S : 467.1304, found: 468.1377 (M+H)

Example 201: TV- [5-(naphthalen- l-yl)-6-(propan-2-yl)thieno [2,3-i j pyrimidin-4-yl] -D- phenylalanine, diastereoisomer 1

and

Example 202: V-[5-(naphthalen-l-yl)-6-(propan-2-yl)thieno[2,3-i |pyrimidin-4-yl]-Z⁾- phenylalanine, diastereoisomer 2

Using General Procedure lb and Preparation 4q as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and D-phenylalanine as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 40 mM aqueous NH₄OAc solution (pH = 4, adjusted with AcOH) and acetonitrile as eluents. Example 201 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂8H₂₅N₃0₂S: 467.1667, found: 468.1731 (M+H) Example 202 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂8H2₅N30₂S: 467.1667, found: 468.1720 (M+H) Example 203: V-[6-(l-hydroxyethyl)-5-(naphthalen-l-yl)thieno[2,3-i |pyrimidin-4-yl]- D-phenylalanine, diastereoisomer 1

and Example 204: V-[6-(l-hydroxyethyl)-5-(naphthalen-l-yl)thieno[2,3-i |pyrimidin-4-yl]- D-phenylalanine, diastereoisomer 2

Using General Procedure la and Preparation 4nl as the appropriate 4-chloro-thieno [2,3- ]pyrimidine derivative and D-phenylalanine as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 203 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C27H23N3O3S : 469.1460, found: 470.1511 (M+H)

Example 204 was obtained as the later eluting diastereoisomer. HRMS calculated for C27H23N3O3S : 469.1460, found: 470.1536 (M+H)

Example 205: V-[6-(l-hydroxyethyl)-5-(naphthalen-l-yl)thieno[2,3-i |pyrimidin-4-yl]- D-phenylalanine, diastereoisomer 3

and

Example 206: V-[6-(l-hydroxyethyl)-5-(naphthalen-l-yl)thieno[2,3-i |pyrimidin-4-yl]- D-phenylalanine, diastereoisomer 4

Using General Procedure la and Preparation 4n2 as the appropriate 4-chloro-thieno [2,3- ]pyrimidine derivative and D-phenylalanine as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 205 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₇H₂₃N₃O₃S: 469.1460, found: 470.1539 (M+H)

Example 206 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₇H₃₃N₃O₃S: 469.1460, found: 470.1534 (M+H)

Example 207: TV- [6-(difluoromethyl)-5-(naphthalen-l-yl)thieno [2,3-i j pyrimidin-4-yl] - D-phenylalanine, diastereoisomer 1

and

Example 208 : TV- [6-(difluoromethyl)-5-(naphthalen- l-yl)thieno [2,3-i j pyrimidin-4-yl] - D-phenylalanine, diastereoisomer 2 Using General Procedure la and Preparation 4r as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and D-phenylalanine as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 40 mM aqueous NH₄OAc solution (pH = 4, adjusted with AcOH) and acetonitrile as eluents. Example 207 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂6Hi₉F₂N₃0₂S: 475.1166, found: 476.1242 (M+H) Example 208 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂6Hi9F₂N₃0₂S: 475.1166, found: 476.1244 (M+H)

Example 209 : TV- [6-(2-hydroxypropan-2-yl)-(5R_fl)-5-(naphthalen- l-yl)thieno [2,3-d] pyrimidin-4-yl] -D-phenylalanine

and

Example 210: N- [6-(2-hydroxypropan-2-yl)-(5S_«)-5-(naphthalen- l-yl)thieno [2,3-d] pyrimidin-4-yl] -D-phenylalanine

Using General Procedure la and Preparation 4p as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and D-phenylalanine as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents.

Example 209 was obtained as the earlier eluting diastereoisomer. HRMS calculated for

C₂₈H₂₅N₃0₃S: 483.1617, found: 484.1689 (M+H)

Example 210 was obtained as the later eluting diastereoisomer. HRMS calculated for

C₂₈H₂₅N₃0₃S: 483.1617, found: 484.1704 (M+H)

Example 211 : N- [6-iodo-5-(naphthalen- l-yl)thieno [2,3-i j pyrimidin-4-yl] -D- phenylalanine

Using General Procedure la and Preparation 4s as the appropriate 4-chloro-thieno [2,3-d] pyrimidine derivative and D-phenylalanine as the appropriate amino acid derivative, using DMA as solvent instead of DMSO, a mixture of diastereoisomers was obtained. It was purified via preparative reversed phase chromatography using 40 mM aqueous NH₄OAc solution ( H = 4, adjusted with AcOH) and acetonitrile as eluents. Example 211 was obtained as a mixture of diastereoisomers. HRMS calculated for C25H18IN3O2S: 551.0164, found: 552.0258 (M+H)

Example 212: TV- [(5R_fl)-5-(3-chloro-2-methylphenyl)-6-ethenyl-thieno [2,3- ] pyrimidin-4-yl] -D-phenylalanine

and

Example 213 : TV- [(5S_fl)-5-(3-chloro-2-methylphenyl)-6-ethenyl-thieno [2,3-i ] pyrimidin- 4-yl] -D-phenylalanine

Using General Procedure lie and Preparation 5a as the the appropriate 6-iodo-thieno [2,3- ]pyrimidine and vinylboronic acid pinacol ester as the appropriate boronic acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 212 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C24H20CIN3O2S : 449.0965, found: 450.1038 (M+H)

Example 213 was obtained as the later eluting diastereoisomer. HRMS calculated for C24H20CIN3O2S : 449.0965, found: 450.1050 (M+H)

Example 214: V-[(5R_fl)-5-(3-chloro-2-methylphenyl)-6-(prop-l-en-2-yl)thieno[2,3-i ] pyrimidin-4-yl] -D-phenylalanine

and

Example 215: V-[(5S«)-5-(3-chloro-2-methylphenyl)-6-(prop-l-en-2-yl)thieno[2,3-i ] pyrimidin-4-yl] -D-phenylalanine

Using General Procedure lie and Preparation 5a as the the appropriate 6-iodo-thieno [2,3- ]pyrimidine and 2-isopropenyl-4,4,5,5-tetramethyl-l,3,2-dioxaborolane as the appropriate boronic acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 214 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C25H22CIN3O2S : 463.1121, found: 464.1178 (M+H) Example 215 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₅H₂₂C1N30₂S: 463.1121, found: 464.1179 (M+H)

Example 216: N- [(5R_fl)-5-(3-chloro-2-methylphenyl)-6-cyclopropyl-thieno [2,3-d\ pyrimidin-4-yl] -^-phenylalanine

and

Example 217: N- [(5S_fl)-5-(3-chloro-2-methylphenyl)-6-cyclopropyl-thieno [2,3-d\ pyrimidin-4-yl] -D-phenylalanine

Using General Procedure Ila and Preparation 5a as the the appropriate 6-iodo-thieno [2,3-d]pyrimidine and cyclopropylboronic acid as the appropriate boronic acid derivative, and Bu₄NOH instead of K₂C0₃, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 216 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₅H₂₂C1N₃0₂S: 463.1121, found: 464.1177 (M+H) Example 217 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₅H₂₂C1N₃0₂S: 463.1121, found: 464.1182 (M+H)

Example 218: TV- [(5S«)-5-(3-chloro-2-methylphenyl)-6-(propan-2-yl)thieno [2,3-d] pyrimidin-4-yl] -/.-phenylalanine

and

Example 219: N- [(5R_fl)-5-(3-chloro-2-methylphenyl)-6-(propan-2-yl)thieno [2,3-d] pyrimidin-4-yl] -/.-phenylalanine

Using General Procedure lb and Preparation 4u as the the appropriate 4-chloro- thieno[2,3-d]pyrimidine derivative and ^-phenylalanine as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 218 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₅H₂₄C1N₃0₂S: 465.1278, found: 466.1371 (M+H)

Example 219 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₅H₂₄C1N₃0₂S: 465.1278, found: 466.1361 (M+H) Example 220 : TV- [(5R_fl)-5-(3-chloro-2-methylphenyl)-6-(propan-2-yl)thieno [2,3-d\ pyrimidin-4-yl] -D-phenylalanine

and

Example 221 : N- [(5S«)-5-(3-chloro-2-methylphenyl)-6-(propan-2-yl)thieno [2,3-d] pyrimidin-4-yl] -D-phenylalanine

Using General Procedure lb and Preparation 4u as the the appropriate 4-chloro- thieno[2,3-d]pyrimidine derivative and D-phenylalanine as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 220 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₅H₂₄CIN₃O₂S: 465.1278, found: 466.1348 (M+H)

Example 221 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₅H₂₄CIN₃O₂S: 465.1278, found: 466.1350 (M+H)

Example 222 : N- [(5R_fl)-5-(3-chloro-2-methylphenyl)-6-(propan-2-yl)thieno [2,3-d] pyrimidin-4-yl] -2-methoxy-D-phenylalanine

and

Example 223 : N- [(5S_fl)-5-(3-chloro-2-methylphenyl)-6-(propan-2-yl)thieno [2,3-d] pyrimidin-4-yl]-2-methoxy-D-phenylalanine

Using General Procedure lb and Preparation 4u as the the appropriate 4-chloro- thieno[2,3-d]pyrimidine derivative and (2i?)-2-amino-3-(2-methoxyphenyl)propanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 222 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₆H₂₆CIN₃O₃S: 495.1383, found: 496.1460 (M+H) Example 223 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₆H₂₆CIN₃O₃S: 495.1383, found: 496.1454 (M+H) Example 224 : TV- [(5R«)-5-(3-chloro- lH-indol-4-yl)-6-ethyl-thieno [2,3-d\ pyrimidin-4- yl] -D-phenylalanine

and

Example 225 : N- [(5S«)-5-(3-chloro- lH-indol-4-yl)-6-ethyl-thieno [2,3-d\ pyrimidin-4- yl] -D-phenylalanine

522 mg Preparation 7h (1 mmol), 164 mg NCS (1.2 mmol), 15 mL CC1₄ and 10 mL THF were stirred at r.t. under N₂ atmosphere for 2 hours. Then the mixture was poured into icy water and extracted with DCM. The combined organic phases were dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. The formed diastereoisomers were separated via preparative reversed phase chromatography using 40 mM aqueous NH₄OAc solution (pH = 4, adjusted with AcOH) and acetonitrile as eluents. Example 224 was obtained as the later eluting diastereoisomer.HRMS calculated for C₂₅H₂iClN₄0₂S: 476.1074, found: 477.1133 (M+H)

Example 225 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₅H₂iClN₄0₂S: 476.1074, found: 477.1137 (M+H)

Example 226 : N- [(5S«)-5-(3-bromo- lH-indol-4-yl)-6-ethylthieno [2,3-d\ pyrimidin-4- yl] -D-phenylalanine

and

Example 227: N- [(5R«)-5-(3-bromo- lH-indol-4-yl)-6-ethylthieno [2,3-d\ pyrimidin-4- yl] -D-phenylalanine

522 mg Preparation 7h (1 mmol), 216 mg NBS (1.2 mmol), 15 mL CCL_. and 5 mL THF were stirred at r.t. under N₂ atmosphere for 2 hours. Then the mixture was poured into icy water and extracted with DCM. The combined organic phases were dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. The formed diastereoisomers were separated via preparative reversed phase chromatography using 40 mM aqueous NH₄OAc solution (pH = 4, adjusted with AcOH) and acetonitrile as eluents. Example 226 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₅H₂iBrN₄0₂S: 520.0569, found: 521.0653 (M+H) Example 227 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₅H₂iBrN₄0₂S: 520.0569, found: 521.0629 (M+H)

Example 228: V-[6-ethyl-(5S_fl)-5-(3-iodo-lH-indol-4-yl)thieno[2,3-i ]pyrimidin-4-yl]- D-phenylalanine

and

Example 229: V-[6-ethyl-(5R_fl)-5-(3-iodo-lH-indol-4-yl)thieno[2,3-i ]pyrimidin-4-yl]- D-phenylalanine

522 mg Preparation 7h (1 mmol), 196 mg KOH (3.5 mmol), 15 mL DMF and 267 mg iodine (1.05 mmol) were stirred at r.t. under N₂ atmosphere for 18 hours. Then the mixture was poured into icy water and saturated Na₂S₂0₃ solution was added. The mixture was extracted with DCM, the combined organic phases were dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. The formed diastereoisomers were separated via preparative reversed phase chromatography using 40 mM aqueous NH₄OAc solution (pH = 4, adjusted with AcOH) and acetonitrile as eluents. Example 228 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂sH₂iIN₄0₂S: 568.043, found: 569.0498 (M+H)

Example 229 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₅H₂iIN₄0₂S: 568.043, found: 569.0502 (M+H)

Example 230: V-((5S_fl)-5-{3-chloro-l-[2-(dimethylamino)ethyl]-lH-indol-4-yl}-6- ethyl-thieno [2,3-i/] pyrimidin-4-yl)-D-phenylalanine

and

Example 231 : V-((5R«)-5- {3-chloro- 1- [2-(dimethylamino)ethyl] - lH-indol-4-yl}-6- ethyl-thieno [2,3-i ] pyrimidin-4-yl)-D-phenylalanine

Using General Procedure VIII and Preparation 7i as the appropriate indole derivative and 2-(N,N-dimethylamino)ethanol as the appropriate alcohol, Example 230 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂₉H₃₀ClN₅O₂S: 547.1809, found: 548.1902 (M+H) Example 231 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₉H₃oClN₅0₂S: 547.1809, found: 548.1889 (M+H)

Example 232: V-((5R_fl)-5-{3-chloro-l-[2-(pyrrolidin-l-yl)ethyl]-lH-indol-4-yl}-6- ethyl-thieno [2,3-</] pyrimidin-4-yl)-D-phenylalanine

and

Example 233: V-((5S_fl)-5-{3-chloro-l-[2-(pyrrolidin-l-yl)ethyl]-lH-indol-4-yl}-6-ethyl- thieno [2,3-i ] pyrimidin-4-yl)-D-phenylalanine

Using General Procedure VIII and Preparation 7i as the appropriate indole derivative and 2-pyrrolidin-l-ylethanol as the appropriate alcohol, Example 232 was obtained as the later eluting diastereoisomer. HRMS calculated for C₃iH₃₂Cl ₅0₂S: 573.1965, found: 574.2059 (M+H)

Example 233 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₃iH₃₂ClN₅0₂S: 573.1965, found: 574.2060 (M+H)

Example 234: V-((5R_fl)-5-{3-chloro-l-[2-(piperidin-l-yl)ethyl]-lH-indol-4-yl}-6-ethyl- thieno [2,3-i ] pyrimidin-4-yl)-D-phenylalanine

and

Example 235: V-((5S_fl)-5-{3-chloro-l-[2-(piperidin-l-yl)ethyl]-lH-indol-4-yl}-6-ethyl- thieno [2,3-i/] pyrimidin-4-yl)-D-phenylalanine

Using General Procedure VIII and Preparation 7i as the appropriate indole derivative and 2-(l-piperidyl)ethanol as the appropriate alcohol, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 234 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₃₂H₃₄C1 ₅0₂S: 587.2122, found: 588.2201 (M+H)

Example 235 was obtained as the later eluting diastereoisomer. HRMS calculated for C₃₂H₃₄C1N₅0₂S: 587.2122, found: 588.2199 (M+H) Example 236: V-((5R_fl)-5-{3-chloro-l-[2-(morpholin-4-yl)ethyl]-lH-indol-4-yl}-6- ethyl-thieno [2,3-</] pyrimidin-4-yl)-D-phenylalanine

and

Example 237: V-((5S_fl)-5-{3-chloro-l-[2-(morpholin-4-yl)ethyl]-lH-indol-4-yl}-6- ethyl-thieno [2,3-i ] pyrimidin-4-yl)-D-phenylalanine

Using General Procedure VIII and Preparation 7i as the appropriate indole derivative and 2-morpholinoethanol as the appropriate alcohol, Example 236 was obtained as the later eluting diastereoisomer. HRMS calculated for C₃₁H₃₂CI ₅O₃S: 589.1914, found: 590.1998 (M+H)

Example 237 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₃iH₃₂ClN₅0₃S: 589.1914, found: 590.1994 (M+H).

Example 238 : V-((5S_«)-5- {3-chloro- 1- [2-(4-methylpiperazin- l-yl)ethyl] - lH-indol-4- yl}-6-ethyl-thieno [2,3-i ] pyrimidin-4-yl)-Z⁾-phenylalanine

and

Example 239 : V-((5R_«)-5- {3-chloro- 1- [2-(4-methylpiperazin- l-yl)ethyl] - lH-indol-4- yl}-6-ethyl-thieno [2,3-i/] pyrimidin-4-yl)-Z⁾-phenylalanine

Using General Procedure VIII and Preparation 7i as the appropriate indole derivative and 2-(4-methylpiperazin-l-yl)ethanol as the appropriate alcohol, Example 238 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₃₂H₃₅C1N60₂S: 602.2231 , found: 603.2312 (M+H)

Example 239 was obtained as the later eluting diastereoisomer. HRMS calculated for C₃₂H₃₅C1N60₂S: 602.2231 , found: 603.231 1 (M+H)

Example 240 : V-((5S_«)-5- {3-chloro- 1- [3-(4-methylpiperazin- l-yl)propyl] - lH-indol-4- yl}-6-ethyl-thieno[2,3-</]pyrimidin-4-yl)-D-phenylalanine

and

Example 241 : V-((5R_«)-5- {3-chloro- 1- [3-(4-methylpiperazin- l-yl)propyl] - lH-indol-4- yl}-6-ethyl-thieno [2,3-i/] pyrimidin-4-yl)-Z⁾-phenylalanine Using General Procedure VIII and Preparation 7i as the appropriate indole derivative and 3-(4-methylpiperazin-l-yl)propan-l-ol as the appropriate alcohol, Example 240 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C33H37CI 6O2S : 616.2387, found: 617.2466 (M+H)

Example 241 was obtained as the later eluting diastereoisomer. HRMS calculated for C33H37CIN6O2S : 616.2387, found: 617.2473 (M+H)

Example 242 : 3-cyclohexyl-iV- [6-ethyl-5-(lH-indol-4-yl)thieno [2,3-d\ pyrimidin-4-yl] - D-alanine, diastereoisomer 1

and

Example 243: 3-cyclohexyl- V-[6-ethyl-5-(lH-indol-4-yl)thieno[2,3-i ]pyrimidin-4-yl]- D-alanine, diastereoisomer 2

Using General Procedure la and Preparation 4v as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-cyclohexyl-propanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 0.1 % aqueous TFA solution and acetonitrile as eluents. Example 242 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C25H28N4O2S : 448.1933, found: 449.1994 (M+H)

Example 243 was obtained as the later eluting diastereoisomer. HRMS calculated for C25H28N4O2S : 448.1933, found: 449.2006 (M+H) Example 244: V-[(5S_fl)-5-(3-chloro-lH-indol-4-yl)-6-ethyl-thieno[2,3-i |pyrimidin-4- yl] -3-pyridin-2-yl-D- alanine

and

Example 245 : TV- [(5R«)-5-(3-chloro- lH-indol-4-yl)-6-ethyl-thieno [2,3-d\ pyrimidin-4- yl] -3-pyridin-2-yl-D- alanine Using General Procedure la and Preparation 7j as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(2-pyridyl)propanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 40 mM aqueous NH₄OAc solution ( H = 4, adjusted with AcOH) and acetonitrile as eluents. Example 244 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C24H20CIN5O2S : 477.1026, found: 478.1087 (M+H)

Example 245 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₄H₂oClN₅0₂S: 477.1026, found: 478.1089 (M+H)

Example 246: V-((5S_fl)-5-{3-chloro-l-[2-(morpholin-4-yl)ethyl]-lH-indol-4-yl}-6- ethyl-thieno [2,3-i/] pyrimidin-4-yl)-3-pyridin-2-yl-D- alanine

Step A: methyl (2R)-2-[[ (5S_a)-5-(3-chloro-lH-indol-4-yl)-6-ethyl-thienof2,3-d]pyrimidin- 4-yl] amino] -3-(2-pyridyl)propanoate

0.13 g Example 244 (0.27 mmol) was dissolved in 13 mL MeOH, then 0.3 mL cc. H₂S0₄ was added and the mixture was stirred at r.t. until no further conversion was observed. Then it was concentrated under reduced pressure and saturated aqueous NaHC0₃ solution was added and the mixture was agitated. The formed precipitate was collected by filtration to obtain methyl (2i?)-2-[[(55'_ii)-5-(3-chloro-lH-indol-4-yl)-6-ethyl-thieno[2,3- ] pyrimidin-4-yl]amino]-3-(2-pyridyl)propanoate.

Step B: Example 246

Using General procedure VIII and methyl (2i?)-2-[[(55'_iJ)-5-(3-chloro-lH-indol-4-yl)-6- ethyl-thieno[2,3-(i]pyrimidin-4-yl]amino]-3-(2-pyridyl)propanoate as the appropriate indole derivative and 2-morpholinoethanol as the appropriate alcohol, Example 246 was obtained. HRMS calculated for C₃₀H₃iCl ₆O₃S: 590.1867, found: 591.1938 (M+H)

Example 247: V-((5R_fl)-5-{3-chloro-l-[2-(morpholin-4-yl)ethyl]-lH-indol-4-yl}-6- ethyl-thieno [2,3-i ] pyrimidin-4-yl)-3-pyridin-2-yl-D- alanine

Step A: methyl (2R)-2-[[ (5R_a)-5-(3-chloro-lH-indol-4-yl)-6-ethyl-thienof2,3-d]pyrimidin- 4-yl] amino] -3-(2-pyridyl)propanoate

0.157 g Example 245 (0.33 mmol) was dissolved in 15 mL MeOH, then 0.3 mL cc. H₂S0₄ was added and the mixture was stirred at r.t. until no further conversion was observed. Then it was concentrated under reduced pressure and saturated aqueous NaHC0₃ solution was added and the mixture was agitated. The formed precipitate was collected by filtration to obtain methyl (2^)-2-[[(5^_Ω)-5-(3-ΰωοΓθ-1^ίηάο1-4^1)-6-6 1-ώίεηο[2,3-ύΓ| pyrimidin-4-yl]amino]-3-(2-pyridyl)propanoate.

Step B: Example 247

Using General procedure VIII and methyl (2i?)-2-[[(5i?a)-5-(3-chloro-lH-indol-4-yl)-6- ethyl-thieno[2,3-(i]pyrimidin-4-yl]amino]-3-(2-pyridyl)propanoate as the appropriate amine and 2-morpholinoethanol as the appropriate alcohol Example 247 was obtained. HRMS calculated for C₃₀H₃iClN₆O₃S: 590.1867, found: 591.1918 (M+H)

Example 248 : V-((5S_«)-5- {3-chloro- 1- [2-(4-methylpiperazin- l-yl)ethyl] - lH-indol-4- yl}-6-ethyl-thieno [2,3-i ] pyrimidin-4-yl)-3-pyridin-2-yl-D- alanine

Step A: methyl (2R)-2-[[ (5S^-5-(3-chloro-lH-indol-4-yl)-6-ethyl-thieno[2,3-d]pyrimidin- 4-yl] amino] -3-(2-pyridyl)propanoate

Step B: Example 248

Using General procedure VIII and methyl (2i?)-2-[[(5¾-5-(3-chloro-lH-indol-4-yl)-6- ethyl-thieno[2,3-(i]pyrimidin-4-yl]amino]-3-(2-pyridyl)propanoate as the appropriate indole derivative and 2-(4-methylpiperazin-l-yl)ethanol as the appropriate alcohol Example 248 was obtained. HRMS calculated for C₃iH₃₄ClN₇0₂S: 603.2183, found: 302.6172 (M+2H) Example 249: V-((5R_fl)-5-{3-chloro-l-[2-(4-methylpiperazin-l-yl)ethyl]-lH-indol-4- yl}-6-ethyl-thieno[2,3-i ]pyrimidin-4-yl)-3-pyridin-2-yl-Z⁾-alanine Step A: methyl (2R)-2-[[ (5Ra)-5-(3-chloro-lH-indol-4-yl)-6-ethyl-thieno[2,3-dJpyrimidin- 4-yl] amino] -3-(2-pyridyl)propanoate

Step B: Example 249

Using General procedure VIII and methyl (2i?)-2-[[(5¾)-5-(3-chloro-lH-indol-4-yl)-6- ethylthieno[2,3-(i]pyrimidin-4-yl]amino]-3-(2-pyridyl)propanoate as the appropriate indole derivative and 2-(4-methylpiperazin-l-yl)ethanol as the appropriate alcohol Example 249 was obtained. HRMS calculated for C₃iH₃₄ClN₇0₂S: 603.2183, found: 302.6164 (M+2H)

Example 250 : TV- [6-(difluoromethyl)-(5S_fl)-5-(naphthalen- l-yl)thieno [2,3-i/] pyrimidin- 4-yl] -3-pyridin-2-yl-D- alanine

and

Example 251 : TV- [6-(difluoromethyl)-(5R_fl)-5-(naphthalen- l-yl)thieno [2,3-i ] pyrimidin- 4-yl] -3-pyridin-2-yl-D- alanine

Using General Procedure la and Preparation 4r as the appropriate 4-chloro-thieno[2,3-<i] pyrimidine derivative and (2i?)-2-amino-3-(2-pyridyl)propanoic acid as the appropriate amino acid derivative, a mixture of diastereoisomers was obtained. They were separated via preparative reversed phase chromatography using 40 mM aqueous NH₄OAc solution (pH = 4, adjusted with AcOH) and acetonitrile as eluents. Example 250 was obtained as the earlier eluting diastereoisomer. HRMS calculated for C₂5Hi8F₂N₄0₂S: 476.1119, found: 477.1195 (M+H)

Example 251 was obtained as the later eluting diastereoisomer. HRMS calculated for C₂₅Hi₈F₂N₄0₂S: 476.1119, found: 477.1182 (M+H) Example 252 : TV- [(5S_«)-5-(naphthalen- l-yl)-6-propylthieno [2,3-d\ pyrimidin-4-yl] -D- phenylalanine

266 mg Example 108 (0.57 mmol) was dissolved in 10 mL MeOH and 2 mL AcOH, then 61 mg 10 % Pd/C was added. The mixture was stirred under H₂ atmosphere at 40°C for 2 hours. It was filtered through Celite and the filtrate was concentrated under reduced pressure. The crude product was purified via preparative reversed phase chromatography using 40 mM aqueous NH₄OAc solution (pH = 4, adjusted with AcOH) and acetonitrile as eluents to obtain Example 252. HRMS calculated for C₂₈H₂₅N₃0₂S: 467.1667, found: 468.1746 (M+H) Example 253: iV-[(5R_fl)-5-(naphthalen-l-yl)-6-propylthieno[2,3-i |pyrimidin-4-yl]-Z⁾- phenylalanine

266 mg Example 109 (0.57 mmol) was dissolved in 10 mL MeOH and 2 mL AcOH, then 61 mg 10 % Pd/C was added. The mixture was stirred under H₂ atmosphere at 40 °C for 2 hours. It was filtered through Celite and the filtrate was concentrated under reduced pressure. The crude product was purified via preparative reversed phase chromatography using 40 mM aqueous NH₄OAc solution (pH = 4, adjusted with AcOH) and acetonitrile as eluents to obtain Example 253. HRMS calculated for C₂₈H₂₅N₃0₂S: 467.1667, found: 468.1736 (M+H)

Example 254: methyl V-[6-ethyl-(5S_fl)-5-(naphthalen-l-yl)thieno[2,3-i ]pyrimidin-4- yl]-D-phenylalaninate

102 mg Example 101 (0.225 mmol) was dissolved in 2 mL MeOH and the mixture was cooled to 0°C under N₂ atmoshphere. Then 135 diazomethyl(trimethyl)silane solution (2M in Et₂0) was added and the mixture was allowed to warm up to r.t. Then the mixture was concentrated in vacuo and purified via flash chromatography using heptane and EtOAc as eluents to obtain Example 254. HRMS calculated for C₂₈H₂₅N₃0₂S: 467.1667, found: 468.1746 (M+H) Example 255: methyl V-[6-ethyl-(5R_fl)-5-(naphthalen-l-yl)thieno[2,3-i ]pyrimidin-4- yl] -D-phenylalaninate

102 mg Example 100 (0.225 mmol) was dissolved in 2 mL MeOH and the mixture was cooled to 0 °C under N₂ atmoshphere. Then 135 diazomethyl(trimethyl)silane solution (2M in Et₂0) was added and the mixture was allowed to warm up to r.t. The mixture was concentrated in vacuo and purified via flash chromatography using heptane and EtOAc as eluents to obtain Example 255. HRMS calculated for C28H25N3O2S : 467.1667, found: 468.1737 (M+H)

Example 256: ethyl V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl) ethoxy] phenyl}-6-(4-fluor ophenyl)thieno [2,3-i j pyrimidin-4-yl] -2- { [2-(2-methoxy phenyl)pyrimidin-4-yl]methoxy}-D-phenylalaninate

Example 7 was dissolved in HC1 solution (20 mL/mmol, 1.25M in EtOH) and the mixture was stirred at r.t. overnight. Then the mixture was neutralized with NaHC0₃ solution and it was extracted with DCM. The organic phase was dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via preparative reversed phase chromatography using 25 mM aqueous NH₄HCO₃ solution and acetonitrile as eluents to give Example 256. HRMS calculated for C₄9H₄9CIFN7O5S: 901.3188, found: 902.3225 (M+H)

Example 257: ethyl 2-[(l-teri-butyl-lH-pyrazol-5-yl)methoxy]- V-[(5S_fl)-5-{3-chloro-2- methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy]phenyl}-6-(prop-l-yn-l-yl)thieno[2,3-i ] pyrimidin-4-yl]-D-phenylalaninate

Example 40 was dissolved in HC1 solution (20 mL/mmol, 1.25M in EtOH) and the mixture was stirred at r.t. overnight. Then the mixture was neutralized with NaHC0₃ solution and it was extracted with DCM. The organic phase was dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via preparative reversed phase chromatography using 25 mM aqueous NH₄HC0₃ solution and acetonitrile as eluents to give Example 257. HRMS calculated for C₄2H₅oClN₇0₄S: 783.3334, found: 392.6744 (M+2H)

Example 258: ethyl V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl) ethoxy] phenyl}-6-(prop- 1-yn- l-yl)thieno [2,3-i/] pyrimidin-4-yl] -2- { [2-(2-methoxy phenyl)pyrimidin-4-yl] methoxy}-D-phenylalaninate

Example 45 was dissolved in HC1 solution (20 mL/mmol, 1.25M in EtOH) and the mixture was stirred at r.t. overnight. Then the mixture was neutralized with NaHC0₃ solution and it was extracted with DCM. The organic phase was dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via preparative reversed phase chromatography using 25 mM aqueous NH₄HC0₃ solution and acetonitrile as eluents to give Example 258. HRMS calculated for C₄₆H₄₈C1N₇0₅S: 845.3126, found: 423.6650 (M+H)

Example 259: ethyl V-[(5S_fl)-5-{3-chloro-4-[2-(dimethylamino)ethoxy]-2-methyl phenyl}-6-(prop- 1-yn- l-yl)thieno [2,3-i ] pyrimidin-4-yl] -2- { [2-(2-methoxyphenyl) pyrimidin-4-yl] methoxy}-D-phenylalaninate

Example 49 was dissolved in HC1 solution (20 mL/mmol, 1.25M in EtOH) and the mixture was stirred at r.t. overnight. Then the mixture was neutralized with NaHC0₃ solution and it was extracted with DCM. The organic phase was dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via preparative reversed phase chromatography using 25 mM aqueous NH₄HC0₃ solution and acetonitrile as eluents to give Example 259. HRMS calculated for C₄₃H₄₃C1N₆0₅S: 790.2704, found: 396.1425 (M+2H)

Example 260: ethyl V-[(5S_fl)-5-{3-chloro-4-[2-(dimethylamino)ethoxy]-2-methyl phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]-2-({2-[2-(2-methoxyethoxy) phenyl] pyrimidin-4-yl}methoxy)-D-phenylalaninate Example 51 was dissolved in HC1 solution (20 mL/mmol, 1.25M in EtOH) and the mixture was stirred at 60 °C until no further conversion was observed. Then the mixture was neutralized with NaHC0₃ solution and it was extracted with DCM. The organic phase was dried over Na₂S0₄, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via preparative reversed phase chromatography using 25 mM aqueous NH₄HC0₃ solution and acetonitrile as eluents to obtain Example 260. HRMS calculated for

890.3029, found: 891.3105 (M+H)

Example 261: (5-methyl-2-oxo-l,3-dioxol-4-yl)methyl V-[(5S_«)-5-{3-chloro-4-[2- (dimethylamino)ethoxy] -2-methylphenyl}-6-(4-fluorophenyl)thieno [2,3-i/] pyrimidin- 4-yl]-2-({2-[2-(2-methoxyethoxy)phenyl]pyrimidin-4-yl}methoxy)-Z⁾-phenylalaninate

1 eq. Example 51 and 1.1 eq. 4-(chloromethyl)-5-methyl-l,3-dioxol-2-one were dissolved in DMF (10 mL/mmol), then 2 eq. Nal and 2 eq. Cs₂C0₃ were added and the mixture was stirred until no further conversion was observed. Then the mixture was directly injected and purified via preparative reversed phase chromatography using 25 mM aqueous NH₄HC0₃ solution and acetonitrile as eluents to obtain Example 261. HRMS calculated for C₅iH₄₈ClFN60₉S: 974.2876, found: 975.2949 (M+H)

Example 262: l-[(ethoxycarbonyl)oxy] ethyl V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4- methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-i ] pyrimidin-4-yl] - 2-{[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy}-D-phenylalaninate Example 263: l-[(dimethylcarbamoyl)oxy] ethyl V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2- (4-methylpiperazin-l-yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-i ]pyrimidin-4- yl] -2- { [2-(2-methoxyphenyl)pyrimidin-4-yl] methoxy}-D-phenylalaninate

Example 264: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]-2-({2-[3-(hydroxymethyl) phenyl] pyrimidin-4-yl}methoxy)-D-phenylalanine

Example 265: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]-2-({2-[2-(hydroxymethyl) pyridin-4-yl]pyrimidin-4-yl}methoxy)-D-phenylalanine

Example 266: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]-2-({2-[6-(hydroxymethyl) pyridazin-4-yl]pyrimidin-4-yl}methoxy)-D-phenylalanine

Example 267: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]-2-({2-[6-(hydroxymethyl) pyrazin-2-yl]pyrimidin-4-yl}methoxy)-D-phenylalanine

Example 268: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluor ophenyl)thieno [2,3-i j pyrimidin-4-yl] -2- { [2 '-(hydroxymethyl)-2,5 '- bipyrimidin-4-yl]methoxy}-D-phenylalanine

Example 269: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]-2-({2-[4-(phosphonooxy) phenyl]pyrimidin-4-yl}methoxy)-D-phenylalanine

Example 270: V-[5-{3,5-dichloro-2,6-dimethyl-4-[2-(4-methylpiperazin-l-yl) ethoxy] phenyl}-6-(4-fluor ophenyl)thieno [2,3-i j pyrimidin-4-yl] -2- { [2-(2-methoxy phenyl)pyrimidin-4-yl]methoxy}-D-phenylalanine

Step A: 4-bromo-2, 6-dichloro-3, 5-dimethyl-phenol

30.16 g 4-bromo-3, 5-dimethyl-phenol (150 mmol) was dissolved in a mixture of 75 mL 1 ,2-dichloroethane and 75 mL acetonitrile, then 40.06 g NCS (300 mmol) was added portionwise and the mixture was stirred at r.t. until no further conversion was observed. Reaction mixture was concentrated under reduced pressure, the residue was dissolved in DCM, washed with water and brine. The organic layer was dried over Na₂S0₄ and concentrated under reduced pressure and used in the next step without further purification. 1H NMR (400 MHz, DMSO-de): 10.10 (s, 1H), 2.46 (s, 6H) Step B: l-bromo-3, 5-dichloro-4-methoxy-2, 6-dimethyl-benzene

To a solution of 26.0 g 4-bromo-2,6-dichloro-3,5-dimethyl-phenol (96.3 mmol) and 26.6 g K₂C0₃ (192.6 mmol) in 300 mL MeCN 6.6 mL Mel (105.9 mmol) was added and the mixture was stirred at r.t. until no further conversion was observed. The solids were filtered off and the filtrate was concentrated under reduced pressure. The crude product was dissolved in DCM, washed with water and brine. The organic layer was dried over Na₂S0₄ and concentrated under reduced pressure and used in the next step without further purification. 1H NMR (400 MHz, DMSO-d₆): 3.78 (s, 3H), 2.49 (s, 6H)

Step C: 2- ( 3, 5-dichloro-4-methoxy-2, 6-dimethyl-phenyl)-4, 4, 5, 5-tetramethyl-l, 3, 2- dioxaborolane

10.0 g l-bromo-3, 5-dichloro-4-methoxy-2, 6-dimethyl-benzene (35.2 mmol) was dissolved in 360 mL dry THF under nitrogen and was cooled to -78 °C with dry ice-acetone. 23.2 mL nBuLi (1.6 M in hexanes) (37.0 mmol) was added and the mixture was stirred for 15 minutes, then 8.6 mL 2-isopropoxy-4,4,5, 5-tetramethyl-l, 3,2-dioxaborolane (42.24 mmol) was added and the mixture was allowed to warm up to r.t. It was quenched with brine, extracted with DCM, dried over Na₂S0₄, filtered and concentrated under reduced pressure. The crude product was purified via flash chromatography using heptane and EtOAc as eluents to obtain 2-(3,5-dichloro-4-methoxy-2,6-dimethyl-phenyl)-4,4,5,5- tetramethyl-1, 3,2-dioxaborolane. 1H NMR (400 MHz, DMSO-d₆): 3.81 (s, 3H), 2.33 (s, 6H), 1.34 (s, 12H)

Step D: ethyl 4- ( 3, 5-dichloro-4-methoxy-2, 6-dimethyl-phenyl) thiophene-3-carboxylate 3.92 g ethyl 4-bromothiophene-3-carboxylate (16.68 mmol) and 9.9 g 2-(3,5-dichloro-4- methoxy-2,6-dimethyl-phenyl)-4,4, 5, 5-tetramethyl-l, 3,2-dioxaborolane (30.0 mmol) were dissolved in 140 mL dioxane, then 10.87 g CS₂CO₃ (33.36 mmol) dissolved in 40 mL water was added. Then 590 mg AtaPhos (0.83 mmol) was added, and the mixture was stirred under nitrogen at reflux temperature until no further conversion was observed. Then it was diluted with DCM and brine. After phase separation the aqueous phase was extracted with DCM. The organic layers were combined and dried over Na₂S0₄, filtered and concentrated under reduced pressure. The crude product was purified via flash chromatography using heptane and EtOAc as eluents to obtain ethyl 4-(3,5-dichloro-4-methoxy-2,6-dimethyl- phenyl)thiophene-3-carboxylate.

1H NMR (400 MHz, DMSO-d₆): 8.53 (d, 1H), 7.47 (d, 1H), 4.02 (q, 2H), 3.83 (s, 3H), 1.95 (s, 6H), 1.00 (t, 3H)

HRMS (M+NH₄)⁺ = 376.0538

Step E: ethyl 4-(3,5-dichloro-4-methoxy-2,6-dimethyl-phenyl)-2,5-diiodo-thiophene-3- carboxylate

2.65 g 4-(3,5-dichloro-4-methoxy-2,6-dimethyl-phenyl)thiophene-3-carboxylate (7.38 mmol) was dissolved in 75 mL acetonitrile, then 2.2 mL fluoroboric acid diethyl ether complex (16.23 mmol) and 3.65 g N-iodosuccinimide (16.23 mmol) was added and the mixture was stirred at r.t. until no further conversion was observed. Reaction mixture was concentrated under reduced pressure, and the crude product was purified via flash chromatography using heptane and EtOAc as eluents to obtain ethyl 4-(3,5-dichloro-4- methoxy-2,6-dimethyl-phenyl)-2,5-diiodo-thiophene-3-carboxylate. 1H NMR (400 MHz, DMSO-dg): 3.98 (q, 2H), 3.84 (s, 3H), 1.92 (s, 6H), 0.84 (t, 3H)

Step F: ethyl 4-(3,5-dichloro-4-methoxy-2, 6-dimethyl-phenyl)-5-iodo-thiophene-3- carboxylate

5.29 g 4-(3,5-dichloro-4-methoxy-2,6-dimethyl-phenyl)-2,5-diiodo-thiophene-3- carboxylate (8.66 mmol) was dissolved in 90 mL dry THF, then cooled to -78 °C under argon atmosphere. 6.7 mL isopropyl magnesium chloride, lithium chloride complex (1.3 M in THF) (8.66 mmol) was added and the mixture was stirred at -78 °C for 30 minutes. Then saturated aq. NH₄C1 was added and the mixture was extracted with ethyl acetate. The organic layer was dried over Na₂S0₄ and concentrated under reduced pressure. The crude product was purified via flash chromatography using heptane and EtOAc as eluents to obtain ethyl 4-(3,5-dichloro-4-methoxy-2,6-dimethyl-phenyl)-5-iodo-thiophene-3- carboxylate. 1H NMR (400 MHz, DMSO-dg): 8.71 (s, 1H), 4.01 (q, 2H), 3.86 (s, 3H), 1.89 (s, 6H), 0.99 (t, 3H)

Step G: ethyl 4-(3,5-dichloro-4-methoxy-2,6-dimethyl-phenyl)-5-(4-fluorophenyl) thiophene-3-carboxylate 4.20 g ethyl 4-(3,5-dichloro-4-methoxy-2,6-dimethyl-phenyl)-5-iodo-thiophene-3- carboxylate (8.66 mmol) and 1.82 g 4-fluorophenylboronic acid (13.0 mmol) were dissolved in 80 mL dioxane, then 5.64 g CS₂CO₃ (17.32 mmol) dissolved in 20 mL water was added. Then 500 mg Pd(PPh₃)₄ (0.43 mmol) was added, and the mixture was stirred under nitrogen at 80 °C until no further conversion was observed. Then it was diluted with DCM and brine. After phase separation the aqueous phase was extracted with DCM. The organic layers were combined and dried over Na₂S0₄, filtered and concentrated under reduced pressure. The crude product was purified via flash chromatography using heptane and EtOAc as eluents to obtain ethyl 4-(3,5-dichloro-4-methoxy-2,6-dimethyl-phenyl)-5- (4-fluorophenyl)thiophene-3-carboxylate.

1H NMR (400 MHz, DMSO-d₆): 8.58 (s, 1H), 7.22-7.10 (m, 4H), 4.03 (q, 2H), 3.82 (s, 3H), 1.92 (s, 6H), 1.00 (t, 3H)

HRMS (M+H)⁺ = 453.0498

Step H: ethyl 4-(3,5-dichloro-4-methoxy-2, 6-dimethyl-phenyl)-5-(4-fluorophenyl)-2-nitro- thiophene-3-carboxylate

1.97 g ethyl 4-(3,5-dichloro-4-methoxy-2,6-dimethyl-phenyl)-5-(4-fluorophenyl) thiophene-3-carboxylate (4.34 mmol) was dissolved in 40 mL dry acetonitrile, then 576 mg nitronium tetrafluoroborate (4.34 mmol) was added and the mixture was stirred at r.t. until no further conversion was observed. Then it was diluted with DCM and brine. After phase separation the aqueous phase was extracted with DCM. The organic layers were combined and dried over Na₂S0₄, filtered and concentrated under reduced pressure. The crude product was purified via flash chromatography using heptane and EtOAc as eluents to obtain ethyl 4-(3,5-dichloro-4-methoxy-2,6-dimethyl-phenyl)-5-(4-f uorophenyl)-2-nitro- thiophene-3-carboxylate. 1H NMR (400 MHz, DMSO-d₆): 7.37-7.33 (m, 2H), 7.32-7.26 (m, 2H), 4.14 (q, 2H), 3.82 (s, 3H), 2.06 (s, 6H), 0.88 (t, 3H)

Step I: ethyl 2-amino-4-(3,5-dichloro-4-methoxy-2, 6-dimethyl-phenyl)-5-(4-fluorophenyl) thiophene-3-carboxylate

1.85 g ethyl 4-(3,5-dichloro-4-methoxy-2,6-dimethyl-phenyl)-5-(4-fluorophenyl)-2-nitro- thiophene-3-carboxylate (3.71 mmol) was dissolved in a mixture of 90 mL acetic acid and 18 mL water, then 2.43 g zinc dust (37.1 mmol) was added portionwise and the mixture was stirred at r.t. until no further conversion was observed. Reaction mixture was concentrated under reduced pressure, and the crude product was purified via flash chromatography using heptane and EtOAc as eluents to obtain ethyl 2-amino-4-(3,5- dichloro-4-methoxy-2,6-dimethyl-phenyl)-5-(4-fluorophenyl)thiophene-3-carboxylate. 1H NMR (400 MHz, DMSO-d₆): 7.73 (s, 2H), 7.12-7.06 (m, 2H), 7.02-6.97 (m, 2H), 3.86- 3.80 (m, 2H), 3.80 (s, 3H), 2.01 (s, 6H), 0.72 (t, 3H)

HRMS (M+H)⁺ = 456.0598

Step J: 5-(3,5-dichloro-4-methoxy-2,6-dimethyl-phenyl)-6-(4-fluorophenyl)-3ii-thieno [ 2, 3-dJpyrimidin-4-one

1.1 g ethyl 2-amino-4-(3,5-dichloro-4-methoxy-2,6-dimethyl-phenyl)-5-(4-fluorophenyl) thiophene-3-carboxylate (2.35 mmol) was dissolved in 20 mL formamide and it was stirred at 150 °C until no further conversion was observed. Then it was poured onto water and the precipitated product was collected by filtration to give 5-(3,5-dichloro-4-methoxy-2,6- dimethyl-phenyl)-6-(4-fluorophenyl)-3H-thieno[2,3-d]pyrimidin-4-one.

1H NMR (400 MHz, DMSO-d₆): 12.53 (br s, 1H), 8.18 (s, 1H), 7.23-7.16 (m, 4H), 3.84 (s, 3H), 1.96 (s, 6H)

HRMS (M+H)⁺ = 449.0289

Step K: 4-chloro-5-(3,5-dichloro-4-methoxy-2,6-dimethyl-phenyl)-6-(4-fluorophenyl) thienof 2, 3-dJpyrimidine

700 mg 5-(3,5-dichloro-4-methoxy-2,6-dimethyl-phenyl)-6-(4-fluorophenyl)-3H-thieno [2,3- ]pyrimidin-4-one (1.56 mmol) was dissolved in 6 mL phosphorous oxychloride and it was stirred at 90 °C until no further conversion was observed. Reaction mixture was concentrated under reduced pressure, then to the crude product icy water was added and it was sonicated for 10 minutes. The precipitated product was collected by filtration to give 4-chloro-5-(3,5-dichloro-4-methoxy-2,6-dimethyl-phenyl)-6-(4-fluorophenyl)thieno[2,3-(i] pyrimidine.

1H NMR (400 MHz, DMSO-de): 9.02 (s, 1H), 7.38-7.26 (m, 4H), 3.86 (s, 3H), 1.99 (s, 6H) HRMS (M+H)⁺ = 466.9954 Step L: 2, 6-dichloro-4-[ 4-chloro-6-(4-fluorophenyl)thieno [2 , 3-d]pyrimidin-5-yl]-3, 5- dimethyl-phenol and 4-f 4-bromo-6-(4-fluorophenyl)thieno[2, 3-dJpyrimidin-5-ylJ-2, 6- dichloro-3, 5 -dimethyl-phenol

To a stirred solution of 700 mg 4-chloro-5-(3,5-dichloro-4-methoxy-2,6-dimethyl-phenyl)- 6-(4-fluorophenyl)thieno[2,3-d]pyrimidine (1.50 mmol) in 15 mL DCM 3.0 mL boron tribromide (1 M in DCM) (3.0 mmol) was added at 0 °C and the mixture was allowed to warm up to r.t. and it was stirred until no further conversion was observed. The mixture was quenched with saturated aq. NH₄C1 and extracted with DCM. The combined organic phases were dried over Na₂S0₄ and concentrated under reduced pressure. The residue was purified via flash chromatography using heptane and EtOAc as eluents to obtain 2,6- dichloro-4- [4-chloro-6-(4-fluorophenyl)thieno [2,3 - ]pyrimidin-5 -yl] -3 ,5 -dimethyl-pheno 1 and 4-[4-bromo-6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-5-yl]-2,6-dichloro-3,5- dimethyl-phenol as a 37:63 mixture of products.

1H NMR (400 MHz, DMSO-d₆): 10.14 (br s, 1H), 9.01 (s, 1H), 7.40-7.23 (m, 4H), 1.95 (s, 6H) and 10.14 (br s, 1H), 8.93 (s, 1H), 7.40-7.23 (m, 4H), 1.93 (s, 6H)

HRMS (M+H)⁺ = 452.9800 and 496.9287

Step M: 4-chloro-5-[ 3, 5-dichloro-2, 6-dimethyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl] -6-(4-fluorophenyl)thieno [2, 3-dJpyrimidine and 4-bromo-5-[ 3, 5-dichloro-2, 6- dimethyl-4-f 2- ( 4-methylpiperazin-l-yl) ethoxy] phenyl] -6- ( 4-fluorophenyl) thienof 2, 3-d] pyrimidine

300 mg mixture of 2,6-dichloro-4-[4-chloro-6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-5- yl] -3 ,5 -dimethyl-pheno 1 and 4- [4-bromo-6-(4-fluorophenyl)thieno [2,3 - ]pyrimidin-5 -yl] - 2,6-dichloro-3,5-dimethyl-phenol (0.62 mmol), 286 mg 2-(4-methylpiperazin-l-yl)ethanol (1.98 mmol) and 520 mg triphenyl phosphine (1.98 mmol) were dissolved in 10 mL dry toluene, then 460 mg ditertbutyl azodicarboxylate (1.98 mmol) was added. The mixture was stirred at 50 °C under nitrogen until no further conversion was observed. The volatiles were evaporated under reduced pressure and the crude intermediate was purified via flash chromatography using EtOAc and methanol as eluents to obtain 4-chloro-5-[3,5-dichloro- 2,6-dimethyl-4-[2-(4-methylpiperazin-l-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-(i] pyrimidine and 4-bromo-5-[3,5-dichloro-2,6-dimethyl-4-[2-(4-methylpiperazin-l- yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-(i]pyrimidine as a 35:65 mixture of products.

1H NMR (400 MHz, DMSO-d₆): 9.02 (S, 1H), 7.40-7.22 (m, 4H), 4.11 (t, 2H), 2.78 (t, 2H), 2.63-2.20 (m, 8H), 2.17 (br s, 3H), 1.98 (s, 6H) and 8.94 (S, 1H), 7.40-7.22 (m, 4H), 4.11 (t, 2H), 2.78 (t, 2H), 2.63-2.20 (m, 8H), 2.15 (br s, 3H), 1.98 (s, 6H)

HRMS (M+H)⁺ = 579.0968 and 623.0455

Step N: Example 270

250 mg mixture of 4-chloro-5-[3,5-dichloro-2,6-dimethyl-4-[2-(4-methylpiperazin-l- yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-(i]pyrimidine and 4-bromo-5-[3,5- dichloro-2,6-dimethyl-4-[2-(4-methylpiperazin-l-yl)ethoxy]phenyl]-6-(4-fluorophenyl) thieno[2,3-d]pyrimidine (0.41 mmol), 327 mg (2i?)-2-amino-3-[2-[[2-(2-methoxy phenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid (Preparation A4, 0.86 mmol) and 280 mg CS₂CO₃ (0.86 mmol) was dissolved in 5 mL tert-butanol and the mixture was stirred at 70°C until no further conversion was observed. The solids were filtered off and the filtrate was concentrated under reduced pressure. The crude product was purified via preparative reversed phase chromatography using 25 mM aqueous NH₄HCO₃ solution and MeCN, Example 270 was obtained. HRMS calculated for C₄₈H₄₆N₇O₅FSCI₂: 921.2642, found: 461.6398 (M+2H)

Example 271: V-[5-{2,6-dimethyl-4-[2-(4-methylpiperazin-l-yl)ethoxy]phenyl}-6-(4- fluor ophenyl)thieno [2,3-i j pyrimidin-4-yl] -2- { [2-(2-methoxyphenyl)pyrimidin-4- yl] methoxy}-D-phenylalanine

Example 272: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluor ophenyl)thieno [2,3-i j pyrimidin-4-yl] -P-(hydroxymethyl)-2- { [2-(2- methoxyphenyl)pyrimidin-4-yl]methoxy}phenylalanine

Example 273 : TV- [(5S_fl)-5-{3-chloro-2-methyl-4- [2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluor ophenyl)thieno [2,3-i j pyrimidin-4-yl] -P-hydroxy-2- { [2-(2-methoxy phenyl)pyrimidin-4-yl]methoxy}phenylalanine Example 274: V-[(5S_fl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluor ophenyl)thieno [2,3- \ pyrimidin-4-yl] -P-(2-hydroxyethyl)-2- { [2-(2- methoxyphenyl)pyrimidin-4-yl]methoxy}phenylalanine

PHARMACOLOGICAL STUDY

EXAMPLE A: Inhibition of Mcl-l by the fluorescence polarisation technique

The relative binding potency of each compound was determined via Fluorescence Polarisation (FP). The method utilised a Fluorescein labelled ligand (Fluorescein- pAla- Ahx-A-REIGAQLRPvMADDLNAQY-OH; mw 2,765) which binds to the Mcl-l protein (such that Mcl-l corresponds to the UniProtKB^® primary accession number: Q07820) leading to an increased anisotropy measured in milli-polarisation (mP) units using a reader. The addition of a compound which binds competitively to the same site as the ligand will result in a greater proportion of unbound ligand in the system indicated by a decrease in mP units.

Method 1: An 11 point serial dilution of each compound was prepared in DMSO and 2 μΐ transferred into flat bottomed, low binding, 384-well plate (final DMSO concentration 5 %). 38μ1 of buffer (10 mM 4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid [HEPES], 150 mM NaCl, 0.05 % Tween 20, pH 7.4), containing the Fluorescein labelled ligand (final concentration 1 nM) and Mcl-l protein (final concentration 5 nM) was then added.

Assay plates were incubated ~2 hours at r.t. before FP was measured on a Biomek Synergy2 reader (Ex. 528 nm, Em. 640 nm, Cut off 510 nm) and mP units calculated. The binding of increasing doses of test compound was expressed as a percentage reduction in mP compared to a window established between '5 % DMSO only' and Ί00 % inhibition' controls. 11 -point dose response curves were plotted with XL-Fit software using a 4- Parameter Logistic Model (Sigmoidal Dose-Response Model) and the inhibitory concentrations that gave a 50 % reduction in mP (IC₅₀) were determined. Results obtained using Method 1 are presented in Table 1 below; IC₅₀ of Mcl-l inhibition obtained using Method 1 are not underlined. Method 2: An 11 point serial dilution of each compound was prepared in DMSO and 2 μΐ transferred into flat bottomed, low binding, 384-well plate (final DMSO concentration 5 %). 38 μΐ of buffer (20 mM Na₂HP0₄, ImM EDTA, 50 mM NaCl, pH 7.4), containing the Fluorescein labelled ligand (final concentration 10 nM) and Mcl-1 protein (final concentration 10 nM) was then added.

Assay plates were incubated ~2 hours at r.t. before FP was measured on a Biomek Synergy2 reader (Ex. 528 nm, Em. 640 nm, Cut off 510 nm) and mP units calculated. The binding of increasing doses of test compound was expressed as a percentage reduction in mP compared to a window established between '5% DMSO only' and ' 100% inhibition' controls (50 μΜ unlabelled ligand). 11-point dose response curves were plotted with XL- Fit software using a 4-Parameter Logistic Model (Sigmoidal Dose-Response Model) and the inhibitory concentrations that gave a 50 % reduction in mP (IC₅₀) were determined. Results obtained using Method 2 are presented in Table 1 below; IC^n of Mcl-1 inhibition obtained using Method 2 are underlined. The results show that the compounds of the invention inhibit interaction between the Mcl- 1 protein and the fluorescent peptide described hereinbefore.

EXAMPLE B: In vitro cytotoxicity

The cytotoxicity studies were carried out on the H929 multiple myeloma tumour line. The cells are distributed onto microplates and exposed to the test compounds for 48 hours. The cell viability is then quantified by a colorimetric assay, the Microculture Tetrazolium Assay (Cancer Res., 1987, 47, 939-942).

The results are expressed in IC₅₀ (the concentration of compound that inhibits cell viability by 50 %) and are presented in Table 1 below. The results show that the compounds of the invention are cytotoxic. Table 1: ICgn of Mcl-l inhibition (fluorescence polarisation test)

and of cytotoxicity for H929 cells

Note: IC50 of Mcl-l inhibition obtained using Method 2 are underlined.

IC50 (μΜ) Mcl-l FP 1C₅₀ (M) MTT H929 IC50 (μΜ) Mcl-l FP IC50 (M) MTT H929

Example 1 0.127 >6.0E-07 Example 29 0.063 2.52E-06

Example 2 56.9% (¾ 10 μΜ >6.0E-07 Example 30 68.2% (¾ 10 μΜ >3.75E-06

Example 3 0.114 3.18E-07 Example 31 16.7% (¾ 10 uM >3.75E-06

Example 4 0.005 2.15E-07 Example 32 0.007 >3.75E-06

Example 5 ND ND Example 33 54.9% @ 10 μΜ ND

Example 6 0.013 >6.0E-07 Example 34 0.726 4.27E-06

Example 7 0.008 1.38E-08 Example 35 24.78% (¾ 10 μΜ >3.0E-05

Example 8 0.054 2.58E-07 Example 36 0.086 >7.50E-06

Example 9 2.697 >3.75E-06 Example 37 18.7% (¾ 10 uM >3.75E-06

Example 10 72.75% (¾ 3.3 uM >3.75E-06 Example 38 1.871 >3.75E-06

Example 11 35.55% (¾ 10 μΜ >3.75E-06 Example 39 0.025 4.01E-07

Example 12 0.014 6.47E-07 Example 40 0.006 3.28E-08

Example 13 58% (¾ 10 μΜ >3.75E-06 Example 41 0.006 7.38E-09

Example 14 0.038 7.21E-07 Example 42 0.010 6.1E-08

Example 15 40.05% (¾ 10 μΜ >3.75E-06 Example 43 0.006 1.25E-08

Example 16 0.006 9.93E-08 Example 44 0.007 3.44E-09

Example 17 0.057 2.94E-07 Example 45 0.005 8.96E-10

Example 18 1.821 >1.14E-07 Example 46 0.024 1.66E-07

Example 19 0.020 1.75E-07 Example 47 0.008 8.39E-08

Example 20 0.026 7.86E-08 Example 48 0.007 1.61E-08

Example 21 0.006 3.97E-08 Example 49 0.003 4.12E-09

Example 22 0.002 8.59E-09 Example 50 0.007 >1.50E-07

Example 23 41.27% (¾ 1 uM >6.0E-07 Example 51 0.005 2.33E-08

Example 24 0.008 4.73E-08 Example 52 0.301 ND

Example 25 55.5% (¾ 10 μΜ >6.0E-07 Example 53 0.020 ND

Example 26 0.012 6.36E-09 Example 54 0.541 ND

Example 27 0.011 2.09E-09 Example 55 8.839 ND

Example 28 0.116 >1.88E-06 Example 56 0.019 ND IC₅₀ (μΜ) Mcl-1 FP IC₅₀ (M) MTT H929 IC₅₀ (μΜ) Mcl-1 FP 1C₅₀ (M) MTT H929

Example 57 0.106 ND Example 88 1.225 ND

Example 58 52.8% @ 10 μΜ ND Example 89 72.13% @ 200 μΜ ND

Example 59 0.127 ND Example 90 0.023 ND

Example 60 0.092 ND Example 91 6.372 ND

Example 61 0.036 ND Example 92 12.887 ND

Example 62 0.060 ND Example 93 0.080 ND

Example 63 12.18% (¾ 10 μΜ ND Example 94 6.901 ND

Example 64 0.025 ND Example 95 0.077 ND

Example 65 0.345 >2.78E-06 Example 96 1.628 ND

Example 66 36.9% @ 10 μΜ >3.75E-06 Example 97 0.073 ND

Example 67 2.079 ND Example 98 2.873 ND

Example 68 0.142 ND Example 99 28.3% @ 200 μΜ ND

Example 69 0.109 ND Example 100 4.747 ND

Example 70 0.974 ND Example 101 0.462 ND

Example 71 39.015 ND Example 102 0.073 ND

Example 72 12.007 ND Example 103 0.715 ND

Example 73 0.276 ND Example 104 0.046 ND

Example 74 0.621 ND Example 105 0.704 ND

Example 75 0.280 ND Example 106 0.065 ND

Example 76 3.177 ND Example 107 0.544 ND

Example 77 75.45% @ 200 μΜ ND Example 108 0.079 ND

Example 78 0.135 ND Example 109 1.858 ND

Example 79 0.429 ND Example 110 0.839 ND

Example 80 0.487 ND Example 111 4.452 ND

Example 81 20.241 ND Example 112 0.104 ND

Example 82 1.109 ND Example 113 0.045 ND

Example 83 0.258 ND Example 114 0.981 ND

Example 84 4.022 ND Example 115 1.753 ND

Example 85 0.228 ND Example 116 1.059 ND

Example 86 9.976 ND Example 117 2.603 ND

Example 87 62.6 % @ 7.4 μΜ ND Example 118 0.056 ND IC₅₀ (μΜ) Mcl-1 FP IC₅₀ (M) MTT H929 IC₅₀ (μΜ) Mcl-1 FP 1C₅₀ (M) MTT H929

Example 119 1.456 ND Example 150 0.528 ND

Example 120 9.445 ND Example 151 71.3% @ 66.7 μΜ ND

Example 121 0.167 ND Example 152 0.047 ND

Example 122 10.215 ND Example 153 75.7 % @ 50 μΜ ND

Example 123 0.152 ND Example 154 2.316 2.03E-05

Example 124 75.7 % @ 50 μΜ ND Example 155 63.15 % @ 50 μΜ ND

Example 125 13.710 ND Example 156 0.309 ND

Example 126 41.2 % @ 50 μΜ ND Example 157 62.05 % @ 50 μΜ ND

Example 127 0.913 ND Example 158 0.104 ND

Example 128 10.722 ND Example 159 1.770 ND

Example 129 0.053 ND Example 160 11.725 ND

Example 130 67.4 % @ 50 μΜ ND Example 161 12.579 ND

Example 131 0.495 ND Example 162 0.597 ND

Example 132 9.844 ND Example 163 8.375 ND

Example 133 0.079 ND Example 164 0.227 ND

Example 134 0.176 ND Example 165 0.315 ND

Example 135 75.25% @ 50 μΜ ND Example 166 0.064 ND

Example 136 0.146 ND Example 167 1.146 ND

Example 137 71.05% @ 50 μΜ ND Example 168 4.775 ND

Example 138 0.664 ND Example 169 2.105 ND

Example 139 32.75% @ 10 μΜ ND Example 170 0.955 ND

Example 140 0.208 ND Example 171 2.775 ND

Example 141 26.78% (¾ 10 μΜ ND Example 172 28.849 ND

Example 142 0.335 ND Example 173 6.794 ND

Example 143 68.85% @ 50 μΜ ND Example 174 0.466 ND

Example 144 0.154 ND Example 175 3.856 ND

Example 145 3.888 ND Example 176 8.409 ND

Example 146 0.071 ND Example 177 0.957 ND

Example 147 14.236 ND Example 178 3.232 ND

Example 148 0.416 ND Example 179 0.881 ND

Example 149 14.001 ND Example 180 2.104 ND IC₅₀ (μΜ) Mcl-1 FP IC₅₀ (M) MTT H929 IC₅₀ (μΜ) Mcl-1 FP 1C₅₀ (M) MTT H929

Example 181 0.299 ND Example 212 12.674 ND

Example 182 0.407 ND Example 213 0.111 ND

Example 183 2.044 ND Example 214 1.911 ND

Example 184 76.8% @ 200 μΜ ND Example 215 0.015 ND

Example 185 2.533 ND Example 216 58.95% @ 10 μΜ ND

Example 186 7.880 ND Example 217 0.065 ND

Example 187 1.385 ND Example 218 71.5% @ 50 μΜ ND

Example 188 21.302 ND Example 219 10.940 ND

Example 189 8.327 ND Example 220 31.7% @ 10 μΜ ND

Example 190 34.602 ND Example 221 0.097 ND

Example 191 0.171 ND Example 222 70% @ 50 μΜ ND

Example 192 2.082 ND Example 223 0.086 ND

Example 193 36.522 ND Example 224 8.607 ND

Example 194 1.752 ND Example 225 0.053 ND

Example 195 14.228 ND Example 226 0.069 ND

Example 196 2.908 ND Example 227 3.312 ND

Example 197 54.1% @ 200 μΜ ND Example 228 0.025 ND

Example 198 9.862 ND Example 229 6.325 ND

Example 199 0.298 ND Example 230 3.236 ND

Example 200 5.440 ND Example 231 56.75% @ 50 μΜ ND

Example 201 0.136 ND Example 232 62.2% @ 50 μΜ ND

Example 202 0.751 ND Example 233 3.408 ND

Example 203 71.85% @ 100 μΜ ND Example 234 68.7% @ 50 μΜ ND

Example 204 44.8% @ 100 μΜ ND Example 235 1.393 ND

Example 205 26.2% @ 100 μΜ ND Example 236 13.498 ND

Example 206 8.844 ND Example 237 0.569 ND

Example 207 0.136 ND Example 238 2.785 ND

Example 208 0.632 ND Example 239 20.328 ND

Example 209 56.85% @ 200 μΜ ND Example 240 0.958 ND

Example 210 8.363 ND Example 241 14.334 ND

Example 211 0.668 ND Example 242 0.091 ND IC₅₀ (μΜ) Mcl-1 FP IC₅₀ (M) MTT H929 IC₅₀ (μΜ) Mcl-1 FP 1C₅₀ (M) MTT H929

Example 243 0.073 ND Example 259 1.347 >6.0E-07

Example 244 0.120 ND Example 260 1.982 ND

Example 245 11.367 ND Example 261 ND ND

Example 246 0.293 >1.50E-05 Example 262 ND ND

Example 247 11.826 ND Example 263 ND ND

Example 248 2.176 ND Example 264 ND ND

Example 249 36.761 ND Example 265 ND ND

Example 250 0.617 ND Example 266 ND ND

Example 251 12.053 ND Example 267 ND ND

Example 252 0.223 ND Example 268 ND ND

Example 253 1.363 ND Example 269 ND ND

Example 254 22.08% @ 200 μΜ ND Example 270 0.055 5.22E-07

Example 255 41.08% @ 200 μΜ ND Example 271 ND ND

Example 256 1.606 >6.0E-07 Example 272 ND ND

Example 257 57.15% (¾ 10 μΜ ND Example 273 ND ND

Example 258 1.070 4.28E-07 Example 274 ND ND

ND: not determined

For partial inhibitors, the percentage fluorescence polarisation inhibition for a given concentration of the test compound is indicated. Accordingly, 45.1% @10 μΜ means that 45.1 % fluorescence polarisation inhibition is observed for a concentration of test compound equal to 10 μΜ.

EXAMPLE C: Quantification of the cleaved form of PARP in vivo

The ability of the compounds of the invention to induce apoptosis, by measuring cleaved PARP levels, is evaluated in a xenograft model of AMO-1 multiple myeloma cells.

1.10⁷ AMO-1 cells are grafted sub-cutaneously into immunosuppressed mice (SCID strain). 12 to 14 days after the graft, the animals are treated by intraveinous or oral routes with the various compounds. After treatment, the tumour masses are recovered and lysed, and the cleaved form of PARP is quantified in the tumour lysates.

The quantification is carried out using the "Meso Scale Discovery (MSD) ELISA platform" test, which specifically assays the cleaved form of PARP. It is expressed in the form of an activation factor corresponding to the ratio between the quantity of cleaved PARP in the treated mice divided by the quantity of cleaved PARP in the control mice.

The results (presented in Table 2 below) show that the compounds of the invention are capable of inducing apoptosis in AMO-1 tumour cells in vivo.

Table 2: Quantification of the cleaved form of PARP in vivo

EXAMPLE D: Anti-tumour activity in vivo

The anti-tumour activity of the compounds of the invention is evaluated in a xenograft model of AMO-1 multiple myeloma cells.

lxlO⁷ AMO-1 cells are grafted sub-cutaneously into immunosuppressed mice (SCID strain).

6 to 8 days after the graft, when the tumour mass has reached about 150 mm³, the mice are treated with the various compounds in a daily schedule (5 -day treatment). The tumour mass is measured twice weekly from the start of treatment.

The compounds of the invention have anti-tumour activities (tumour regression) in the AMO-1 multiple myeloma model with ΔΤ/C (qualification parameter of the activity of a product, which is measured by subtracting the median tumor volume on the day of last treatment from the median tumor volume on the day of first treatment / tumour volume of the untreated control group on the day of last treatment) ranging from -1.5 to -24.5 %. The results obtained show that the compounds of the invention induce significant tumour regression during the treatment period. EXAMPLE E: Pharmaceutical composition: Tablets

1000 tablets containing a dose of 5 mg of a compound selected from Examples 1 to 274.

Wheat starch

Maize starch

Lactose

Magnesium stearate

Silica

Hydroxypropylcellulo se

Claims

Compounds of formula (I)

in which 1 is linked to the -NH- group and 2 is linked to the aromatic ring,

♦ X represents a nitrogen atom or a C-R₄ group,

♦ Y represents a nitrogen atom or a C-R₃ group,

♦ R₂, R₃, R₄ and R₅ independently of one another represent a hydrogen atom, a halogen atom, a linear or branched (Ci-Ce)alkyl group, a linear or branched (C₂-C₆)alkenyl group, a linear or branched (C₂-C₆)alkynyl group, a linear or branched (Ci-C6)polyhaloalkyl group, a hydroxy group, a hydroxy(Ci-Ce)alkyl group, a linear or branched (Ci-Ce)alkoxy group, -S-(Ci-Ce)alkyl, a cyano group, a nitro group, -alkyl(Co-C₆)-NR₉R9', -0-alkyl(Ci-C₆)-NR₉R9', -0-alkyl(Ci-C₆)-Rio, -C(0)-OR₉, -0-C(0)-R₉, -C(0)-NR₉R₉', -NR₉-C(0)-R₉', -NR₉-C(0)-OR₉', -alkyl(Ci-C₆)-NR₉-C(0)-R₉', -S0₂-NR₉R₉', or -S0₂-alkyl(Ci-C₆),

♦ R₇ represents a hydrogen atom, a linear or branched (Ci-Cs)alkyl group, a -CHR_aR_b group, an aryl group, a heteroaryl group, an arylalkyl(Ci-C₆) group, or a heteroarylalkyl(Ci-Ce) group,

♦ R_a represents a hydrogen atom or a linear or branched (Ci-Ce)alkyl group,

♦ n is an integer equal to 0, 1 or 2, it being understood that:

- "aryl" means a phenyl, naphthyl, biphenyl group,

"heteroaryl" means any mono- or bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen,

"cycloalkyl" means any mono- or bi-cyclic non-aromatic carbocyclic group containing from 3 to 10 ring members,

"heterocycloalkyl" means any mono- or bi-cyclic non-aromatic carbocyclic group containing from 3 to 10 ring members, and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, which may include fused, bridged or spiro ring systems, it being possible for the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups so defined and the alkyl, alkenyl, alkynyl, alkoxy groups, to be substituted by from 1 to 4 groups selected from optionally substituted linear or branched (Ci-C₆)alkyl, optionally substituted linear or branched (C₂-Ce)alkenyl, optionally substituted linear or branched (C₂-Ce)alkynyl, optionally substituted linear or branched (Ci-C₆)alkoxy, optionally substituted (Ci-C₆)alkyl-S-, hydroxy, hydroxy(Ci-C₆)alkyl, oxo (or N-oxide where appropriate), nitro, cyano, -C(0)-OR', -0-C(0)-R', -C(0)-NR'R", -0-C(0)-NR'R", -NR'R", -(C=NR')-OR", -0-P(0)(OR')₂, -0-P(0)(0^"M⁺)₂, linear or branched (Ci-Ce)polyhaloalkyl, trifluoromethoxy, halogen, or an aldohexose of formula:

in which each R' is independent; it being understood that R' and R' ' independently of one another represent a hydrogen atom or an optionally substituted linear or branched (Ci-Ce)alkyl group and M⁺ represents a pharmaceutically acceptable monovalent cation, their enantiomers, diastereoisomers and atropisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.

2. Compound of formula (I) according to claim 1, wherein:

♦ R6 represents a hydrogen atom, a halogen atom, a linear or branched (Ci-Ce)alkyl group, a linear or branched (Ci-C6)polyhaloalkyl group, a hydroxy group, a linear or branched (Ci-Ce)alkoxy group, a cyano group, a nitro group, -alkyl(Co-C₆)-NR₉R9' , -alkyl(C₀-C₆)-Cyi, -0-alkyl(Ci-C₆)-Rio, or -C(0)-NR₉R₉',

♦ R₉ and R₉' independently of one another represent a hydrogen atom, or a linear or branched (Ci-Ce)alkyl group,

♦ Rio represents -Cy₃ or -Cy₃-alkyl(Co-Ce)-Cy4,

♦ R_{1 1} represents a linear or branched (Ci-C₆)alkyl group, it being possible for the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups so defined and the alkyl, alkenyl, alkynyl, alkoxy groups, to be substituted by from 1 to 4 groups selected from optionally substituted linear or branched (Ci-C₆)alkyl, optionally substituted linear or branched (Ci-Ce)alkoxy, hydroxy, oxo (or N-oxide where appropriate), -C(0)-OR', -C(0)-NR'R", -0-C(0)-NR'R", -NR'R", -0-P(0)(OR')₂, -0-P(0)(0^~M⁺)₂, linear or branched (Ci-C6)polyhaloalkyl, halogen, or an aldohexose of formula:

3. Compounds according to claim 1 , wherein n is an integer equal to 1.

4. Compounds according to claim 1, wherein at least one the groups selected from R₂, R₃, R4 and R₅ does not represent a hydrogen atom.

5. Compounds according to claim 1, wherein Ri₂ represents a hydrogen atom.

6. Compounds according to claim 1, wherein Ri represents a linear or branched (Ci-C₆)alkyl group or a halogen atom.

7. Compounds according to claim 1, wherein R₂ represents a linear or branched (Ci-C₆)alkoxy group, a hydroxy group or a halogen atom.

8. Compounds according to claim 1, wherein X represents a C-R4 group.

9. Compounds according to claim 1, wherein Y represents a C-R₃ group.

10. Compounds according to claim 1, wherein R4 and R₅ represent a hydrogen atom.

11. Compound according to claim 1, wherein the substituents of the pair (R_{l s} R₅) are identical and the substituents of the pair (R₂, R4) are identical.

12. Compounds according to claim 1, wherein :

wherein Ri, R₂, R₉ and R₉' are as defined in claim 1.

13. Compounds according to claim 1, wherein :

wherein R₉ and R₉' are as defined in claim 1.

14. Compounds according to claim 1, wherein E represents a phenyl group, a pyridin-2-yl, a cyclohexyl group, a pyrazol-l-yl group, a cyclopentyl group, an indol-4-yl group, a cyclopropyl group, a pyridin-3-yl group, an indol-3-yl group, a naphth-l-yl group, an imidazol-4-yl group or a pyridin-4-yl group.

15. Compounds according to claim 1, which are compounds of formula (I-b):

wherein R_{l s} R₂, R₅, 5, R7, R12, X, Y, A and n are as defined for formula (I).

16. Compounds according to claim 1, wherein 5 represents a hydrogen atom; a fluorine atom; a chlorine atom; a bromine atom; a methyl group; a trifluoromethyl group; a hydroxy group; a methoxy group; a linear (Ci-C₆)alkoxy group substituted by halogen atoms, a -C(0)-NR'R" group or a -NR'R" group; a cyano; a nitro group; an aminomethyl group; a benzyl group; -0-alkyl(Ci-C6)-Rio; -C(0)-NR9Rc>'.

17. Compounds according to claim 1, wherein R₇ represents a hydrogen atom, an optionally substituted linear or branched (Ci-Ce)alkyl group, a -CHR_aR_b group, or a heteroarylalkyl(Ci-Ce) group.

18. Compounds according to claim 1, wherein Rs represents a linear or branched (C₂-C₆)alkynyl group, an aryl group or a heteroaryl group.

19. Compounds according to claim 1, wherein R9 and R9 ' independently of one another represent a linear or branched (Ci-Ce)alkyl group, or the substituents of the pair (R9, R9 ') form together with the nitrogen atom carrying them a non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen atom from 1 to 3 heteroatoms selected from oxygen and nitrogen, it being understood that the nitrogen in question may be substituted by a linear or branched (Ci-C₆)alkyl group.

20. Compounds according to claim 1, wherein Rio represents -Cy3-alkyl(Co-C₆)-Cy₄.

21. Compounds according to claim 20, wherein Cy₃ represents a cycloalkyl group, an aryl group or a heteroaryl group.

22. Compounds according to claim 20, wherein Cy₄ represents phenyl group or a morpholinyl group.

23. Compounds according to claim 20, wherein

Rio represents

in which p is an integer equal to 0 or 1 and R15 represents a hydrogen atom, a hydroxy group, an optionally substituted linear or branched (Ci-Ce)alkyl group, a linear or branched (Ci-Ce)alkoxy group, a -0-(CHRi₆-CHRi7-0)_q-R' group, a -0-P(0)(OR')₂ group, a -0-P(0)(0^~M⁺)₂ group, a -0-C(0)-NRi₈Ri9 group, a di(Ci-C6)alkylamino(Ci-C6)alkoxy group, a halogen atom, or an aldohexose of formula:

in which each R' is independent; it being understood that:

♦ R' represents a hydrogen atom or a linear or branched (Ci-Ce)alkyl group,

♦ Ri6 represents a hydrogen atom or a (Ci-C6)alkoxy(Ci-Ce)alkyl group, ♦ Ri7 represents a hydrogen atom or a hydroxy(Ci-Ce)alkyl group,

♦ Ri8 represents a hydrogen atom or a (Ci-C₆)alkoxy(Ci-Ce)alkyl group,

♦ q is an integer equal to 1 , 2 or 3 and r is an integer equal to 0 or 1 ,

♦ M⁺ represents a pharmaceutically acceptable monovalent cation.

24. Compounds according to claim 23, wherein the aldexose is D-mannose.

25. Compounds according to claim 1 , which are:

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(4- fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]-2-[(l -methyl- lH-pyrazol-5-yl) methoxy] -D-phenylalanine,

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(4- fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]-2-[(2-ethoxypyrimidin-4-yl)methoxy]- D-phenylalanine,

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(4- fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]-2- {[2-(2-methoxyphenyl)pyrimidin-4- yljmethoxy} -D-phenylalanine,

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(furan- 2-yl)thieno[2,3-(i]pyrimidin-4-yl]-2-methoxy-Z⁾-phenylalanine,

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(5- fluorofuran-2-yl)thieno[2,3-(i]pyrimidin-4-yl]-2-methoxy-Z⁾-phenylalanine,

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(5- fluorofuran-2-yl)thieno[2,3- ]pyrimidin-4-yl]-2-(2,2,2-trifluoroethoxy)-Z⁾- phenylalanine,

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(5- fluorofuran-2-yl)thieno[2,3- ]pyrimidin-4-yl]-2-(pyridin-2-ylmethoxy)-Z⁾- phenylalanine,

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(5- fluorofuran-2-yl)thieno [2,3- ]pyrimidin-4-yl] -2- [( 1 -methyl- lH-pyrazo 1-5 -yl) methoxy] -D-phenylalanine, - N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(5- fluorofuran-2-yl)thieno [2,3-d]pyrimidin-4-yl] -2- [( 1 -ethyl- IH-pyrazo 1-5 -yl) methoxy] -D-phenylalanine,

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(5- fluorofuran-2-yl)thieno[2,3- ]pyrimidin-4-yl]-2-[(2-ethoxypyrimidin-4-yl) methoxy] -D-phenylalanine,

- 2-[( 1 -butyl- IH-pyrazo 1-5 -yl)methoxy] -N- [5 - {3 -chloro-2-methyl-4- [2-(4-methyl piperazin- 1 -yl)ethoxy]phenyl} -6-(5-fluorofuran-2-yl)thieno[2,3-<i]pyrimidin-4-yl]- D-phenylalanine,

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(5- fluorofuran-2-yl)thieno[2,3- ]pyrimidin-4-yl]-2-{[2-(2,2,2-trifluoroethoxy) pyrimidin-4-yl]methoxy} -D-phenylalanine,

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(5- fluorofuran-2-yl)thieno[2,3- ]pyrimidin-4-yl]-2-{[2-(2-methoxyphenyl)pyrimidin- 4-yl]methoxy } -D-phenylalanine,

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(prop- 1 yn- 1 -yl)thieno[2,3-(i]pyrimidin-4-yl]-2-methoxy-D-phenylalanine,

- 2-[( 1 -tert-butyl- 1 H-pyrazo 1-5 -yl)methoxy] -N-[5- {3 -chloro-2-methyl-4- [2-(4- methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(prop- 1 -yn- 1 -yl)thieno[2,3-d]pyrimidin-4- yl] -D-phenylalanine,

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(prop- 1 yn-l-yl)thieno[2,3- ]pyrimidin-4-yl]-2-{[2-(2-methoxyethyl)pyrimidin-4-yl] methoxy} -D-phenylalanine,

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(prop- 1 yn- 1 -yl)thieno[2,3-(i]pyrimidin-4-yl]-2- {[ 1 -(2,2,2-trifluoroethyl)- lH-pyrazol-5-yl] methoxy} -D-phenylalanine,

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(prop- 1 yn-l-yl)thieno[2,3- ]pyrimidin-4-yl]-2-{[2-(morpholin-4-yl)pyrimidin-4-yl] methoxy} -D-phenylalanine,

- N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(prop- 1 yn-l-yl)thieno[2,3- ]pyrimidin-4-yl]-2-{[2-(2,2,2-trifluoroethoxy)pyrimidin-4-yl] methoxy} -D-phenylalanine, - N-[5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(prop- 1- yn-l-yl)thieno[2,3- ]pyrimidin-4-yl]-2-{[2-(2-methoxyphenyl)pyrim₁

methoxy } -D-phenylalanine,

- N-[5- {3-chloro-4-[2-(dimethylamino)ethoxy]-2-methylphenyl} -6-(prop- 1 -yn- 1 -yl) thieno[2,3-d]pyrimidin-4-yl]-2- {[ 1 -(2,2,2-trifluoroethyl)- lH-pyrazol-5-yl] methoxy} -D-phenylalanine,

- N-[5- {3-chloro-4-[2-(dimethylamino)ethoxy]-2-methylphenyl} -6-(prop- 1 -yn- 1 -yl) thieno[2,3-d]pyrimidin-4-yl]-2-{[2-(m

phenylalanine,

- N-[5- {3-chloro-4-[2-(dimethylamino)ethoxy]-2-methylphenyl} -6-(prop- 1 -yn- 1 -yl) thieno[2,3- ]pyrimidin-4-yl]-2-{[2-(2,2,2-trifluoroethoxy)pyrimidin-4-yl] methoxy} -D-phenylalanine,

- N-[5- {3-chloro-4-[2-(dimethylamino)ethoxy]-2-methylphenyl} -6-(prop- 1 -yn- 1 -yl) thieno[2,3-(i]pyrimidin-4-yl]-2-{[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy}-D- phenylalanine,

- N-[5- {3-chloro-4-[2-(dimethylamino)ethoxy]-2-methylphenyl} -6-(4-fluoro phenyl)thieno[2,3-(i]pyrimidin-4-yl]-2-({2-[2-(2-methoxyethoxy)phenyl]pyrimidin- 4-yl} methoxy)-D-phenylalanine;

- ethyl N-[(5Sa)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy] phenyl} -6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]-2-{[2-(2-methoxyphenyl) pyrimidin-4-yl]methoxy}-D-phenylalaninate;

- ethyl N-[(5Sa)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy] phenyl} -6-(prop- 1 -yn- 1 -yl)thieno[2,3-<i]pyrimidin-4-yl]-2- {[2-(2-methoxyphenyl) pyrimidin-4-yl]methoxy}-D-phenylalaninate;

- ethyl N-[(55'_iJ)-5- {3-chloro-4-[2-(dimethylamino)ethoxy]-2-methylphenyl} -6- (prop- 1 -yn- 1 -yl)thieno [2,3 - ]pyrimidin-4-yl] -2- { [2-(2-methoxyphenyl)pyrimidin- 4-yl]methoxy}-D-phenylalaninate;

- N-[5-{3,5-dichloro-2,6-dimethyl-4-[2-(4-methylpiperazin-l-yl)

ethoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]-2-{[2-(2- methoxyphenyl)pyrimidin-4-yl]methoxy} -D-phenylalanine.

26. Process for the preparation of a compound of formula (I) according to claim 1 , characterised in that there is used as starting material the compound of formula (Il-a):

wherein Z represents bromine or iodine and A is as defined for formula (I) in which 1 is linked to the chlorine atom and 2 is linked to the Z group, which compound of formula (II-a) is subjected to coupling with a compound of formula (III):

wherein R^, R₁₂, A, E and n are as defined for formula (I) and, Z and Alk is as defined before, compound of formula (IV) which is further subjected to coupling with compound of formula (V): (V)

R_B20 OR_{B 1} wherein R_{L S} R₂, R₅, X and Y are as defined for formula (I), and RBI and RB₂ represent a hydrogen atom, a linear or branched (Ci -C₆) alkyl group, or R_Bi and RB₂ form with the oxygen carrying them an optionally methylated ring, to yield the compound of formula (VI) :

wherein R_{l s} R₂, R₅, 5, R12, X, Y, A, E and n are as defined for formula (I) and Alk is as defined before, the Alk-O-C(O)- ester function of which compound of formula (VI) is hydrolysed to yield the carboxylic acid, which may optionally be reacted with an alcohol of formula Rv'-OH or a chlorinated compound of formula Ry'-Cl wherein R₇ ' represents a linear or branched (Ci-Cs)alkyl group, a -CHRaRb group, an aryl group, a heteroaryl group, an arylalkyl(Ci-C₆) group, or a heteroarylalkyl(Ci -C6) group, Ra and Rb are as defined for formula (I), to yield the compound of formula (I), which may be purified according to a conventional separation technique, which is converted, if desired, into its addition salts with a pharmaceutically acceptable acid or base and which is optionally separated into its isomers according to a conventional separation technique,

it being understood that at any moment considered appropriate during the course of the process described above, some groups (hydroxy, amino. ..) of the starting reagents or of the synthesis intermediates can be protected, subsequently deprotected and functionalized, as required by the synthesis.

27. Process for the preparation of a compound of formula (I) according to claim 1 , characterised in that there is used as starting material the compound of formula (Il-b):

wherein R_{l s} R₂, R₅, A, X and Y are as defined in formula (I), which compound of formula (VII) is further subjected to coupling with a compound of formula (III) :

wherein R^, R12, E and n are as defined for formula (I), and Alk represents a linear or branched (Ci -C₆)alkyl group, to yield the compound of formula (VI) :

28. Pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 25 or an addition salt thereof with a pharmaceutically acceptable acid or base in combination with one or more pharmaceutically acceptable excipients.

29. Pharmaceutical composition according to claim 28 for use as pro-apoptotic agents.

30. Pharmaceutical composition according to claim 29 for use in the treatment of cancers and of auto-immune and immune system diseases.

31. Pharmaceutical composition according to claim 30 for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemias, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non- small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer.

32. Use of a pharmaceutical composition according to claim 28 in the manufacture of medicaments for use as pro-apoptotic agents.

33. Use of a pharmaceutical composition according to claim 28 in the manufacture of medicaments for use in the treatment of cancers and of auto-immune and immune system diseases.

34. Use of a pharmaceutical composition according to claim 28 in the manufacture of medicaments for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemias, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer.

35. Compound of formula (I) according to any one of claims 1 to 25, or an addition salt thereof with a pharmaceutically acceptable acid or base, for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemias, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer.

36. Use of a compound of formula (I) according to any one of claims 1 to 25, or an addition salt thereof with a pharmaceutically acceptable acid or base, in the manufacture of medicaments for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemias, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer.

37. Combination of a compound of formula (I) according to any one of claims 1 to 25 with an anti-cancer agent selected from genotoxic agents, mitotic poisons, anti-metabolites, proteasome inhibitors, kinase inhibitors and antibodies.

38. Pharmaceutical composition comprising a combination according to claim 37 in combination with one or more pharmaceutically acceptable excipients.

39. Combination according to claim 37 for use in the treatment of cancers.

40. Use of a combination according to claim 37 in the manufacture of medicaments for use in the treatment of cancers.

41. Compound of formula (I) according to any one of claims 1 to 25 for use in the treatment of cancers requiring radiotherapy.